Biomaterials from the sea: Future building blocks for biomedical applications.

Introduction

Oceans and seas account for more than 70% of the earth's surface area [ 1 ]. Ocean ecosystem is the largest one on Earth with approximately 2.2 million different species reside in. Close to 91% of these species still await identification and exploration [ 2 ]. The ocean provides such an abundant source of materials that humans have been using marine-derived biomaterials since ancient times. Marine-derived biomaterials are, in general, devoid of human pathogens [ 3 ].

Contemporary research on marine biomaterials is currently undergoing a renaissance. The efficacy in utilizing these renewable natural resources has been greatly improved because of technological revolution [ 4 ]. Marine organisms possess a plethora of excellent bioactive properties. Many of these organisms have been utilized in biomedical applications, either directly, or in modified forms, as biomimetic templates. The first use of marine biomaterials dates back to the last century, when a substance known as holothurin was extracted from marine organisms in 1967. Holothurin is the earliest biologically-active substance of marine origin that was used experimentally as an anti-tumor agent in in vivo cancer models [ 5 ]. This discovery spurred intensive researches on marine-derived biomaterials.

Review of prior literature indicates that marine biomaterials have undergone four major stages of discovery and development. In the first stage, studies were focused on coral bone graft substitutes. Dr. Chiroff first extracted calcium carbonate exoskeleton from coral (coralline hydroxyapatite) via the replamineform process. This biomaterial resembles natural bone and possesses considerable osteoconductivity, excellent biocompatibility and osteogenic potential [ [6] , [7] , [8] , [9] ]. In vivo application of this biomaterial paves the way for future investigations on ocean-derived biomaterials [ 10 ].

The focus of marine biomaterials shifted to polysaccharide-based polymers during the second stage of development. Chitin, the most abundant polysaccharide of marine origin, was identified as early as 1972 [ 11 ]. However, chitin did not receive its deserved attention until the early 21th century, when studies revealed its important biological characteristics as well as those of its derivatives. In 2007, chitin was discovered as a significant component of skeletal fibers in certain classes of marine sponges [ 12 , 13 ]. Subsequent identification of chitin-silicon composite by Professor Hermann Ehrlich further led to intense investigations of novel biomaterials based on chitin and its deacetylated form, chitosan [ 13 ]. These investigations identified that chitin has low-toxicity, biocompatible, biodegradable and possesses hemostatic activity and antimicrobial capability [ 14 , 15 ].

In the third stage, rapid advances in tissue regeneration during the last decade redirected the focus of marine biomaterials research to marine-derived collagen. The increasing risks of pathogen exposure generated by terricolous animal-derived collagen greatly stimulated exploration of new collagen alternatives. A novel porous jellyfish collagen scaffold was discovered in 2006. Further research validated the low immunogenicity, excellent biocompatibility and biodegradability of marine-derived collagens [ 16 ]. Sophisticated approaches have since been used to generate highly valuable marine collagen-based materials [ 17 ]. These inspiring advances revolutionized tissue regeneration and other industrial fields [ 18 , 19 ]. For instance, echinoderm-derived collagen membranes were identified as a promising material for guided tissue regeneration. These echinoderm-derived collagen membranes are thinner but stiffer compared with commercial collagen membranes [ 20 ]. Likewise, collagen derived from squids in Antarctic and sub-Antarctic areas were recognized as inspiring hybrid scaffolds for tissue regeneration [ 21 ].

The fourth developmental stage of marine-derived biomaterials involves the combination of marine-derived composites with other materials via advanced approaches such as nanotechnology and three-dimensional (3D) printing. Hybrid scaffolds that combine collagen with other modified materials possess improved mechanical and biological properties. Lyophilized scaffolds, for example, were fabricated with eel skin-derived collagen and alginate hydrogel through extrusion-based 3D printing technology. Compared with pristine alginate hydrogels that are devoid of collagen, the hybrid scaffolds exhibited enhanced metabolic and cell proliferation activities [ 18 ]. Likewise, hybrid sponge-like scaffolds have been prepared using ulvan and gelatin. The sponge-like scaffold possessed both porous and interconnected structures, with excellent bioactivity, making it a valuable biomaterial in bone tissue engineering [ 22 ]. Taken together, these studies indicate that marine-derived materials are capable of enhancing the properties of these raw materials and hold great promise for future applications.

The last century has witnessed rapid development in the interdisciplinary utilization of marine biomaterials such as regenerative medicine, antimicrobial materials and drug delivery systems. Marine biomaterials are still abundant despite industrial pollution, overfishing and unanticipated climate change. Hence, the present review aims to provide a detailed coverage of advanced marine biomaterials. The structures, characteristics, origin, extraction, processing and applications of maribe-based biomaterials will be discussed in subsequent sections. The present review should be of interest to researchers in marine biology, bioengineering, biochemistry, biomineralization and biomimetics.

Biomaterials from marine organisms

The marine environment encompasses a wide range of habitats with colossal microbial biodiversity. More than 25,000 biologically-active compounds have been identified from these habitats [ 23 ]. Fungi, fungi-like protists and bacteria exhibit the highest potential of producing bioactive materials. Mycosporines and mycosporine-like amino acids, carotenoids, exopolysaccharides, fatty acids and chitosan derived from these marine microorganisms represent sustainable, low-cost and fast-production alternatives to the use of other natural molecules in photo-protective, anti-aging and skin-whitening products for facial, body and hair care [ 24 ]. Extraction of polyketides, peptides and alkaloids from marine bacteria and fungi has been investigated extensively [ 25 ]. The excellent properties of these marine biomaterials are elucidated in this section.

Polysaccharides and glycans from marine organisms

Marine organisms such as shellfish, macro-algae, fungi, micro-algae and coral produce polysaccharides with variable structures and diverse biological activities that terrestrial organisms lack. This is because the marine environment is featured by high pressure, high salinity, low temperature and oxygen deficiency. The polysaccharides and glycans have been investigated extensively because of their anticoagulant [ 26 ], antimicrobial, antioxidant, antithrombotic and antitumor properties [ 27 ].

Recently, researchers have proposed that polysaccharides extracted from marine organisms are potential antiviral therapeutic agents against SARS-CoV-2, the coronavirus accounting for the ongoing COVID-19 pandemic [ 28 ]. In addition, sulfated polysaccharides such as ulvan, carrageenan and fucoidan exhibit exceptional properties that include hydrogel formation, scaffold formation, extracellular matrix-mimicking, augmentation of alkaline phosphatase activity, reinforcement of stem cell differentiation and biomineralization ability [ 29 ]. Six kinds of representative polysaccharides or glycans with excellent properties are listed below.

Chitin and chitosan

Chitin is the second most common polysaccharide on earth, after cellulose. Chitin originates from the shells of crustaceans like crabs and shrimps, and is also present in cytoderm of fungi and green algae. Chitosan is a natural amino-polysaccharide composed of (1–4)-linked 2-acetamido-2-deoxy- d -glucosamine, which is obtained through the deacetylation of chitin ( Fig. 1 A). Chitin and chitosan exist in nature as pure chitin, nanoorganized chitin-proteins, chitin-pigments and chitin-mineral composite biomaterials, among which pure chitin exhibits the strongest resistance to alkaline condition [ 30 ]. The deacetylation and molecular weight of chitin and chitosan have great impact on their physicochemical and biological properties including solubility, hydrophilicity and cell response [ 31 ]. Chitin-based scaffolds are also involved in calcium biomineralization and biosilica formation. These scaffolds provide the inspiration for biomimetic synthesis [ 32 ]. Fig. 1 A ) Structural formula of chitin and chitosan; B ) Monosaccharides in glycosaminoglycans; C ) Chemical structures of different forms of carrageenan; D ) Putative anti-inflammatory mechanisms of fucoidan; E ) Collagen extraction process for producing acid-soluble and pepsin-soluble marine collagen. Tissue homogenization is conducted with the aim of size reduction via physical methods and mild chemical pretreatment. Ethylenediamine tetra-acetic acid or HCl is then employed to demineralize the raw materials to facilitate extraction. Acidic solutions (e.g. CH 3 COOH) are subsequently used for dissolving the demineralized collagen to complete the extraction process. Pepsin is co-cultured with the mixture for eradication of non‐collagenous components. Finally, the soluble collagen is processed via lyophilization by mixing the collagen pellets, CH 3 COOH and H 2 O. ( A is reproduced from Ref. [ 33 ] with permission from the publisher; B is reproduced from Ref. [ 34 ] with permission from the publisher; C is reproduced from Ref. [ 35 ] with permission from the publisher; D is reproduced from Ref. [ 36 ] with permission from the publisher; E is reproduced from Ref. [ 37 ] with permission from publisher). Fig. 1

Intensive research have been conducted on the antibacterial properties of chitosan and its derivatives. Compared with chitin, chitosan has more potent antibacterial ability because of its positively-charged amines. The latter interact electrostatically with the negatively-charged macromolecules on the surface of bacteria to form a thick layer around the cell wall, thereby preventing the exchange of pivotal solutes [ 33 ]. There is robust evidence that chitosan is capable of combating Streptococcus mutans , Actinomyces actinomycetemcomitans, and Porphyromonas gingivalis [ 38 ]. These bacteria are commonly identified in teeth with caries and periodontal diseases. Glass ionomer cement modified with chitosan exhibits apparent antibacterial effect against dental caries and periodontal diseases [ 39 ]. Chitin and chitosan are potential substitutes for antibiotics against drug-resistant pathogens. Another remarkable property of sponge chitin is that it can be used as a thermostable template for the preparation of inorganic-organic nanostructured composites in extreme conditions due to its excellent thermal stability up to 200 °C [ 40 ]. The electrochemical deposition of copper and copper (I) oxide nanoparticles on chitin-based scaffold provides novel insight in Extreme Biomimetics [ 41 ].

Nevertheless, the applications of chitin and chitosan are restricted by their poor solubility. The firm inter-molecular and intra-molecular hydrogen bonds in their sturdy structure is responsible for the low solubility in common solvents such as water and organic solvent [ 31 ]. Extensive efforts have been devoted to enhancing their water solubility and antimicrobial properties. For example, chitosan was functionalized via the addition of cationic and anionic groups. The introduction of cationic groups, including quaternary ammonium functionalities [ 42 ] and metal/metal oxide nanoparticles [ 43 ], apparently increased the antibacterial capability of chitosan. Reducing the positive charges of the protonated amino groups on the surface of chitosan is another method for improving its water solubility. Chitosan modified by sulfonate groups produced anionic chitosan with enhanced water solubility and selective antimicrobial activity [ 44 ].

Glycosaminoglycans

Glycosaminoglycans (GAGs) are sulfated polysaccharides. They are found extensively in the extracellular matrix and cell surface of animals. The basic structure of GAGs comprises a linear sequence of repetitive disaccharide units. The latter is composed of an amino sugar and uronic acid or galactose. Glycosaminoglycans derived from marine animals are different from those present in terrestrial organisms in both molecular weight and sulfation characteristics. The GAGs include chondroitin sulfate derived from shark cartilage, heparan sulfate dervied from scallops, dermatan sulfate derived from shark skin and heparin derived from shrimp heads ( Fig. 1 B).

Glycosaminoglycans are involved in inflammation, thrombosis, cancer, coagulation and tissue development. The sulfation patterns of GAGs, even when they are of the same class, can vary among marine animals, which are closely related to their physiological functions. Glycosaminoglycans exert their influence through interaction with other proteins indirectly (including regulating protein folding through steric hindrance, elimination) or directly (via electrostatic interaction). These interactions are greatly affected by their degree of sulfation and negative charges [ 45 ]. Holothurian fucosylated chondroitin sulfate extracted from sea cucumbers is a typical example of marine GAG [ 46 ]. Exotic disaccharide units such as CS-K are unique to marine organisms. The GAGs in some marine animals feature a special pattern of saccharide arrangement, such as a specific sequence of consecutive saccharides [ 34 ]. Marine organisms also produce GAGs mimetics with structures that are different from those derived from terrestrial sources, such as the presence of sulfated glycans. These marine organisms include macro-algae (brown, red and green algae) and invertebrates (ascidians, mollusks, crustaceans and echinoderms).

Alginate

Alginates are salts of alginic acid, a linear anionic polysaccharide copolymer consisting of (1–4)-linked β-mannuronic acid and α-guluronic acid monomers. Alginates form the cell walls of brown algae. They possess gelling, viscosity modification and stabilizing properties, and are used extensively as thickeners and emulsification stabilizers.

Recently, the anti-obesity capability of alginate has been investigated extensively. Alginate has been shown to inhibit digestive enzymes. These properties are not influenced by the cooking process (even when cooking at temperature up to 200 °C) and digestion. This renders alginate a potential drug for obesity management [ 47 ]. The anti-obesity effect of alginate is influenced by the conformational structure of the polysaccharide; studies have reported that the anti-obesity of enzyme-digested alginate is stronger than acid-hydrolyzed alginate [ 48 ]. In addition, blood cholesterol levels may be reduced after the administration of calcium alginate [ 49 ].

A significant feature of alginates is gelation. Hence, they may be used to fabricate highly-biocompatible hydrogels, the physical properties of which may be customized to guide 3D cell growth and differentiation. The pore size (5–200 mm) of alginate accelerates the spread of large molecules. Consequently, alginate is frequently used as bioink in 3D bioprinting for tissue regeneration. The stiffness of scaffolds synthesized by alginate as bioink in 3D bioprinting may be controlled by altering the ratio of alginate to ionic crosslinker. Such a property enables spatial regulation of mesenchymal stem cells (MSCs) in a printed scaffold [ 50 ]. The stability of alginate hydrogels may be enhanced by post-printing treatment with BaCl 2 [ 51 ]. A bioactive peptide may also be covalently linked to the alginate to endow it with cell interaction properties. For example, highly efficient coupling of bioactive peptides to alginates has been achieved using periodate oxidation followed by reductive amination with non-toxic 2-picoline-borane as the reducing agent [ 52 ].

Carrageenan

Carrageenan, a sulfated polysaccharide with mean molecular weight over 100 kDa, contains 15–40% ester sulfate. It is a reproducible and sustainable phycocolloid obtained from red seaweeds. The basic unit of carrageenan is d -galactose and 3,6-anhydrogalactose that are linked by α-1,3- and β-1,4-glycosidic bonds. Carrageenan is classified into three categories (λ, κ, and ι) based on the ester sulfate group cotent [ 53 ] ( Fig. 1 C).

Carrageenan shows great commercialization potential because it is inexpensive, biocompatible and biodegradable. The hydrophilicity and high ester sulfate content make carrageenan films useful in edible food packaging, pharmacology, biomedicine and electrial applications. The overall tensile strength of carrageenan films is better than those of other bio-based films. Films produced from refined κ- or κ/ι-hybrid carrageenan possess excellent properties, including high tensile strength and low water vapor permeability [ 54 ].

The biological activities of carrageenan include anti-inflammatory, antitumor, antimicrobial, antioxidant, anti-hyperlipemic, anticoagulant and immunomodulatory properties. These bioactivities are dependent on the molecular weight, content and site of sulfate groups [ 55 ]. Carrageenan may be functionalized via chemical modifications to achieve improved properties. The antiviral activity of carrageenan against herpes simplex virus (HSV-1 and HSV-2) is enhanced by partial oxidation [ 56 ]. Fully-oxidized or partially-oxidized carrageenan at C-6 of the β- d -galactopyranose units demonstrates better anticoagulant effect [ 57 ]. The anti-proliferative and antitumor activities of carrageenan are novel and promising fields. κ-carrageenan possesses the highest cytotoxic effects. The 50% inhibitory concentration of κ-carrageenan is close to those antineoplastic with alkylating properties with official approval [ 55 ].

The limitation for the application of carrageenan films is their poor water vapor permeability and water-resistance. Different approaches have been used to improve carrageenan film properties, such as blending, plasticizing, and nanoparticle incorporation. By producing a concentrated and stable structure in blended matrix, polymerides such as starch and protein blending with carrageenan greatly improves the mechanical properties of the film. Plasticizers are alternative agents to promote the flexibility of carrageenan films. The inclusion of organic acids and inorganic materials may also improve the antimicrobial activity of these films [ 54 , 58 ]. Reinforcement of carrageenan polymers with homogeneously-dispersed chitin nanofibrils renders the film more smooth and flexible, along with increased tensile stress and Young's modulus [ 59 ]. Although carrageenan is considered as safe for human use, there has been concern regarding the long-term response of carrageenan in vivo . The cumulative effects of carrageenan are similar to chronic low-level inflammation in obesity and other metabolic syndromes. The controversy on the safety of carrageenan should be resolved prior to its practical applications [ 60 ].

Ulvan

Ulvan is a polyanionic sulfated polysaccharide consisting of glucuronic acid, iduronic acid, rhamnose-3-sulfate and a small amount of xylose. Ulvan has been used extensively in chemical, pharmaceutical, agricultural and comestible fields because of its anti-coagulation, anti-oxidation, anti-tumor, blood lipid level reduction activities as well as the capability in eliciting plant defenses. Currently, there are two chemical ulvan saccharification methods: acid hydrolysis and enzymatic hydrolysis. Enzymatic hydrolysis of polysaccharides, which is conducted under mild reaction condition, higher saccharification rate, low energy consumption and low content of aggressive chemicals, is deemed superior to the former [ 61 ].

Compared with those with high-molecular weight, low-molecule weight ulvans have better solubility, lower viscosity, easier absorption and better exposure of reactive groups [ 62 , 63 ]. Degradation of ulvan generates monosaccharides and oligo saccharides with unexpected biological properties, including antiviral and anticoagulant capability, as well as protein localization at the cell surface. Hence, it is promising to utilize depolymerization of monosaccharides as fertilizer to produce bioethanol and high-value food additives [ 61 ].

Ulvan shows a broad range of bioactivities. It possesses excellent antibacterial activities against pathogens such as Pasteurella multocida , Mannheimia haemolytica and Erysipelothrix rhusiopathiae . After administration, ulvan stimulates the human immune system by secreting cytokines that are involved in cell-mediated immunity via the PI3K/Akt signaling pathway [ 64 , 65 ]. As sulfated polysaccharides, ulvan also exhibits potent antiviral activity as well as immunomodulatory activity [ 63 , 66 ]. Ulvan is capable of activating RAW264.7 macrophages to produce pro-inflammatory mediators such as TNF-α, IL-6 and PGE2. These mediators are responsible for initiating immune responses. Because of the heterogeneous composition and stuctures of the polysaccharides present in ulvan, the relationship between their immunomodulating effects and structural features is obscure and requires further investigation [ 67 ]. Ulvan also demonstrates anti-tumor activity against human breast cancer, hepatocellular carcinoma and cervical cancer [ 68 ]. The antioxidant and anti-hyperlipidemic activities of ulvan has also been reported [ 69 ]. Ulvan also shows affinity to heavy metal ions. Hydrogels prepared with gelatin and ulvan are potential adsorbents of heavy metals and the dye methylene blue. These hydrogels are also promising alternatives as anti-pollution agents [ 70 ].

Fucoidan

Fucoidans are obtained from the cell walls of brown algae, seagrasses and other marine invertebrates. They are composed of sulfated polysaccharides, including repeating α-(1 → 3)-linked l -fucopyranose residues or alternating α-(1 → 3)- and α-(1 → 4)-linked l-fucopyranoses. Other monosaccharides such as xylose, galactose and uronic acids may also combine with the fucosyl main chain to form fucoidan. The specific structure of fucoidans is complicated and variable, depending on the source and extraction process [ 36 , 71 , 72 ].

Fucoidans possess biomedically-significant pharmacological properties including anti-inflammatory, antimicrobial, immunomodulatory and antitumor properties. For anti-inflammatory activity, fucoidans are able to block lymphocyte adhesion and invasion, inhibit multiple enzymes, induce apoptosis and regulate excretion of pro-inflammatory cytokines ( Fig. 1 D) [ 36 ]. Moreover, fucoidan initiates a variety of immunoregulatory effects. It activates dendritic cells, natural killer cells and T cells to enhance antiviral and anti-tumor responses [ 73 ]. For example, fucoidan derived from the algae Nizamuddinia zanardinii exhibits well-defined immune-enhancing activity on murine macrophage cell and human natural killer cells. In this in vitro model, fucoidan contributes to the secretion of cytokines, including nitrous oxide, TNF-α, IL-1β, IL-6, NF-κB and stimulates the MAPK signaling pathways [ 74 ].

The immunomodulatory activity of fucoidans is regulated by different parameters. The content of fucose and sulfate groups in fucoidans is considered as one of the most significant parameters. For example, fucoidan extracted from Macrocystis pyrifera has higher uronic acid content and is the most effective in activating natural killer cells, dendritic cells and T cells, producing the strongest adjuvant effect [ 73 ]. Molecular weight is another essential factor that determines the biological activity of fucoidans. High molecular-weight fucoidan (130 kDa) increases the survival rate of cells and secretion of IFN-γ and nitrous oxide, while low-molecular-weight fucoidan (30 kDa) with similar composition has lower activity [ 75 , 76 ].

Fucoidan are also considered effective agents for combating cancer. This is achieved via the regulation of cancer cell apoptosis. The ratio of monosaccharides, the content of sulfate groups and binding of sugar residues all account for the anti-tumor activity of fucoidans [ 77 ]. Fucoidan is a reactive oxygen species (ROS) scavenger. It reduces ROS accumulation by amyloid-β-reduction [ 78 ]. The antioxidant ability of fucoidans is determined by their concentration, molecular weight, sulfate content, extent of polymerization, presence of substitution groups, the position and type of sugar and glycosylation branching [ 71 , 79 ]. Fucoidan enhances angiogenesis in a dose-dependent manner by inflencing tube formation and movement of human microvascular endothelial cells [ 80 ]. The angiogenesis potential of fucoidan is attributed to the activation of p38 and C-Jun N-terminal kinase via affecting the AKT/MMP-2 signaling axis [ 81 ].

Proteins and peptides from marine organisms

Collagen

Collagen is the most abundant extracellular matrix protein [ 82 ]. It is commonly found in tendons, skin, bones and blood vessel walls. To date, researchers have recognized and categorized 29 types of collagen, among which type I collagen makes up 90% of the collagen present in the animal body [ 83 ]. Collagen possesses complex supramolecular structure. A collagen molecule is around 2–6 nm thick, 30–50 nm wide and 60–100 nm long [ 84 ]. The collagen molecule consists of three characteristic α‐chains, which form a triple‐helical α‐domain(s) known as “tropocollagen” [ 85 ]. Repetition of the Gly-X-Y triplet constitutes the α chain, in which proline and hydroxyproline constitute the X and Y domains [ 86 ]. Self-assemblly of the tropocollagen molecules is responsible for maintaining the structural and biological integrity of a collagen fibril on a molecular scale. The collagen fibril contains well-defined protein binding sites for cell interactions [ 89 ].

The collagen content in the human body decreases due to aging [ 87 ], infection [ 88 ] and exposure to ultraviolet light [ 89 ]. The loss of collagen results in disorders such as skin mismanagement and stiffened joints. Consequently, afforable and easily extractable collagen sources are highly sought after especially in the fields of regenerative medicine.

Type I collagen originates mainly from animals [ 90 ]. Animal-derived collagen, which serves as the gold standard for collagen application, is obtained from donated human tissues or large mammals such as cattle, horses, pigs or sheep [ 91 ]. However, the availability of land-derived materials is hampered by the outbreak and pathophoresis of zoonotic infectious diseases. Extraction of collagen from marine organisms is now regarded as the safest approach for large-scale collagen acquisition [ 92 ]. Marine collagen is usually extracted from sponges [ [93] , [94] , [95] ], fishes [ 96 , 97 ], squids [ 21 ] and echinoderms [ 33 ]. These collagen sources may be categorized into those that are derived from invertebrate animals and those that are extracted from vertebrate sources [ 37 ] ( Table 1 ). Marine vertebrate collagen has always been identified as alternative biomaterials. However, similar to land-derived collagen, the potential risks arising from bovine spongiform encephalopathy and the swine influenza crisis greatly hampered its further application [ 98 ]. Table 1 Collagen derived from marine organisms. Table 1 Genre Source Scientific Name Collagen Type Activity Refs Invertebrate organisms Jellyfish Catostylus tagi Collagen V/XI Healthy food. [ 113 ] Jellyfish Rhopilema esculentum Collagen I Enhance cell migration, heal wound, hemostatic properties, modulate chondrogenic differentiation of human mesenchymal stem cells and cell culture substrate. [ 114 ] [ 115 ] [ 116 ] [ 117 ] Jellyfish Rhizostoma pulmo Collagen I Trigger similar responses in cell adhesion, proliferation or migration [ 118 ] Jellyfish Catostylus mosaicus Collagen I Support cell attachment and proliferation [ 119 ] Sea urchin Paracentrotus lividus Collagen I Skin regenerative medicine and collagenous extracellular matrix biomaterials for tissue engineering [ 120 ] [ 121 ] Squid Peru squid Collagen II Degenerative osteoarthritis-relieving effects [ 122 ] Persian Gulf squid skin Uroteuthis duvauceli Collagen I Anti-cytotoxic properties [ 123 ] Starfish Asterias amurensis Collagen I Production of two-dimensional membranes [ 124 ] Vertebrate organisms Cat Fish Ictalurus punctatus Collagen I Food, medical and cosmetic industries, produce high-value-added product [ 125 ] [ 126 ] Cat Fish Pangasius sp. Collagen I Substitutes for commercial collagen [ 127 ] Sponges Chondrosia reniformis Collagen IV ROS scavenging capability; photo-protective activivy as well as wound-healing characteristic [ 128 ] Blue Shark Prionace glauca Collagen I Promote osteoblast proliferation rates [ 129 ] Blue Shark Prionace glauca Collagen II Antioxidant activity and increase apoptotic gene expression [ 130 ] Salmon Salmo salar Tilapia nilotica Collagen I Accelerate wound healing by altering cutaneous microbiome colonization [ 131 ] Yellowfin tuna Thunnus albacares Collagen I Antioxidant activities [ 132 ] Sardine Sardinella longiceps Collagen I Mosquito larvae against Aedes aegypti [ 133 ] Salmon N/A Collagen I Protect DNA against oxidation-induced damage [ 134 ] Medusa fish Centrolophus niger Collagen I Antibacterial active food and packaging film [ 135 ]

Marine-derived collagen is a remarkable source of raw biomaterials for multidisciplinary applications [ 99 ]. This is because collagen extracted from marine sources has an amino acid composition that is similar to human type I collagen [ 100 ]. In addition, owing to their low molecular weight and small particle size, marine-derived collagen circulates rapidly in the blood stream and is absorbed into human body up to 1.5 times faster than conventional collagen derived from terricolous sources [ 91 , 101 ]. Most importantly, marine-derived collagen is available in high yield and at low cost [ 102 ]. The principal procedures involved in the isolation of marine-derived collagen are illustrated in Fig. 1 E [ 101 ]. Vertebrate marine animal-derived collagen, such as fish collagen, is one of the most important sources of marine-derived collagen. These extracted pepsin-soluble and acid-soluble collagen moieties are capable of accelerating wound healing in vivo [ 103 ]. The principal procedures involved in the isolation of fish-derived collagen include preparation, extraction and recovery [ 101 ]. The preparation process includes cleaning and size reduction via physical methods and mild chemical pretreatment for the eradication of noncollagenous components. Ethylenediamine tetra-acetic acid or HCl is then employed to demineralize the raw materials to facilitate extraction. Acidic solutions are subsequently used for dissolving the demineralized collagen to complete the extraction process [ 104 ]. Collagen extracted from marine invertebrate, especially those extracted from glass sponges, are excellent organic templates for in vitro silicification [ 105 ]. Marine glass sponge-derived collagen accounts for the most abundant naturally-silicified biomaterials on earth. Heavy interfibrillar silicification and structural hierarchy were detected when silica precursors were mixed with these collagen moieties. The silicified collagen possesses considerable toughness, stiffness as well as resilience. Owing to its superior biocompatible and mechanical properties, silicified marine-derived collagen has generated intense interest in hard tissue regeneration research [ 106 ].

Among the invertebrate-derived collagen, there is a special sponge-derived collagen known as spongin. Spogin displays distinct morphological traits and chemical constitution. Spongin fibers are large microstructures which are identified as halogenated scleroproteins or neurokeratin-like proteins [ 107 ]. There are two categories of spongin, spongin A and spongin B. Spongin A is the fine intercellular collagen fibrils which can be detected only with electron microscopy. Spongin B corresponds to the typical macroscopical and rigid fibrils present keratosan demosponges [ 108 ]. Spongin had a long scientific research record dated as far back as 1705 [ 109 ]. Spongin chemistry is considerably complex. Halogens (I, Br) and other unknown biological constituents account for the water-insoluble characteristic of spongin [ 110 ]. In addition, spongin possesses excellent resistence to harsh chemical substances and extremely thermal conditions. What is even more inspiring is that spongin can be fabricated as nanoscale biomaterials which maintain their excellent properties at extreme conditions [ 111 ]. Because of the aforementioned advantages, spongin is considered an attractive macroscopical biomaterials in contemporary bioinspired materials science and regenerative medicine [ 112 ].

There are problems associated with the application of marine-derived collagen. For example, mackerel collagen is an important pan-allergen in the Japanese population [ 136 ]. Marine-derived collagen denatures easily, which limits its biomedical applications. Collagen gels derived from chum salmon ( Oncorhynchus keta ), for example, denatures at 19 °C [ 37 ]. Religious constraints are another factor that hampers the marketing of marine collagen-based products.

Gelatin

Gelatin is a heterogeneous mixture of peptides. It is extracted from fishes and sponges [ 100 , 137 , 138 ], jellyfish [ 139 ], squids [ 140 ] and snails [ 141 ] via enzymatic or acidic process [ 142 ]. Gelatin is produced by destruction of the tertiary, secondary and even primary structures of collagen [ 143 ]. Marine gelatins possess high protein values (91.5% for acid-soluble gelatin and 83.1% for pepsin-soluble gelatin). The hydroxyproline content of marine gelatin is similar to that of commercial mammalian gelatin but with higher melting temperatures [ 144 ]. Some marine gelatin such as those derived from saithe ( Pollachius virens ) skin has a considerable mineral content (>20%) compared to the commercially available gelatin (<0.2%) [ 145 ]. Gelatin has been used extensively in clinical platforms such as eutherapeutic plasma expanders, nanoparticles for gene delivery and drug loading [ [146] , [147] , [148] ].

Marine enzymes

Enzymes obtained from marine sources, including proteases, peroxidases, oxidoreductases, hydrolases, transferases, isomerases, ligases and lyases, have found comestic, industrial and medical applications. These enzymes are capable of controlling immune functions, some of which directly kill bacteria. They possess considerable immunomodulatory activities that enhance the innate immune response; they also control infection of the host effectively [ 149 ] ( Table 2 ). Table 2 Marine-derived enzymes. Table 2 Name of enzymes Sources Enzyme type Activity ref l -asparaginase Bacterial sources E. coli Erwinia carotovora) Asparaginase Convert l -asparagine into aspartic acid and ammonia Anti-carcinogenic activity Reduce carcinogenic acrylamide [ 150 ] [ 152 ] [ 157 ] Fungal sources Aspergillus oryzae Microalgae sources Spirulina maxima Chlamydomonas sp Carbonic anhydrase containg cadmium Marine diatom Thalassiosira weissflogii Metalloenzymes Catalyze the reversible hydration of CO2 Acquire inorganic carbon for photosynthesis [ 158 ] [ 159 ] Alkaline protease marine Psychrobacter Aureobasidium pullulan Bacillus mojavensis A21 Pseudoalteromonas sp Protease Peptide hydrolases [ 160 ] [ 161 ] Extracellular phospholipase C marine streptomycete Pseudoalteromonas sp Lipases Hydrolyze different oils [ 162 ] [ 163 ] Chitinase Chitosanase Vibrio fluvialis, Vibrio parahaemolyticus, Vibrio mimicus Vibrio alginolyticus Listonella anguillarum Aeromonas hydrophila Aspergillus griseoaurantiacus KX010988 . Hydrolase Degrade chitin and chitosan [ [164] , [165] , [166] ] Alginate lyases Algae marine invertebrates Vibrio splendidus 12B01 Lyases Degrade alginate [ [167] , [168] , [169] ] Agarases Cytophaga Bacillus Vibrio Alteromonas Pseudoalteromonas Streptomyces Vibrio sp. F-6 Hydrolase Hydrolyze agar [ 170 , 171 ] Carrageenases Pseudomonas, Cytophaga, Alteromonas atlantica, Wingyingzhuangia aestuarii OF219 Flavobacterium sp. YS-80-122 Hydrolase Degrade carrageenans [ [172] , [173] , [174] , [175] ] Cellulose and hemicellulose hydrolase Cytophaga, Cellulomonas, Vibrio, Clostridium, Streptomyces Fusarium, Chaetomium, Phoma, Sporotrichum, Glaciecola sp. strain 4H-3–7+YE-5 Hydrolase Break down cellulose [ [176] , [177] , [178] ]

Some marine-derived enzymes show great potential in anti-cancer applications. l -asparaginase, an enzyme which catalyzes the hydrolysis of l -asparagine to l -aspartic acid, is an important enzyme of marine origin [ 150 ] ( Fig. 2 A). l -asparaginase is a homologous mixture of different conformations, of which the tetramer is the predominant conformation [ 151 ]. Because of its anti-neoplastic and chemotherapeutic potential, l -asparaginase formulations occupy up to one-third of the global demand on anti-leukemia/anti-lymphoma agents [ 152 ]. Fig. 2 Marine enzymes and protein-based bioadhesives. A ) Schematic of the reaction mechanism of l -asparaginase. B ) Monomeric units of natural-derived eumelanin and polydopamine melanin (PDAM). i ) dopamine (DA); and ii ) DOPA, DHI; iii ) DHICA; and iv ) the porphyrin-like tetramer. C ) Schematic of MAPs and their functional location in a byssal plaque. D ) Schematic of the adhesive mechanism of catechols. As a DOPA analog, catechols are considered significant groups for wet adhesion because they possess strong bidentate binding ability toward mineral oxide surfaces. ( A is reproduced from Ref. [ 153 ] with permission from the publisher; B is reproduced from Ref. [ 154 ] with permission from publisher; C is reproduced from Ref. [ 155 ] with permission from the publisher; D is reproduced from Ref. [ 156 ] with permission from the publisher). Fig. 2

Cadmium-containing carbonic anhydrase obtained from Thalassiosira weissflogii (a marine diatom) has gained recent attention. The cadmium present in this enzyme occupies the metal-binding part of the enzyme carbonic anhydrase and plays a significant role in the acquisition of inorganic carbon for photosynthesis [ 179 ]. A protein extracted from T. weissflogii with cadmium inside possesses carbonic anhydrase activity [ 180 ]. This metal-loading enzyme participates in the activities of marine organisms and facilitates trace-metal cycling in the oceans.

The last two decades have witnessed escalating attention in the identification of enzymatic hydrolysates from marine invertebrates. Enzymatic hydrolysates, also known as antioxidant peptides, are extracted and purified from mussels [ 181 ], clams [ 182 ] and oysters [ 183 ]. Enzymatic hydrolysates scavenge free radicals and chelate metal ions, suppress lipid peroxidation and protect cells against ROS-induced toxicity [ 184 , 185 ].

A wide range of marine-derived enzymes possess antimicrobial, anti-cancer, antioxidant, antihypertensive as well as immunomodulatory properties. The functions of these enzymes are usually intercrossed. A lot of work needs to be done before these attractive enzymes can be harnessed for clinical use.

Protein-based bioadhesives

The demand for bioadhesives has spurred remarkable advances in the identification of their characteristics. Many marine organisms have the ability to adhere to substrates for survival in dynamic environments with continuous mechanical stresses in the ocean. Medical grade bioadhesives are in huge demand because moisture in the human body serves as an interfacial contaminant, weakening the boundary layer at the bonding site. Stable and instant adhesion is challenging to be achieved for wet surfaces within body tissues [ 186 ].

Mussels synthesize mussel adhesive proteins (MAPs). These proteins are secreted by mussel byssuses. Byssus is a bundle of filaments that enable these bivalve mollusks to anchor their bodies efficiently to solid surfaces such as rocks and ship hulls [ 155 ] ( Fig. 2 C). The MAPs possess excellent adhesive capability because they bond to varous surfaces in aqueous conditions. The distinct amino acid 3,4-dihydroxyphenylalanine (DOPA) [ 162 ], which can be easily conjugated with other components [ 154 ], determines the superior adhesive capability of MAPs. To date, MAPs that have been identifed range from proteins type 1 (fp-1) to type 6 (fp-6). Each of these MAPs distributes at a specific site and plays a distinctive role in attachment. The type-3 fast variant (fp-3F) and the type-5 (fp-5) variant are significant compositions for mussel adhesive initiation. They possess primer-like activity that facilitates firm adhesion to wet marine substrata [ 187 ].

Another attractive bioadhesive protein, eumelanin, is extracted from cuttlefish ( Sepia officinalis ) ink ( Fig. 2 B). Eumelanins are DOPA-based, melanin-like heterogeneous polymers that contain aryl–aryl covalent bonds between uncycled and cycled DOPA and their analogs [ 171 ]. Eumelanins have been investigated as potential sealing and hemostatic biomaterials [ 188 ]. Catechols, derivatives of DOPA in adhesive mussel foot proteins, have recently been used to synthesize mussel-inspired adhesives. The relevant adhesive mechanism is illustrated in Fig. 2 D.

Other protein-based adhesives that originate from marine invertebrates have also been envisaged as potential candidates for medical and industrial applications. The tubeworm Phragmatopoma californica assemble their tubes by gluing siliceous and calcareous particles together with a polyelectrolytic bio-cement [ 189 ]. The bio-cement is composed of several highly-repetitive and oppositely-charged proteins, DOPA, sulfated polysaccharides and metal ions such as magnesium and calcium ions [ 190 ]. Adhesive proteins derived from sandcastle worms serve as in-situ embolic coacervate agents for treating vascular malformations and defects in a rabbit renal artery model [ 191 ].

Oxazole-containing peptides

Oxazole-containing peptides belong to a significant category of 5-membered N,O-heterocyclic compounds. The five-membered aromatic ring binds readily to enzymes and receptors via non-covalent interactions [ 183 ]. Oxazoles extracted from marine organisms range from short linear peptides to long complex structures [ 192 ]. They can be produced via ribosomal, non-ribosomal approaches or by synthetic pathways [ [193] , [194] , [195] ]. Oxazole-containing peptides derived from marine organisms possess antibacterial [ 196 ], antiviral [ 197 ], anti-malarial [ 198 ] and anti-algal properties [ 199 ].

Marine secondary metabolites

The ocean is a promising source of structurally-novel and pharmaceutically-active marine secondary metabolites. These metabolites include alkaloids, polyketides, terpenes, lignans, steroids and cyclic peptides [ 200 ]. The bioactivity of secondary metabolites derived from marine fungi has long been recognized. However, these secondary metabolites have not yet been commercialized for pharmaceutical applications [ 201 ].

Mycosporines and mycosporine-like amino acids (MMAs)

Mycosporines and MMAs are water-soluble molecules that absorb ultraviolet-A and ultraviolet-B light ( Fig. 3 A and B). Their absorption maxima range from 268 to 362 nm, which is determined by their molecular structure [ 202 ]. Many MMAs have been identified from red algae, sea stars, corals, dinoflagellates and cyanobacteria after the initial discovery of the mycosporines porphyra-334 and shinorine. Porphya-334 and shinorine are potent monoamine oxidase inhibitors. They are present in high concentrations in Aphanizomenon flos-aquae (a species of cyanobacteria) and Klamath blue-green microalgae [ 203 ]. Fig. 3 Chemical structures of marine secondary metabolites. ( A ) The core of mycosporine-like amino acids (MAAs) is composed of a cyclohexenone, or a cyclohexenimine ring conjugated to an amino acid residue or its imino alcohol; ( B ) MAA precursor 4-deoxygadusol and common MAAs. The latter include mycosporine-glycine, mycosporine-2-glycine, shinorine, palythine and porphyra-334. The maximum absorbance values of these molecules are included. ( A , B are reproduced from Ref. [ 222 ] with permission from the publisher). Fig. 3

Mycosporine-like amino acids are synthesized through the conjugation of amino acids to an intermedium via a common metabolic pathway. They are regarded as natural sunscreen molecules [ 204 ]. Hence, MAAs are promising natural alternatives for both direct (ultraviolet light absorption) and indirect (antioxidant) protection because they show strong photo-stability with absence of cytotoxicity [ 205 ]. Mycosporine-like amino acids have been incorporated into a sunscreen reagent, Helioguard®365, which contains porphyra-334 and shinorine [ 206 ].

Bromophenols

Bromophenols are secondary metabolites present in marine organisms. They contain at least one benzene ring with several hydroxyl and bromine groups ( Fig. 5 C). Bromophenols are biosynthesized via bromoperoxidases, bromase, laccase, hydrogen peroxide and bromide. The majority of bromophenols originate from marine red algae, green algae and brown algae [ 207 , 208 ]. Bromophenols extracted from the marine algae Leathesia nana and Rhodomela confervoides efficiently suppress the growth of human cancer cell lines ex vivo and inhibit tumor angiogenesis [ 209 ]. It has been shown that bromophenols initiate cell cycle arrest at the G0/G1 phase of adenocarcinomic human alveolar basal epithelial (A549) cells and trigger ROS-mediated apoptosis in those cells [ 210 ].

Bromophenols may be used to control diabetes and obesity via the inhibition of α-glucosidase, protein tyrosine phosphatase 1B [ 211 ], α-amylase [ 212 ] and aldose reductase [ 213 ]. Bromophenols extracted from a marine red alga Symphyocladia latiuscula showed antifungal activities against Candida albicans [ 214 ].

Bromotyrosines refer to a series of bioactive secondary metabolites that originate from marine demosponges, especially from Verongida [ 215 ]. These demosponges possess two important structures: a rigid three dimensional skeleton and a broad range of secondary metabolites. These two armomentaria enable demosponges to successfully survive natural selection. Demosponges obtain nutrients by filtering water via their flexible chitinous skeletons. However, different pathogens enter the sponge body along with the nutrients simultaneously. These pathogens must be neutralized or eradicated to prevent invasive infection [ 216 ]. Secondary metabolites, mainly bromotyrosines, play significant roles in combating these pathogens. Bromotyrosines possess simple brominated tyrosine and tyramine units [ 217 , 218 ]. They are obtained from extraction from sponges or analog synthesis. Bromotyrosines are released when the sponges are mechanically damaged or when there are changes in the marine environment [ 216 ]. According to the latest research, the yield of bromotyrosines extracted from cultivated sponges is as high as 90% [ 219 ]. More recently, synthesis of bromotyrosines analogs has become an alternative for the extraction of naturally-occurring bromotyrosines [ 220 ]. However, many organic solvents may be involved in this multistep procedure, which will be more expensive, laborious and complex [ 221 ]. Related applications of bromotyrosines will be discussed in subsequent sections.

Hierarchical structure of marine skeletons from a macroscopical perspective

Marine skeletons are characterized by tailored architectures with distinct traits such as interconnected pores that resemble natural bone architecture. Compared with synthetic materials, marine skeletons have excellent biological and structural properties. There is an ongoing trend in tissue engineering to utilize marine skeletons with distinct structure and chemical composition as scaffolds [ 231 ] ( Fig. 4 ). Fig. 4 Marine skeleton with hierarchical and porous architecture applied for tissue engineering and drug delivery system, including sea urchin, cuttlebone, coral with interconnected porous structures and seashells with dense lamellar structure (reproduced from Ref. [ 223 ] with permission from the publisher). Fig. 4 Fig. 5 ( A ) Images of the scleractinian coral Acropora digitifera . ( B ) SEM images of ultrastructural features of the coral Balanophyllia europaea . ( C ) Sectional view of calcium carbonate spines derived from the sea urchin Heterocentrotus mammillatus . ( D ) SEM images of the inner structures of sea urchin spines ( A , B are reproduced from Ref. [ 227 ] with permission from the publisher; C,D are reproduced [ 226 ] from with permission from the publisher). Fig. 5

Sponges

It has been estimated that half of the marine-derived biomaterials are obtained from different species of marine sponges [ 223 ]. Sponge skeletons are soft-bodied organic and inorganic compounds with an interconnected porous architecture. The porous architecture facilitates the flow of fluids. Consequently, marine sponges are reliable sources of bone substitutes for bone tissue engineering. For example, the stony sponge Petrosia ficidormis has a highly porous (pore size 364 μm in average), interconnected 3D architecture, which is beneficial for the integration between grafting material and bone [ 224 ].

Sponge spicules are composed of amorphous silica produced under natural physiological conditions. Polyphosphate is an important component of spicules. The combination of biosilica and polyphosphate stimulates differentiation of human MSCs and increase their mineralization potential. In addition, these sponge spicules account for the intrinsic stiffness and toughness of the sponge skeleton [ 225 ]. Nanoscopical silica spheres are aligned in microscopic concentric rings and surrounded by an organic matrix to produce laminated spicules. These spicules are arranged into bundles, forming a macroscopical cylindrical lattice-like structure. The hierarchical arrangement of these spicules contributes to the mechanical strength of the sponge skeleton [ 223 ].

Corals

Coral skeletons are composed of a hierarchical arrangement of a calcium carbonate mineral phase known as aragonite with interconnected pores. The pores are tubular and slit-like, with a diverse range of pore size distribution that resembles the porosity and pore sizes of natural bone. The pores and channel framework are suitable for cell colonization and invasion of blood vessels. Some coral genera possess similar structure and physical properties to bone, such as Lobophylia , Acropora and Porites . Clinical applications of coral are restricted to those below 100 μm diameter pores and >20% pore volume [ 226 ]. Although coral skeletons have elegant microstructure, their mechanical properties are unfit for application as clinical bone repair scaffolds ( Fig. 5 A and B).

Sea urchins

Sea urchin skeletons have hierarchical porous structures. They have superior mechanical properties compared with corals and marine sponges. In particular, the hierarchical open-cell structure of Heterocentrotus mammillatus resembes human trabecular bone and is applicable for machinery processing because of its excellent mechanical property (compressive strength ~43 MPa) [ 228 ]. Another advantage in using sea urchin skeletons for bone tissue engineering is their interconnective porous structure, which facilitates cell penetration and vascular ingrowth [ 224 ] ( Fig. 5 C and D).

Molluscan shells

Molluscan shells are characterized by specific mineral-organic structures. Accordingly, they have been extensively used as a classic system model to study biomineralization mechanisms [ 229 ]. For example, organic scaffolds named conchixes were isolated from molluscan shells. The shells were demineralized gently by a EDTA-based method to acquire mineral-free biomaterials. Intriguingly, conchixes completely repeat the size and shapes of the shells. In the future, molluscan shells may have broad applications in biomineralization [ 230 ].

Siliceous skeletal structures

Silicon exists in nature as silicic acid. When concentrations are above 1–2 mM and pH is neutral, siloxane (Si-O-Si) bonds are formed between orthosilicic acid ([Si(OH) 4 ]) through a series of polycondensation reactions, resulting in the formation of silicon. Biosilica consists of glassy amorphous silica [ 231 ]. Ehrlich et al. reviewed the diversity and potential applications of biosilicon in detail. Biosilification is an ancient and fundamental process that involves incorporation of inorganic silicon into an organic matrix. Many unicellular and multicellular marine organisms produce minerals through this biological process. A variety of biosilicon structures are formed in sponges, diatoms, mollusks, crustaceans, algae, bacteria and viruses. The siliceous skeletons produced by marine organisms, especially sponges, have attracted the attention of scientists involved in the study of biomimtics and biomedicine [ 232 ]. Biosilica skeletons and natural bone structures are both formed through biomineralization and they are quite resemblant to each other. Thus, biosilificified organic matrices for foreseeable applications in tissue regeneration. Diataom biosilica is a composite material. Apart from silica, the diatom skeleton contains other elements such as zwitterionic proteins and long‐chain polyamines. The cell walls of diatoms (diatom frustules) possess optical and highly stable properties [ 233 ]. The spicules of demosponges are silica-based with triaxonic and hexactinic symmetry. Because of these repetitive organized structures, hierarchically arranged biosilica skeletons up to 2 m have been identified in selected hexactinellid sponge species [ 3 ].

Other hierarchical structures of marine organisms have also been reported. For example, cuttlebone, the endoskeleton of the mollusk Sepia officinalis , has an interconnected porous structure with 80% porosity and pore size between 200 and 500 μm [ 234 ]. A simple enzymatic and hydrogen peroxide-based treatment has been proposed to produce nanostructurally-organized sea dollar spines [ 235 ]. Because of their porosity, microstructure and biocompatibility, marine skeletons have great potential in bone tissue engineering.

Structural coloration

Marine organisms exhibit diverse colors because of the presence of colored molecules that absorb light (i.e. chlorophyll), luminescent compound (i.e. luciferin), as well as nano-structural and brightly-reflective cells. Marine organisms possess optical properties that are responsible for their colors. The bio-photonic structure in marine organisms consists of highly-ordered organic materials such as collagen and chitin [ 236 ]. For example, the blue iridescent stripes on the shell of the limpet Patella pellucida is produced by a microscopic mineralized multilayer with regular lamella thickness and gap spacings, which account for the light interference ( Fig. 6 A-E). Frustules of diatoms can also reflect ultraviolet light via their nanostructured silica [ 237 ]. Fig. 6 ( A ) Optical image of a Patella pellucida shell that reflects light. ( B) Optical image of reflection from a single stripe. ( C , D , E ) Types of microstructures observed in the shell of blue-rayed limpet. ( F , G ) Macroscopical and microscopical views of Tridacna maxima and T. derasa . ( F ) Top view of two T. maxima approximately 4–5 cm in length. ( G ) Transmission electron micrograph of a T. derasa iridocyte in cross section. ( A , B , C , D , E are reproduced from Ref. [ 236 ] with permission from the publisher; F , G are reproduced from Ref. [ 238 ] with permission from the publisher). Fig. 6

Apart from their integral macrostructure, photosynthetic cells also account for the brilliant colors of many marine organisms. Iridocytes, cells with optical behavior that are found in the epithelia of giant clams, contribute to the brilliant iridescent blue, green and gold colors of these molluscs. This phenomenon is attributed to the presence of Bragg lamellae (intracellular reflective structures) inside the iridocytes. The Bragg lamellae consist of repetitive layers with high and low refractive indices. Their unique light scattering phenomenon opens new vistas in the design of solar-transductive, optical and other photo-transductive devices [ 238 ] ( Fig. 6 F and G). The color in the alga Cystoseira tamariscifolia is produced by opal-like photonic crystals that are present within its photosynthetic cells [ 239 ].

Multilayers of guanine crystals are the basis of highly effiective reflectors for silvery fish. They are isolated from the fish scales and exhibit anisotropic light scattering properties, which could be controlled by magnetic field [ 240 ].

Medical applications

Anti-cancer activity

Cancer is a global medical concern. Malignant tumors threaten 8.8 million lives every year and are responsible for 1 out of 6 deaths globally. Clinical scientists have long been looking for less toxic and more efficacious approaches to combat cancer. Natural compounds, especially marine-derived materials, have immense potential in treating cancers because of their low cost and availability. It has been almost 50 years since the approval of cytarabine (aka. cytosine arabinoside), a marine-derived chemotherapeutic medication used to treat different forms of leukemia and non-Hodgkin's lymphoma. There are currently four approved marine-derived anti-cancer drugs. In addition, eighteen compounds are in various phases of clinical trials, six of which are already in the final stage of development [ 241 ].

Anti-cancer mechanism of marine-derived materials

Apoptosis downregulation of cancer cells is the principal obstacle encountered in cancer suppression. Accordingly, activation of apoptosis is an important target in anti-cancer therapy. There are two pathways to initiate apoptosis: the mitochondrial (intrinsic) pathway [ 242 ] and the receptor-mediated (extrinsic) pathway [ 243 ]. The intrinsic pathway of apoptotic cell death originates from an array of intracellular damages or stress signals including oxidative stress, DNA damage, cytokine withdrawal and endoplasmic reticulum stress [ 244 , 245 ]. The extrinsic pathway is activated via specific receptors such as tumor necrosis factor-family receptors or Fas (CD95/TNFRSF6/Apo-1) [ 246 ]. To date, more than 60 marine sponges have demonstrated anti-cancer potential through the induction of apoptosis. However, the chemistry and anti-cancer mechanisms of pro-apoptotic marine-derived compounds have not been completely elucidated.

Marine seaweeds have been used to synthesize a wide range of bioactive substances in accordance with their maturity and ability to interact with environmental changes. Among the abundant pool of compounds derived from seaweed, terpenes, polysaccharides and polyphenols are of clinical relevance in terms of their anti-cancer activities [ 247 ]. Fucoidans refer to an array of sulfated polysaccharides that originate from the cell wall of brown seaweeds. These sulfated polysaccharides are the principal components of the sticky molecules present in brown seaweeds [ 248 ]. Compared with high molecular-weight fucoidans, the low molecular-weight versions are more biologically active [ 249 ]. The Akt signaling pathway, a significant signal transduction pathway, enhances extracellular signals on growth and survival. Studies have shown that fucoidans inhibit phosphorylation of proteins related to Akt and phosphoinositide 3-kinase (PI3K) in in vitro and in vivo models. This, in turn, inhibits tumor cell proliferation [ 250 ].

Approved drugs

Cytarabine is the first commercially available anti-cancer drug of marine origin [ 251 ]. It is a pyrimidine nucleoside analog that functions as a cytotoxic drug that acts selectively on the cell cycle. It functions principally in the S phase of cell division when the cells are undergoing DNA synthesis [ 252 ]. Cytarabine was approved by the US Food and Drug Administration (FDA) and commercialized under the trade name Cytosar-U®. Cytosar-U® has been recognized as a mainstay drug in the management of acute myeloid leukemia, acute lymphoblastic leukemia and chronic myelogenous leukemia [ 253 ]. Other marine-derived anti-cancer formulations have since been available. For example, CPX-351 (Vyxeos®), a liposomal formulation, consists of cytarabine and daunorubicin in a 5:1 ratio. Delivery of CPX-351 to the leukemia cells of patients diagnosed with secondary acute myeloid leukemia resulted in significant improvement in the overall survival status, compared with conventional standard of care [ 254 ].

Trabectedin (Yondelis®), an extract from the Caribbean tunicate Ecteinascidia turbinate , has also been approved by the European Medicines Agency and by the US FDA for the treatment of advanced soft tissue sarcomas. Trabectedin is a tetra-hydro isoquinoline alkaloid that can be produced synthetically [ 255 ]. This molecule acts against crucial processes in tumor cells as well as the tumor microenvironment via tissue-resident histiocytes and tumor-associated macrophages [ 256 ]. This agent demonstrated remarkable efficacy in different settings, including treatment-naïve and pre-treated patients with local advanced disease and tumor metastasis [ 257 ]. A phase III multicenter randomized clinical trial on the safety and efficacy of Trabectedin has been conducted ( NCT01343277 ; ClinicalTrials.gov ) [ 258 ]. In this clinical trial, patients with metastatic leiomyosarcoma or liposarcoma after failure of conventional chemotherapy were included. Recall after ten years of treatment demonstrated acceptable treatment outcomes without detrimental side effects.

Eribulin (Halaven®) is the third market-authorized formulation for combating cancer. Eribulin mesylate (eribulin) is the analog of halichondrin B, a natural product from marine-sponge [ 259 ]. Eribulin is now used as a third-line (United States) or second-line (Europe) formulation to address pretreated metastatic breast cancer [ 260 ]. Approved for use in more than 50 countries in the last decade, eribulin is the only anti-cancer drug showing improved overall survival and acceptable toxicity profile, especially for serious pre-treated patients with metastatic breast cancer [ 261 ]. A phase II non-randomized clinical trial demonstrated the tolerability and effectiveness of eribulin for partients with advanced or metastatic soft-tissue sarcoma ( NCT03810976 ; ClinicalTrials.gov ) [ 262 ]. Apart from its remarkable efficacy in treating breast cancer and sarcoma, eribulin also showed anti-cancer activity against other tumor types, such as non-small cell lung cancer [ 263 ], tumor metastases [ 264 ] and gastric cancer [ 265 ].

The CD30-targeting antibody-drug conjugate (ADC) brentuximab vedotin (Adcetris®) is derived from a sea hare known as Dolabella auricularia . It is the first commercially available medication to treat the principal cells in Hodgkin's lymphoma (HL) such as malignant Hodgkin and Reed/Sternberg cells via affecting the tumor microenvironment. Brentuximab vedotin was rapidly approved by the US FDA in 2011 to treat systemic anaplastic large cell lymphoma (sALCL) and relapsed classical HL. The CD30 membrane receptor, one of the tumor necrosis factor receptors, is expressed extensively on specific tumor cells, especially in classical HL and sALCL. For normal cells, CD30 shows limited expression. Taking all these advantages into account, the CD30 membrane receptor is currently used as a potential target for ADC-related therapy [ 266 , 267 ]. Brentuximab vedotin, an ADC, binds to the CD30 antibody and conjugates to the monomethyl auristatin E, a dolastatin 10 synthetic analog, via a protease cleavable linker [ 268 ]. Brentuximab vedotin provides patients with sustained, progression-free survival (PFS), instead of best supportive care alone following autologous hematopoietic stem cell transplant. In addition, peripheral neuropathy, the most common and unsatisfactory side effect of chemotherapy, was alleviated in 90% of the patients [ 269 ].

Agents in clinical trials

Eighteen candidates based on marine-derived metabolites are currently enrolled in the oncological pipeline ( Table 3 ). These trials reflect preliminary interests in the marine-derived anti-cancer market. Table 3 Marine-derived chemotherapeutics in clinic trials. Table 3 Stage Compound Name Source Molecular Target Interventions Cancer Types Status NCT number Refs Phase III Plitidepsin (Aplidin®) Aplidium albicans Rac1 and JNK activation Plitidepsin; Dexamethasone Relapsed/refractory myeloma Completed; Has Results NCT01102426 [ 270 ] [ 271 ] Phase III Plinabulin Aspergillus ustus Inhibit tubulin polymerization Plinabulin; Nivolumab Recurrent or metastatic non-small cell lung cancer in Stage IIIB-IV, Terminated; Has Results NCT02846792 [ 272 ] [ 273 ] Phase III Depatuxizumab mafodotin ABT-414 N/A Noncleavable maleimidocaproyl linker, epidermal growth factor receptor and microtubule cytotoxin ABT-414; Temozolomide; Whole Brain Radiation Glioblastoma multiforme Completed NCT01800695 [ 274 ] [ 275 ] Phase III Salinosporamide A Salinospora tropica Suppressing the MAPK pathway Marizomib; Temozolomide; Radiotherapy Newly diagnosed glioblastoma Active, not recruiting NCT03345095 N/A Phase III Lurbinectedin (Zepsyre®) Trabectedin Phosphorylated RNA polymerase II Lurbinectedin; Pembrolizumab Small cell lung carcinoma Recruiting NCT04358237 [ 276 ] Phase II Polatuzumab vedotin DCDS-4501A Dolabella auricularia CD79b and microtubules Obinutuzumab;Pinatuzumab Vedotin;Polatuzumab Vedotin;Rituximab Relapsed or refractory B-Cell non-Hodgkin's lymphoma Completed Has Results NCT01691898 [ 277 ] Phase II Glembatumumab vedotin CDX-011 Dolabella auricularia Inhibit microtubule and monomethyl auristatin E Capecitabine;CDX-011 Recurrent osteosarcoma Completed Has Results NCT02487979 [ 278 ] Phase II Glembatumumab vedotin CDX-011 Dolabella auricularia Inhibit microtubule and monomethyl auristatin E Glembatumumab vedotin; CDX-301 Advanced melanoma Terminated Has Results NCT02302339 [ 279 ] Phase II Glembatumumab vedotin CDX-011 Dolabella auricularia Inhibit microtubule and monomethyl auristatin E Glembatumumab Vedotin Metastatic or locally-recurrent uveal melanoma Completed Has Results NCT02363283 [ 280 ] Phase II Tisotumab vedotin (HuMax®-TF-ADC) Dolastatin 10 Inhibit microtubules Tisotumab Vedotin (HuMax-TF-ADC) Bladder cancer, ovary cancer, prostate cancer, cervix cancer, endometrium cancer, lung cancer, esophagus cancer and squamous cell carcinoma of the head and neck Completed NCT02001623 [ 281 ] Phase II Telisotuzumab vedotin ABBV-399 Dolastatin 10 c-Met ABBV-399 Recurrent squamous cell lung carcinoma and stage IV squamous cell lung carcinoma AJCC V7 Active, not recruiting NCT03574753 [ 282 ] Phase II Telisotuzumab vedotin ABBV-399 Dolastatin 10 c-Met Telisotuzumab vedotin Non-small cell lung cancer Recruiting NCT03539536 N/A Phase II AGS-16C3F Dolastatin 10 ENPP3 and Inhibit Microtubules AGS-16C3F Metastatic renal cell carcinoma Active, not recruiting Has Results NCT02639182 N/A Phase II GSK2857916 Dolastatin 10 B-cell maturation antigen GSK2857916 and Pembrolizumab Multiple myeloma Recruiting NCT03848845 [ 283 ] Phase II PM060184 Plocabulin Lithoplocamia lithistoides Microtubules PM060184 Advanced colorectal cancer Unknown NCT03427268 [ 284 ] Phase II Ladiratuzumab vedotin SGN-LIV1A Dolastatin 10 LIV-1 and microtubules ladiratuzumab vedotin Small cell lung cancer, esophageal squamous cell carcinoma, gastroesophageal junction adenocarcinoma, squamous, non-small cell lung cancer, non-squamous head and neck squamous cell carcinoma, gastric adenocarcinoma, prostate cancer and melanoma Recruiting NCT04032704 [ 285 ] Phase II Enfortumab vedotin ASG-22ME Dolastatin 10 Nectin-4 and microtubules Enfortumab vedotin, pembrolizumab, cisplatin, carboplatin, gemcitabine Urothelial cancer Recruiting NCT03288545 [ 286 ] Phase III Enfortumab vedotin ASG-22ME Dolastatin 10 Nectin-4 and microtubules Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection, Enfortumab Vedotin Urinary bladder cancer, muscle-invasive Recruiting NCT03924895 N/A Phase I Enfortumab vedotin ASG-22ME Dolastatin 10 Nectin-4 and microtubules Enfortumab vedotin Metastatic urothelial cancer Completed NCT03070990 [ 287 ] Phase I Enfortumab vedotin ASG-22ME Dolastatin 10 Nectin-4 and microtubules ASG-22CE, AGS-22M6E Neoplasms Completed NCT01409135 N/A Phase I ABBV-085 Dolastatin 10 from Symploca sp. Direct against LRRC15 on CAFs Cytotoxic drug through antimitotic activity PF-06647020 Advanced solid tumors, squamous cell carcinoma of the head and neck carcinoma of the breast, undifferentiated pleomorphic sarcoma Completed NCT02565758 [ 288 ] [ 289 ] Phase I PF-06647020 Marine polyphenols from seaweeds PTK7-targeted; Cytotoxic anti-cancer agent ASG-15ME Breast cancer Recruiting NCT03243331 [ 290 ] [ 291 ] [ 292 ] Phase I ASG-15ME Dolastatin 10 from Symploca sp. Target SLITRK6 Microtubule-disrupting agent. AGS-67E Metastatic urothelial cancer Completed NCT01963052 [ 293 ] [ 294 ] [ 295 ] Phase I AGS-67E Dolastatin 10 from Symploca sp. Target CD37 Anti-tubulin activities AGS67E Relapsed lymphoid malignancy Refractory lymphoid malignancy Completed NCT02175433 [ 296 ]

Antimicrobial agents

Multidrug resistance is a major healthcare threat caused by the abuse of antibiotics. Finding a substitute for antibiotics has attracted much attention. Marine organism-derived potential antimicrobial agents include peptides, terpenes, alkaloids and proteins. In this section, typical antimicrobial agents derived from marine organisms will be thoroughly discussed.

Antimicrobial peptides (AMPs) originate from marine organisms are structurally diverse. These AMPs exhibit a broad range of antibacterial activities. The AMPs are classified into four groups depending on their stuctures: amphipathic α-helical, β-sheet, β-hairpin or loops, as well as extended AMPs [ 297 ] ( Fig. 7 A). These AMPs target specifically to pathogens and overcome antimicrobial resistance efficiently. Marine-derived AMPs discovered in the last 5 years are discussed in this section. Fig. 7 ( A ) Antimicrobial peptides (AMPs) kill bacteria by inducing membrane damage and/or internalization. An alternative antibacterial mechanism of AMPs is intracellular targeting. Some AMPs act on intracellular targets by inhibiting cell wall synthesis, nucleic acid binding and synthesis, protein production and enzyme activity. ( B ) Schematic of crosslinking reactions between 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) and hexamethylene diisocyanate (HMDI) crosslinking agents. ( C ) Various forms in which chitin and chitosan constructs can be fabricated. ( D ) Gelatin used for bone tissue repair. ( A is reproduced from Ref. [ 298 ] with permission from publisher; B is reproduced from Ref. [ 299 ] with permission from publisher; C is reproduced from Ref. [ 300 ] with permission from publisher; D is reproduced from Ref. [ 301 ] with permission from publisher). Fig. 7

Tilapia piscidin 4 obtained from Nile tilapia is capable of killing Helicobacter pylori and halting the progression of gastric ulcer [ 302 ]. Venerupis philippinarum defensin (VpDef) is isolated from the clam V. philippinarum . Recombinant VpDef shows broad-spectrum antimicrobial activity. The minimum inhibitory concentration is as low as 50 μg/mL against Escherichia coli O157. Recombinant VpDef is resistant to proteinase digestion and stable under temperature and pH fluctuation. Hence, VpDef is suitable for large-scale production [ 303 ]. Cathelicidins derived from sea snakes are also regarded as potent candidates for peptide-based antimicrobial agents [ 304 ]. A study reporetd that cathelicidins kill bacteria within 1 h in zebrafish [ 305 ]. A peptidic compound obtained from Aneurinibacillus sp. YR247 , has excellent antifungal ability [ 306 ]. Theonellamides are dodecapeptides originated from the marine sponge Theonella sp. These dodecapeptides show attractive antifungal and cytotoxic bicyclic activities. Theonellamides bind to 3β-hydroxysterols on the yeast membrane surface and cause membrane damage [ 307 ]. Aeroplysinin-1 from Aplysina aerophoba demosponge acts as an antibacterial agent against clinically-relevant mircoorganisms [ 308 ]. In addition, chitin-based skeletal scaffolds from marine sponges covered with silver nanoparticles and silver-bromide exhibited excellent antibacterial ability. These scaffolds may be used in water filtration systems [ 309 ]. Apart from antimicrobial ability, hepcidins derived from the spotted scat Scatophagus argus also possess antiviral activities. Hepcidins effectively eliminate Siniperca chuatsi (Chinese perch) rhabdovirus and largemouth bass Micropterus salmoides reovirus [ 310 ].

Recent reports suggest that chitin-bromotyrosine hybrid scaffolds possess superior antimicrobial activities against clinical strains of Staphylococcus aureus , Enterococcus faecalis and Propionibacterium acnes . Marine-derived chitinous skeletons have long been identified as excellent three-dimensional biomaterials-based matrices [ 311 ]. Bromotyrosines possess multitarget activities including antimicrobial, anti-cancer, antiviral as well as cytotoxic traits [ 312 ]. In the chitin-bromotyrosine hybrid scaffolds, chitin is used as drug delivery vehicles because of its mesh-like structure and capillary network [ 313 ]. A recent study reported that simultaneous extraction of both chitin and bromotyrosine is feasible [ 219 ]. Typical chitin-bromotyrosine hybrid scaffolds such as aeroplysinin-1 demonstrated effective antibacterial activity in vitro [ 219 ]. Inhibition of microbial chitinases via these halogenated compounds are highly relevant [ 314 ]. From an economical perspective, demosponge-derived chitin-bromotyrosine hybrid scaffolds are easily available. For example, A. aerophoba , a kind of demosponge with abundant bromotyrosine, grows 10 cm annually and are located at 2–5 m beneath the sea level. This easily reachable ocean depth ensues a easily obtainable and sufficient supply of bromotyrosine. It is estimated that 99 g of bromotyrosine can be harvested from every 10 m 2 of A. aerophoba colony. Such an amount of extracted bromotyrosine value up to US$14,850,000 [ 219 ]. Although these naturally-occurring biomaterials possess immense potential, the gap between the ocean and clinical application remains abysmal. There is an urgent need for in-depth research in this exciting field.

Regrettably, the majority of AMPs have not undergone clinical trials. Several challenges have to be taken into consideration prior to untaking clinical trials. These challenges include how to achieve potent antimicrobial activities under physiological conditions such as pH, serum conditions, salinity, rapid degradation of AMPs by proteases as well as the high cost of production [ 298 ].

Tissue engineering and regenerative medicine

Tissue engineering refers to the promotion of tissue regeneration or replacement within the confines of engineering and life sciences. Tissue engineering utilizes 3D scaffolds for temporary support to provide a suitable environment and structure for tissue regeneration. Three dimensional scaffolds with suitable pore sizes are critical for cell migration, proliferation and diffusion of oxygen and nutrients. Qualified 3D scaffolds should possess appropriate biodegrading rate and excellent mechanical properties. In addition, low immunogenicity and low toxicity are highly-esteemed traits [ 225 , 315 , 316 ]. Many natural materials (e.g. gelatin, chitosan) and synthetic materials (e.g. bioactive ceramics and synthetic polymers) have been used for construction of scaffolds. Natural marine materials with unique and attractive architectures are promising candidates for the preparation of tissue engineering scaffolds.

Biomaterials extracted from marine organisms

Natural polymers are important components of the extracellular matrix. They exhibit superior biocompatibility and low immunogenic potential. Collagen obtained from marine organisms may be used for preparation of 3D composites with excellent osteogenesis potential. Scaffolds prepared by combining marine bioapatite particles with marine collagen demonstrate superior mechanical properties, bioactivity and ability to promote osteogenic differentiation ( Fig. 7 B) [ 299 ]. Gelatin has been extensively investigated as 3D scaffolds for bone tissue repair and regeneration ( Fig. 7 D). Several collagen/gelatin-based products are commercially available for bone tissue engineering. These products include DBX® and RegenOss® [ 317 ] ( Table 4 ). Table 4 Biomaterials from marine organisms applied in tissue engineering. Table 4 Biomaterials Marine Sources Tested cell types Cell viability or improved properties Application Advantages(A) and disadvantage (DA) Refs Gelatin methacryloyl Cold water fish NIH3T3 cells 90% Tissue engineering and drug delivery A: High degradation rate, appropriate melting and gelling points (~37 °C) DA: low compressive moduli [ 332 ] Collagen Salmon skin Mesenchymal stem cells Improved proliferative and differential ability of mesenchymal stem cells Bone tissue engineering A: Excellent mechanical properties, increased degradation rate and the compressive strength [ 333 ] Shark skin ( Prionace glauca ) Osteoblast-like cell Majority of the cells are viable Bone tissue engineering A: Bioactive stable composite structures, feasibility, low cost [ 299 ] Fish T-Lymphocyte leukemia cell lines and osteoblast Decreased (T-cells), Improved osteogenic ability (osteoblast) Bone tissue engineering A: Biocompatibility, high stiffness, low biodegradation rate, and osteogenesis ability [ 334 ] Sea urchin Fibroblast Increased proliferation rate Tissue regenerative medicine A: Biocompatiblity, mechanically stable in wet conditions, resemblance the dermal layer in structure and function. [ 334 ] Alginate Brown sea algae Mesenchymal stem cells Increased cell number Bone tissue engineering A: Excellent mechanical properties, suitability for cell attachment and spread [ 335 ] Human osteoblasts Improved osteoblasts proliferation Bone tissue engineering, drug delivery A: Suitable physical performance, bioactivity [ 336 ] Chitin Demosponge Ianthella basta Mesenchymal stromal cells High percentage of viability, improved differential ability Tissue engineering and regeneration, such as artificial skin A: Ability to improve adipogenic differentiation of cells, simplicity of the isolation, interconnected porosity and excellent biocompatibility [ 337 ] Demosponge Aplysina aerophoba Human mesenchymal stromal cells Increased metabolic activity, cell numbers, and differential ability Tissue engineering A: Excellent cytocompatibility [ 338 ] Collagen-chitosan-fucoidan cryogels Jellyfish (collagen), brown algae(fucoidan), giant squid(chitosan) L929 cells 70% Tissue engineering A: Mechanical stability, adequate porosity for cell proliferation [ 339 ]

Chitosan has been extensively investigated for bone regeneration applications. It is positively-charged with excellent biodegradability, biocompatibility, muco-adhesive and hemostasis properties ( Fig. 7 C). A chitosan-polycaprolactone copolymer improves the ability of pre-osteoblastic cells to form bone tissue [ 318 ]. Combining chitosan with other polymers or biomaterials helps to control its porosity and water retention capability, reduce its biodegradation rate, increase its mechanical properties and enhance its bioactivity [ 319 ]. The use of a chitosan scaffold with stromal vascular fraction aliquots demonstrated excellent bone regeneration ability [ 320 ]. In vitro experiments showed that chitin-based scaffold supported chondrocyte attachment and extracellular matrix synthesis [ 321 ]. In vivo experiment showed that whitlockite/chitosan scaffold significantly improves bone repair in skull defect [ 322 ]. The chemotaxis and regenerative potential of human dental pulp cells could also be enhanced by porous chitosan-calcium aluminate scaffolds [ 323 ]. Incorporation of silver-doped bioactive glass in chitosan enhances the odontogenic differentiation potential of dental pulp stem cells [ 324 ]. The mechanical properties, bioactivity and osteogenic potential of chitosan-based scaffolds are improved when chitosan is combined with other polymers and biomaterials such as hydroxyapatite, bioglass ceramic and silicon dioxide [ 300 ]. The production of 3D chitinous scaffolds using microwave-assisted extraction is efficient and environmentally friendly. Such a fabrication method facilitates the application of 3D chitinous scaffolds in the biomedical and technological arena [ 325 ].

Three-dimensional bioprinting is rapidly developing in tissue engineering and regeneration. Bioprinting is accomplished through layer-by-layer deposition of cell-containing biomaterials in a predetermined structural architecture. High-resolution printed cell-containing scaffolds are biocompatible, biodegradable, bioactive and possess optimal mechanical properties ( Fig. 8 A). Compared with synthetic materials, 3D bioprinting using marine-derived biopolymers have additional advantages such as resemblance to extracellular matrix composition or structure and self-assembling capability [ 326 ] ( Table 5 ) Fig. 8 A ) Properties of bioink in 3D bioprinting. B ) The structure of polyunsaturated fatty acids and originated oils. C ) Interrelations between polysaccharides of marine origin and drug delivery systems for advanced therapeutic applications. ( A is reproduced from Ref. [ 326 ] with permission from the publisher; B is reproduced from Ref. [ 327 ] with permission from the publisher; C is reproduced from Ref. [ 328 ] with permission from the publisher). Fig. 8 Table 5 Biomaterials from marine organisms applied in 3D bioprinting. Table 5 Biomaterials Marine Sources Tested cell types Cell density and viability Advantages(A) and disadvantages (DA) Application 3D bioprinting method Refs Alginate Brown algae Mesenchymal stem cells 85.0 ± 5.9% A: Spatially varying mechanical microenvironment extrusion printing Bone tissue engineering Extrusion printing [ 340 ] Alginate Brown algae Human mesenchymal stem cells 84% ± 0.7% A: Excellent scaffold fidelity and mechanical properties (higher alginate concentration); Excellent cell viability and cell spreading morphology (lower alginate concentration) Bone tissue engineering Extrusion printing [ 332 ] Silk-like protein (aneroin) Sea anemone Mouse pre-osteoblasts, rat myoblasts, mouse fibroblasts, and rat-derived mesenchymal stem cells 99% A: Accurate printability, structural integrity, and biocompatibility Cartilage or skeletal tissue regeneration Extrusion printing [ 341 ] Gelatin Cold water fish NIH3T3 cells Over 80% A: Inexpensive, high emulsion stability DA: low viscosity and rapid polymerization Drug delivery Extrusion printing [ 342 , 343 ] κ-carrageenan-gelatin hydrogel Carrageen C2C12 cells Over 90% A: Excellent structural stability and cell viability. Biological binder for tissue scaffolds Extrusion printing [ 344 ] Chitosan Crab shell Mouse pre-osteoblast cells Over 90% A: Good viscoelastic properties, stable under physiological conditions, proper viscosity values. Bone tissue engineering Extrusion printing [ 345 ] Carrageenan Red algae Mesenchymal stem cells Dead cells were negligible A: Excellent structural strength, cyto-compatible and non-toxic. Tissue engineering and regeneration Extrusion printing [ 346 ]

Researchers have combined agarose with collagen to produce a hydrogel blend for long-term cell encapsulation [ 347 ]. Tailored hydrogel blends formed by agarose-based bio-ink incorporating collagen or fibrinogen via 3D bioprinting support endothelial and fibroblast cell growth. These hydrogel blends enable the formation of a vascularized network to ensure adequate nutrition supply [ 348 ]. Gelatin is an attractive candidate for 3D bioprinting. To improve its mechanical modulus and degradation rate, gelatin is modified by methacrylation. The methacrylated gelatin supports cell adhesion and proliferation [ 349 ]. Interpenetrating hydrogels composed of alginate and gelatin exhibit excellent mechanical strength, swelling ratio, degradation and cell behavior, which meets the requirements for tissue engineering [ 350 ].

Marine skeletons used in tissue engineering

Marine skeletons have tailored structures. For example, seashells have dense lamellar structure. Cuttlebone and coral have an interconnected porous structure that resemble native bone structure. The porosity, microstructure, and crystallography of these structural marine skeletons is highly desirable for tissue engineering [ 223 ]. The architectures of marine skeletons have been described in Section 2.5 ( Table 6 ). Table 6 Marine skeletons and other hard tissue applied in tissue engineering. Table 6 Marine skeletons Effective constituents Porosity and pore size Properties Application Refs Shark teeth Apatitic (hydroxyapatite and apatite-(CaF)), non-apatitic (whitlockite), and an apatitic phase (fluorapatite), Pore size: ~50 μm and ~0.5–1 μm) Enrichments of specific trace elements (Mg, F); Improved proliferation and osteogenic activity of cells Bone tissue regeneration [ 352 ] Mussels and oysters Calcium carbonate Particle size: 1.5 μm Enhanced ECM mineralization and osteoblastic differentiation of MSC Bone tissue regeneration [ 353 ] Coral Hydroxyapatite Porosity: 70–75% Excellent osseous tissue formation, carrier for growth factors Tissue regeneration [ 354 ] Acropora coral Pores size: 412 ± 212 μm, porosity: 12 ± 4% Interconnected large pores Tissue regeneration [ 355 ] Cuttlebone Porosity: 90.4 ± 3.5% Interconnective porous structure; High protein adsorption rate; promotes osteogenic differentiation of MSC Bone tissue regeneration [ 356 ] Cuttlebone Biphasic Calcium Phosphate N/A Excellent degradability and bioactivity Bone tissue engineering [ 357 ] Marine sponge Aplysin aarcheri Chitinous scaffolds N/A 3D chitinous scaffold for calcium carbonate deposition Developed mineralized scaffolds [ 358 ] Coral microparticles Calcium carbonate Porosity: 99.05% Enhanced compressive properties; promotes more robust osteogenic differentiation of mesenchymal stromal cells, Bone regeneration. [ 359 ] Deep-sea bamboo coral Calcareous structures alternated with smaller proteinaceous nodes of gorgonin N/A Excellent potential for colonization with human osteoblasts and osteoclasts Tissue regeneration [ 360 ]

Calcium phosphate hydrothermally-converted from coral resembles chemical composition of natural bone tissue. Skeletons of coral such as Pocillopora verrucosa and Acropora formosa meet the requirement of 3D scaffolds for bone tissue engineering [ 329 ]. Two reef-building coral skeletons derived from Goniopora coral and Porites coral have been used commercially as bone graft materials [ 351 ]. Five effects of coral skeletons applied in this field include: (i) increase bioactivity via altering composition and crystal structure; ii) carry osteoinductive factors; (iii) enhance resorption properties; (iv) strengthen against compression forces in bone via converting to hydroxyapatite and fusing with hydroxyapatite nano-coatings; (v) increase bioactivity via interactions with surfaces [ 329 ] ( Fig. 9 A). Fig. 9 A ) New biomedical uses of coral skeletons. B ) Purported cardioprotective mechanisms associated with fish and fish oil-derived n-3 PUFAs. C ) Effect of marine-derived materials on bone metabolism via up-regulation of osteoblastogenesis and downregulation of osteoclastogenesis. Some are directly involved in osteoblastogenesis by increasing the expression of Runx2, BMP and other transcription factors. Others are dependent on the regulation of cytokine production (IL-6 and TNF). Marine-derived compounds suppress osteoclastogenesis through downregulating the expression of RANKL, NFATc1 and TRAP) ( A is reproduced from Ref. [ 329 ] with permission from the publisher; B is reproduced from Ref. [ 330 ] with permission from the publisher; C is reproduced from Ref. [ 331 ] with permission from the publisher). Fig. 9

Incorporation of bioactive molecules into coralline graft enhances its tissue regeneration properties. For example, the combination of coralline graft with vascular endothelial growth factor results in improved neovascularization and mineralization [ 361 ].

The contribution of marine sponges in bone tissue engineering is promising due to their excellent properties. For example, the interconnecting porous architecture of sponges promote the circulation of fluids. They also possess osteogenic properties, improve cell growth, facilitate bone formation and mineralization [ 225 ]. Chitinous scaffolds extracted from marine sponge Ianthella labyrinthus are suitable for cardiomyocyte attachment and growth [ 362 ]. Marine sponges combined with growth factors are effective for bone regeneration [ 363 ]. Bone regeneration results of surface-modified hydroxyapatite sponge scaffolds are comparable with the use of demineralized freeze-dried bone allografts [ 364 ]. In addition, 3D chitinous scaffolds from Aplysin aarcheri demosponges induce calcium carbonate precipitation. When used for bone tissue engineering, these scaffolds are biocompatible, biodegradable and osteoinductive [ 365 ].

Cuttlefish bone is also used as a bone graft material. Compared with commercial synthetic hydroxyapatite, bioactive hydroxyapatite-based bioceramics prepared from cuttlefish bone powder exhibit improved apatite deposition, cell proliferation and alkaline phosphatase activity [ 366 ]. The combination of inorganic components with biopolymers is a feasible method to improve the functional properties of bone graft materials. Silicon-substituted cuttlefish bone-derived hydroxyapatite has been reported to enhance osteoblast differentiation [ 367 ].

Teeth from shark are employed in experimental bone tissue engineering. Shark teeth contain not only apatite, but also comprise additional elements that are beneficial for bone regeneration, such as magnesium. Bioapatite obtained from thermal processing of shark enameloid and dentin is biocompatible and possesses osteogenic activity [ 352 ]. It is presumed that shark teeth may be used as a novel source of bioapatite for bone repair in the future [ 368 ].

Molecules obtained from marine organisms also play an important role in cartilage regeneration. Chondroitin sulfate present in natural cartilage is crucial for chondrogenesis. The mechanical performance of a chondroitin sulfate-containing double network gel is comparable with native cartilage tissue. In addition, this synthetic gel also induces chondrocytes differentiation [ 369 ]. Likewise, an elastic microporous gelatin/chondoitin-6-sulfate/hyaluronan-chitosan cryo-gel scaffold designed for cartilage tissue engineering demonstrated improved mechanical properties and chondrocyte differentiation response [ 370 ].

Drug delivery

The development of personalized, less invasive, sustained release therapeutic agents of drug delivery systems is an ideal target for patients. In the present section, approaches to construct advanced drug delivery systems via marine organisms as raw materials will be discussed.

Collagen-mediated drug delivery

Collagen molecules possess the amazing capability to self-assemble into higher-order fibrillar structures. Hence, collagen serve sas the pivotal component in drug delivery applications. Sophisticated approaches have developed as collagen-based drug delivery systems, such as capsules prepared from gelatin (denatured collagen), injectable hydrogels loaded with growth factor, corneal shields, collagen sponges used in chronic wounds as well as antibiotic dressings [ 371 , 372 ]. Moreover, collagen also serves as an attractive drug targeting site in several disease, such as lung and liver fibrosis, psoriasis and scleroderma [ 373 ]. In the models of these diseases, the use of collagen-binding proteins realizes the targeting and recognition via the signal molecule collagen. However, collagen has poor mechanical properties and inadequate thermal stability compared with synthetic polymers. Thus, the physicochemical properties of marine-derived collagens require modification by incorporation of other biomaterials to make them suitable for drug delivery.

Collagen molecules possess conservative sequences that permit specific collagen-protein interactions. Such interactions can either interfere with collagen-related diseases or supply collagen at the sites where normal collagen function is impaired [ 374 ]. A type IV collagen triple helical peptide has been investigated to bind tightly to target of some tumor cells such as CD44, a chondroitin sulfate proteoglycan receptor that is overexpressed in several tumor cells [ 375 ]. Liposomes loaded with doxorubicin and a triple-helical peptide-amphiphile were capable of targeting the over-expressed CD44 receptors in tumor sites, reducing tumor size to 60% compared with the control group [ 376 ].

Polysaccharide-mediated drug delivery

Marine polysaccharides have currently been applied in food, cosmetics and pharmaceutical industries ( Fig. 8 C). Algae are rich in marine polysaccharides. Commercial alginates originate principally from alginic acid in brown marine algae ( Phaeophyceae ). Alginate may also be obtained from marine bacterial sources such as Laminaria digitata , Laminaria hyperborea , Ascophyllum nodosum , Laminaria japonica and Macrocystis pyrifera via aqueous alkali solutions (NaOH) treatment [ 377 , 378 ].

Alginate hydrogels have been employed as drug delivery systems for a long time because of their biocompatibility, non-toxic nature and bio-availability. It is used as a stabilizer agent in pharmaceutical formulations to control drug release. For example, sodium alginate has long been processed as a tablet binding material. Alginic acid, nevertheless, has been currently used as a tablet disintegrating material with the aim of immediate drug release [ 377 ]. Alginate may also be used for pH-sensitive drug release in the colon region for treating patients with inflammatory bowel diseases [ 379 ].

Carrageenans are typical sulfated polysaccharides originated from the cell walls of red seaweeds. Carrageenans may be categorized accroding to their level of sulfation into kappa (κ), iota (ι), and lambda (λ) carrageenans, which contain one, two or three sulfate groups, respectively [ 380 ]. Because of their organized, ordered and stable networks as well as wide water-pockets, carrageenans are used as vehicles to deliver drug cargoes [ 381 ]. Carrageenan-based formulations used as drug delivery systems include hydrogels, hydrogel beads, microspheres and microparticles [ [382] , [383] , [384] ]. Carrageenan is an ideal excipient for controlled release in drug delivery systems. The dissolution rate and mechanical properties of carrageenan are greatly affected by its sulfation extent. As a result, the drug loading capacity and the release efficiency of the loaded cargo are also altered [ 385 ]. κ-carrageenans resemble native glycosaminoglycans and form fragile hydrogels by ionic crosslinking. They can protect cells from strong shear forces and are excellent devices for cell encapsulation. Human mesenchymal stem cells remain predominatly viable and maintain their circular morphology after encapsulation with κ-carrageenan. Shear-thinning carrageenan-based hydrogels may be used as cell-delivering vehicles in cartilage tissue regeneration and 3D bioprinting [ 386 ].

Fucoidans are sulfated polysaccharides extracted from brown algae. Chitosan/fucoidan nanoparticles have been used experimentally for pulmonary delivery of gentamicin, a commonly used aminoglycoside antibiotic. These nanoparticles demonstrated a zero-order release of gentamicin for the first 10 h. This was followed by stable release of up to 72 h [ 387 ]. Moreover, chitosan/fucoidan nanoparticles were capable of sustained antibiotic release in simulated gastric fluid and effectively suppressed the growth of clinically-relevant pathogens such as S. aureus and E. coli [ 388 ].

Anticoagulant

Fucoidan participates in the blood coagulation cascade by interacting with the natural thrombin inhibitors including antithrombin, heparin cofactor II, activated factor II (thrombin) and activated factor X [ 389 , 390 ]. Fucoidan-modified surfaces possessed potent anticoagulation activity. The thrombin time threshold was prolonged when contacting with the fucoidan-modified surfaces. It is presumed that these fucoidan-modified surfaces may serve as the alternatives as anti-clotting devices such as blood storage bags [ 391 ]. Chitosan-fucoidan nanoparticles possess better in vitro anticoagulant activity than pristine fucoidan. Solid evidences showed that this hybrid nanoparticles could reduce thrombus formation even in a deep vein thrombosis model [ 392 ]. The positive surface charge present in chitosan-fucoidan nanoparticles contributes to the increase in activated partial thromboplastin time and is concentration dependent. It is inspiring that fucoidans also exhibit antithrombotic activity when administered orally. Low molecular weight fucoidans are better absorbed orally and have superior potent anti-thrombotic activity compared to medium molecular weight fucoidans [ 393 ].

Applications in other diseases

Cardiovascular diseases

Cardiovascular diseases (CVD) result in 17.3 million deaths per year and are the major cause of global deaths [ 394 ]. Long-chain omega-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid and docosahexaenoic acid, are produced by fish and other marine organisms. These PUFAs have already been used extensively to combat CVD ( Fig. 8 B). The mechanisms responsible for the use of PUFAs against CVD may be summarized as follows: i) modulation on the function of cardiac ion channels, such as Na and L-type Ca channels; ii) prevention of the transformation from arachidonic acid into pro-inflammatory eicosanoid; iii) anti-inflammatory mediators including enzymatically-oxygenated metabolites ( Fig. 9 B) [ 395 ]. The anti-inflammation properties of these fatty acids are prominent. The PUFAs are involved in the inhibition of leukocyte chemotaxis, interactions between leukocyte and endothelial cells, and secretion of inflammatory cytokines [ 396 ]. In murine models, long-chain monounsaturated fatty acids obtained from fish oil exhibited anti-atherogenic effects [ 397 ]. Clinical trials demonstrated that patients with acute myocardial infarction who took omega-3 fatty acids exhibited less adverse left ventricular remodeling and non-infarct myocardial fibrosis [ 398 ].

Bone diseases

Natural products derived from marine cyanobacteria, dinoflagellates, algae, sponges, soft corals, mollusks, fishes and mangroves significantly affect bone metabolism by inhibiting osteoclastogenesis and up-regulating osteoblastogenesis through regulation of the RANK/RANKL/osteoprotegerin pathway [ 331 ] ( Fig. 9 C).

Osteoporosis, the main cause of bone fracture among the elderly, is a systemic skeletal disorder characterized by low bone mass, micro architectural deterioration of bone tissue. Bisphosphonates refer to one of the most commonly used drugs for prevention and treatment of osteoporosis currently. Bisphosphonates induce apoptosis of osteoclasts, slowing bone loss and inhibiting the digestion of bone. However, prescription of even mild versions of bisphosphonates such as alendronic acid (Forsamax) may result in a medical reaction known as medication-related osteonecrosis of the jaw, a condition manifested by progressive bone destruction in the maxillofacial region of patients. Scientists have resorted to the marine ecosystem to search alternatives for combating osteoporosis-related bone resorption by modulating immune mediators such as transcription factors, immune receptors and key factors like RANKL/osteoprotegerin.

Marine-derived organisms also show considerable effects in remineralization of bone defects in disease models. The gastrointestinal digests obtained from the abalone Haliotis discus hannai have been used with fish collagen and the polymer poly(ε-caprolactone) to create experimental scaffolds via 3D printing for bone tissue engineering. Marine mesenchymal stem cells were seeded onto the fabricated scaffolds and the resultant constructs were implanted into rabbit tibia. The seeded scaffolds that contained osteogenic abalone intestine gastrointestinal digests demonstrated strong osteoinduction capability in the rabbit tibia model, with augmented mineralization levels and alkaline phosphatase activity [ 399 ].

Osteoarthritis causes chronic pain of joint involving the entire joint. In the presence of the nacre extract, which was able to induce the early calcium precipitation in cells (after 7 days), the expression levels of osteogenic markers, including osteocalcin, osteopontin and Runt-related transcription factor, were higher than in normal with a dose-dependent manner. Nacre extract is likely to stimulate MC3T3-E1 and osteoarthritic osteoblasts in vitro through containing ethanol-soluble diffusible factors. Thus, nacre extract was able to restore a physiological phenomenon and induce mineralization of osteoarthritis osteoblasts [ 400 ]. However, no in vivo experiments have been conducted owing possibly to the immunogenic properties of nacre.

Biselyngbyasides are macrolides derived from Lyngbya sp, a marine cyanobacterium. They display potent cytotoxicity against a great variety of human cancer cells. A study showed that biselyngbyasides were potent inhibitors of the sarco/endoplasmic reticulum calcium-ATPases, the Ca 2+ -pumps responsible for establishing calcium ion concentration gradient across the sacrco/endoplasmic reticulum membrane. By binding specifically to cancer cells and inhibition of the aforementioned calcium pumps, biselyngbyasides activates the endoplasmic reticulum stress response in the cancer cells and results in apoptotic cell death [ 401 ]. Furthermore, biselyngbyasides can inhibit RANKL-induced osteoclastogenesis and induce apoptosis of mature osteoclasts in murine RAW 264.7 cells at a low concentration [ 402 ].

Histone deacetylases (HDACs) play significant roles in regulating gene expression in cells epigenetically. They are emerging as therapeutic targets for treating an array of solid tumors and hematological malignancies. Largazole, extracted from the marine cyanobacterium Symploca sp, is a potent inhibitor of HDACs. It has already been approved by the FDA for cancer treatment [ 403 ]. Histone deacetylase inhibitors have also been used to treat non-malignant diseases involving pathological bone loss. Inhibition of HDACs by largazole results in increased Runx2 activation. This, in turn, suppresses bone resorption and increases bone formation, repair and regeneration [ 404 ]. Soft corals such as Sinularia maxima and Lobophytum crassum show potent antioxidant activity (peroxyl radical-scavenging and reducing activity) on pre-osteoblastic MC3T3-E1 cells and anti-osteoporosis capacity on pre-osteoclastic RAW 264.7 cells [ 405 ].

Diabetes

Polyphenol obtained from marine algae has the ability to control diabetes mellitus. Experiments in vitro and in vivo have testified that polyphenol extracted from the brown macroalga Lessonia trabeculate significantly attenuated hyperglycemia and hyperlipidemia in high-fat diet and streptozotocin-induced diabetic rats. Purified polyphenol extracts exhibited superior activities such as antioxidant, α-glucosidase and lipase inhibition. Compared with control diabetic rats, fasting blood glucose levels and insulin levels are lower in diabetic rats treated with polyphenol extracts [ 406 ]. A dieckol-rich extract derived from the brown alga Ecklonia cava was used for pre-diabetic human subjects in a randomized, double-blind clinical trial. The results demonstrated that the levels of postprandial hyperglycemia, insulin and C-peptide were significantly reduced after 12 weeks [ 407 ].

Bioactive marine peptides are efficient in management of type 2 diabetes mellitus. The proposed mechanisms include protection of pancreatic β-cells, enhancing secretion of insulin stimulated by glucose, influence on the insulin sensitivity and its signaling pathways, and inhibiting bioactive peptides to dipeptidyl peptidase IV, α-amylase and α-glucosidase activities [ 408 ].

Other applications

Cosmeceutical applications

Marine-derived biomaterials also have great cosmeceutical potential. Recently, the combination of cosmeceuticals with bioactive ingredients obtained from marine organisms has become the hallmark of cosmetic industries [ 409 ].

Biologically-active proteins and peptides from marine sources possess a broad range of biological activities, including antioxidant, anti-aging, anti-photoaging and antimicrobial activities. Thus, they have attracted great attention in the pharmaceutical and cosmeceutical industries. Collagen is the major component of skin and it may decrease with age. This is the main reason why collagen is utilized extensive in cosmeceuticals like skin and hair care. Collagen obtained from fish, jellyfish and cuttlefish has been investigated for its moisturizing, regenerating and film-forming properties. Collagen fillers are also used as hydrogels to produce cosmetic face masks [ 410 , 411 ]. Collagen is administered via subcutaneous injection for repairing dermatological defects, such as the reduction of wrinkles and healing of acne scars [ 412 ]. Bioactive peptides are obtained from organisms and seafood waste products through enzymatic hydrolysis. These bioactive peptides are employed for anti-aging, light protection, whitening, anti-wrinkle and skin soothing [ 409 ].

Chitosan is another promising cosmeceutical agent because of its biocompatibility, high charge density and muco-adhesive property. Blending chitosan with hyaluronic acid and collagen promotes hair health such as increase in thickness and mechanical properties [ 413 ]. Chitosan oligosaccharide inhibits undesirable changes in hairless mouse skin caused by 10 weeks of ultraviolet light radiation [ 414 ]. Chitosan also exhibits excellent properties to vehiculate active ingredients for cosmeceuticals [ 415 ]. Sponge chitin-based membranes exhibit excellent mechanical stability and electrochemical properties due to the specific structure of the chitinous skeleton derived from demosponges [ 416 ]. Other polysaccharides used as cosmetics include fucoidans, alginate and laminarin, carrageenan and ulvan [ 417 ]. For example, pre-processed laminarin protects skin from ultraviolet radiation. The proposed mechanisms for this protection include decreased oxidative stress and increased antioxidant enzyme production [ 418 ].

Hyaluronic acid is still the most important ingredient in cosmetics because of its ability to replenish skin moisture and make skin softer, smoother and more radiant [ 410 ]. Hyaluronic acid may be cross-linked with different materials, such as 1,4-butanediol diglycidyl ether, to render it more resistant to enzymatic degradation [ 419 ]. Hyaluronic acid-based formulations have been used for skin rejuvenation. These formulations, which include gels, creams, intra-dermal filler injections, dermal fillers, facial fillers, autologous fat gels, lotion, serum and implants, exhibit remarkable anti-wrinkle, anti-nasolabial fold formation, anti-aging and space-filling properties [ 410 ]. Fabrication of hyaluronic acid into different types of porous and 3D structures widens its application in cosmeceuticals [ 420 ].

Food applications

Marine-derived products have been utilized extensively in the food industry as ingredients, additives, preservatives and packaging materials. The last decade has witnessed an upsurge of interest by consumers toward health promotion food products. The health promotion effects of marine-derived ingredients are supported by growing evidence from recent studies. Collagen undergoes degradation with age. Hence, a lot of interest has been devoted to the use of marine-derived collagen for anti-aging applications. Marine-derived collagen is added to health-promoting diets as functional and nutritional ingredients. In addition, collagen derived from marine sources are used as food additives. To reduce food deterioration and spoilage, marine collagen can also function as antioxidants in films or coatings [ 421 ].

Marine-derived chitosan is used increasingly as food preservatives and fruit coatings because of its antimicrobial properties [ 420 ]. Chitosan has also been employed in food packaging to replace plastic packaging materials because of its biocompatibility, edibility, bioadhesivity and biodegradability [ 422 ].

Marine-derived polysaccharides have also been used in food industry. For example, alginate has potential to be employed as an eco-friendly food packaging material by reducing the dependence on fossil resources as well as cutting down carbon output [ 423 ]. Alginate has also been used as coatings for fruits and vegetables and as a gelling, thickening, stabilizing or emulsifying agent in food industry [ 424 ].

A novel polyvinyl alcohol biocomposite film containing cellulose nanocrystals extracted from seaweed has been used as food packaging because of its antimicrobial and antioxidant properties [ 425 ]. Seafood wastes contain important bioactive polysaccharides that are good candidates for food additives. For example, cellulose nanofibers isolated from the waste of brown algae have been used as milk thickeners because of their high viscosity and shear-thinning rheological property [ 426 ].

Perspectives and future directions

Environment pollution and energy shortage are the driving forces in human's quest for renewable and envionmental-friendly resources. The ocean appears to be a perfect choice. More than 70% of the earth's surface is covered by marine environment, the majority of which remain unexplored. Continuous research in this exciting field has unveiled a wide spectrum of biomaterials with superior properties including biocompatibility, biodegradability and bioactivity. Marine-derived materials have generated considerable inspirations as raw materials for bioengineering or building blocks for biomimetics [ 219 , 312 ]. The use of marine-derived materials has undergone a long journey from ancient times. Today, utilization of marine biomaterials has progressed to the industrial level. This is attributed to the advances in research and technology on processing of these biomaterials.

The safety of marine-derived biomaterials has become the principal concerns among users. Marine-derived materials are obtained from heterogeneous sources and most of them contain active biological macromolecules that have unknown immunogenicity. Residual proteins from marine-based biomaterials may lead to hypersensitivity reaction once a certain threshold is exceeded in human body. In addition, the microstructure and physiochemical properties of marine biomaterials are difficult to be standardized owing to the high batch-to-batch variations. Therefore, it is not easy for these biomaterials to be used in the biomedical arena because of stringent quality control requirements. Because the evaluation criteria for these biomaterials has not been well established, there still exists safety concerns associated with the use of marine-derived biomaterials in medicine. Thus, further study and refinement are necessary.

Despite the immense potential of marine-derive biomaterials, the conversion of raw ingredients into ready-to-use market products require further research. A multidisciplinary and multi-scale approach that covers the structures of biomaterials and the mechanisms of thier conversion into useable products is required. Further research and design of new products are impossible if the mechanisms of their formation and their structural characteristics are unknown [ 109 ]. Recent research principally follows the property-application pattern, which explores a bioactive material and identifies its market potential. This pattern narrows the gap between marine-derived biomaterials and their potential markets. Nevetheless, by following this pattern, researchers merely answer the question ‘how’ but do not explain ‘why’. Deeper research that digs into fundamental understand of these biomaterials is required to exploit their full market potential. This will involve financial support from the government as well as collaboration among scientists from interdisciplinary fields.

Declaration of competing interest

The authors declare no conflict of interests.

References

1 Ehrlich H. Marine Biological Materials of Invertebrate Origin first ed. 2019 Springer Nature Switzerland AG Switzerland

2 Mora C. Tittensor D.P. Adl S. Simpson A.G.B. Worm B. How many species are there on earth and in the ocean? PLoS Biol. 9 2011 e1001127 10.1371/journal.pbio.1001127 PMC3160336 21886479

3 Russo P. Kisialiou A. Lamonaca P. Moroni R. Prinzi G. Fini M. New drugs from marine organisms in alzheimer's disease Mar. Drugs 14 2016 5 21 10.3390/md14010005 PMC4728502 26712769

4 Khrunyk Y. Lach S. Petrenko I. Ehrlich H. Progress in modern marine biomaterials research Mar. Drugs 18 2020 589 635 10.3390/md18120589 PMC7760574 33255647

5 Nigrelli R.F. F Stempien M. Jr. Ruggieri G.D. Liguori V.R. Cecil J.T. Substances of potential biomedical importance from marine organisms, fed Proc 26 1967 1197 1205 5339263

6 West T.L. Brustein D.D. Freeze-dried bone and coralline implants compared in the dog J. Periodontol. 56 1985 348 351 2989477 10.1902/jop.1985.56.6.348

7 White E. Shors E.C. Biomaterial aspects of interpore-200 porous hydroxyapatite, dent Clin. North Am. 30 1986 49 67 3514293

8 Lopez E. Gill G.A. Camprasse G. Camprasse S. Lallier F. Soldering without transition (osteoassimilation) between the human maxillary bone and a compact dental implant in natural calcite from marine invertebrate C. R. Acad. Sci. III 309 1989 203 210 2504446

9 Demers C. Reggie Hamdy C. Corsi K. Chellat F. Tabrizian M. Yahia L. Natural coral exoskeleton as a bone graft substitute: a review Bio Med. Mater. Eng. 12 2002 15 35 11847406

10 Chiroff R.T. White E.W. Weber K.N. Roy D.M. Tissue ingrowth of replamineform implants J. Biomed. Mater. Res. 9 1975 29 45 1176509 10.1002/jbm.820090407

11 Peters W. Occurrence of chitin in Mollusca Comp. Biochem. Physiol. Part B Comp. Biochem. 41 1972 541 550

12 Ehrlich H. Maldonado M. Spindler K.D. Eckert C. Born T. Hanke R. Goebel C. Simon P. Heinemann S. Worch H. First evidence of chitin as a component of the skeletal fibers of marine sponges. Part I. Verongidae (demospongia: Porifera) J. Exp. Zool. B Mol. Dev. Evol. 308 2007 347 356 17285638 10.1002/jez.b.21156

13 Ehrlich H. Krautter M. Hanke T. Simon P. Knieb C. Heinemann S. Worch H. First evidence of the presence of chitin in skeletons of marine sponges. Part II. Glass sponges (hexactinellida: Porifera) J. Exp. Zool. B Mol. Dev. Evol. 308 2007 473 483 17520693 10.1002/jez.b.21174

14 Lahiji A. Sohrabi A. Hungerford D.S. Frondoza C.G. Chitosan supports the expression of extracellular matrix proteins in human osteoblasts and chondrocytes J. Biomed. Mater. Res. 51 2000 586 595 10880106 10.1002/1097-4636(20000915)51:4<586::aid-jbm6>3.0.co;2-s

15 Synowiecki J. Al-Khateeb N.A. Production, properties, and some new applications of chitin and its derivatives Crit. Rev. Food Sci. Nutr. 43 2003 145 171 12705640 10.1080/10408690390826473

16 Song E. Yeon Kim S. Chun T. Byun H.-J. Lee Y.M. Collagen scaffolds derived from a marine source and their biocompatibility Biomaterials 27 2006 2951 2961 16457878 10.1016/j.biomaterials.2006.01.015

17 Salvatore L. Gallo N. Natali M.L. Campa L. Lunetti P. Madaghiele M. Blasi F.S. Corallo A. Capobianco L. Sannino A. Marine collagen and its derivatives: versatile and sustainable bio-resources for healthcare Mater. Sci. Eng. C Mater. Biol. Appl. 113 2020 110963 110980 32487384 10.1016/j.msec.2020.110963

18 Govindharaj M. Roopavath U.K. Rath S.N. Valorization of discarded marine eel fish skin for collagen extraction as a 3D printable blue biomaterial for tissue engineering J. Clean. Prod. 230 2019 412 419

19 Sousa R.O. Alves A.L. Carvalho D.N. Martins E. Oliveira C. Silva T.H. Reis R.L. Acid and enzymatic extraction of collagen from atlantic cod (Gadus morhua) swim bladders envisaging health-related applications J. Biomater. Sci. Polym. Ed. 31 2020 20 37 31526303 10.1080/09205063.2019.1669313

20 Ferrario C. Leggio L. Leone R. Di Benedetto C. Guidetti L. Cocce V. Ascagni M. Bonasoro F. La Porta C.A.M. Carnevali M.D.C. Marine-derived collagen biomaterials from echinoderm connective tissues Mar. Environ. Res. 128 2017 46 57 27063846 10.1016/j.marenvres.2016.03.007

21 Coelho R.C.G. Marques A.L.P. Oliveira S.M. Diogo G.S. Pirraco R.P. Moreira-Silva J. Xavier J.C. Reis R.L. Silva T.H. Mano J.F. Extraction and characterization of collagen from antarctic and sub-antarctic squid and its potential application in hybrid scaffolds for tissue engineering Mater. Sci. Eng. C Mater. Biol. Appl. 78 2017 787 795 28576050 10.1016/j.msec.2017.04.122

22 Tziveleka L.A. Sapalidis A. Kikionis S. Aggelidou E. Demiri E. Kritis A. Ioannou E. Roussis V. Hybrid sponge-like scaffolds based on ulvan and gelatin: design, characterization and evaluation of their potential use in bone tissue engineering Materials (Basel) 13 2020 1763 1782 10.3390/ma13071763 PMC7178717 32283814

23 Blunt J.W. Copp B.R. Keyzers R.A. Munro M.H.G. Prinsep M.R. Marine natural products Nat. Prod. Rep. 33 2016 382 431 26837534 10.1039/c5np00156k

24 Corinaldesi C. Barone G. Marcellini F. Dell'Anno A. Danovaro R. Marine microbial-derived molecules and their potential use in cosmeceutical and cosmetic products Mar. Drugs 15 2017 1 21 10.3390/md15040118 PMC5408264 28417932

25 Huang H. Song Y. Li X. Wang X. Ling C. Qin X. Zhou Z. Li Q. Wei X. Ju J. Abyssomicin monomers and dimers from the marine-derived streptomyces koyangensis SCSIO 5802 J. Nat. Prod. 81 2018 1892 1898 30070834 10.1021/acs.jnatprod.8b00448

26 Cui J. Li Y. Wang S. Chi Y. Hwang H. Wang P. Directional preparation of anticoagulant-active sulfated polysaccharides from enteromorpha prolifera using artificial neural networks Sci. Rep. 8 2018 3062 3070 29449622 10.1038/s41598-018-21556-x PMC5814554

27 Gao Y. Zhang L. Jiao W. Chapter seven - marine glycan-derived therapeutics in China Zhang L. Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B 2019 Elsevier. Amsterdam 113 134

28 Pereira L. Critchley A.T. The COVID 19 novel coronavirus pandemic 2020: seaweeds to the rescue? Why does substantial, supporting research about the antiviral properties of seaweed polysaccharides seem to go unrecognized by the pharmaceutical community in these desperate times? J. Appl. Phycol. 32 2020 1875 1877 10.1007/s10811-020-02143-y PMC7263178 32836796

29 Venkatesan J. Anil S. Rao S. Bhatnagar I. Kim S. Sulfated polysaccharides from macroalgae for bone tissue regeneration Curr. Pharmaceut. Des. 25 2019 1200 1209 10.2174/1381612825666190425161630 31465280

30 Tsurkan M.V. Voronkina A. Khrunyk Y. Wysokowski M. Petrenko I. Ehrlich H. Progress in chitin analytics Carbohydr. Polym. 252 2021 117204 33183639 10.1016/j.carbpol.2020.117204

31 El Knidri H. Belaabed R. Addaou A. Laajeb A. Lahsini A. Extraction, chemical modification and characterization of chitin and chitosan Int. J. Biol. Macromol. 120 2018 1181 1189 30172808 10.1016/j.ijbiomac.2018.08.139

32 Brunner E. Richthammer P. Ehrlich H. Paasch S. Simon P. Ueberlein S. van Pée K.H. Chitin-based organic networks: an integral part of cell wall biosilica in the diatom Thalassiosira pseudonana Angew. Chem. Int. Ed. 48 2009 9724 9727 10.1002/anie.200905028 19924754

33 Khattak S. Wahid F. Liu L.P. Jia S.R. Chu L.Q. Xie Y.Y. Li Z.X. Zhong C. Applications of cellulose and chitin/chitosan derivatives and composites as antibacterial materials: current state and perspectives Appl. Microbiol. Biotechnol. 103 2019 1989 2006 30637497 10.1007/s00253-018-09602-0

34 Valcarcel J. Novoa-Carballal R. Pérez-Martín R.I. Reis R.L. Vázquez J.A. Glycosaminoglycans from marine sources as therapeutic agents Biotechnol. Adv. 35 2017 711 725 28739506 10.1016/j.biotechadv.2017.07.008

35 Cunha L. Grenha A. Sulfated seaweed polysaccharides as multifunctional materials in drug delivery applications Mar. Drugs 14 2016 42 82 10.3390/md14030042 PMC4820297 26927134

36 Apostolova E. Lukova P. Baldzhieva A. Katsarov P. Nikolova M. Iliev I. Peychev L. Trica B. Oancea F. Delattre C. Kokova V. Immunomodulatory and anti-inflammatory effects of fucoidan: a review Polymers 12 2020 2338 2359 10.3390/polym12102338 PMC7602053 33066186

37 Felician F.F. Xia C. Qi W. Xu H. Collagen from marine biological sources and medical applications Chem. Biodivers. 15 2018 e1700557 10.1002/cbdv.201700557 29521032

38 Cicciù M. Fiorillo L. Cervino G. Chitosan use in dentistry: a systematic review of recent clinical studies Mar. Drugs 17 2019 417 431 10.3390/md17070417 PMC6669505 31319609

39 Mishra A. Pandey R.K. Manickam N. Antibacterial effect and physical properties of chitosan and chlorhexidine-cetrimide-modified glass ionomer cements J. Indian Soc. Pedod. Prev. Dent. 35 2017 28 33 28139479 10.4103/0970-4388.199224

40 Wysokowski M. Petrenko I. Stelling A L. Stawski D. Jesionowski T. Ehrlich H. Chitin as a versatile template for extreme biomimetics Polymers 7 2015 235 265

41 Petrenko I. Bazhenov V.V. Galli R. Wysokowski M. Fromont J. Schupp P.J. Stelling A.L. Niederschlag E. Stöcker H. Kutsova V.Z. Jesionowski T. Ehrlich H. Chitin of poriferan origin and the bioelectrometallurgy of copper/copper oxide Int. J. Biol. Macromol. 104 2017 1626 1632 28119189 10.1016/j.ijbiomac.2017.01.084

42 Morkaew T. Pinyakong O. Tachaboonyakiat W. Structural effect of quaternary ammonium chitin derivatives on their bactericidal activity and specificity Int. J. Biol. Macromol. 101 2017 719 728 28363655 10.1016/j.ijbiomac.2017.03.159

43 Yu N. Cai T. Sun Y. Jiang C. Xiong H. Li Y. Peng H. A novel antibacterial agent based on AgNPs and Fe3O4 loaded chitin microspheres with peroxidase-like activity for synergistic antibacterial activity and wound-healing Int. J. Pharm. 552 2018 277 287 30291960 10.1016/j.ijpharm.2018.10.002

44 Sun Z. Shi C. Wang X. Fang Q. Huang J. Synthesis, characterization, and antimicrobial activities of sulfonated chitosan Carbohydr. Polym. 155 2017 321 328 27702518 10.1016/j.carbpol.2016.08.069

45 Soares Da Costa D. Reis R.L. Pashkuleva I. Sulfation of glycosaminoglycans and its implications in human health and disorders Annu. Rev. Biomed. Eng. 19 2017 1 26 28226217 10.1146/annurev-bioeng-071516-044610

46 Vasconcelos A. Pomin V. the sea as a rich source of structurally unique glycosaminoglycans and mimetics Microorganisms 5 2017 51 68 10.3390/microorganisms5030051 PMC5620642 28846656

47 Houghton D. Wilcox M.D. Chater P.I. Brownlee I.A. Seal C.J. Pearson J.P. Biological activity of alginate and its effect on pancreatic lipase inhibition as a potential treatment for obesity Food Hydrocolloids 49 2015 18 24 26146432 10.1016/j.foodhyd.2015.02.019 PMC4429962

48 Nakazono S. Cho K. Isaka S. Abu R. Yokose T. Murata M. Ueno M. Tachibana K. Hirasaka D.K. Kim Anti-obesity effects of enzymatically-digested alginate oligomer in mice model fed a high-fat-diet Bioact. Carbohydrates Diet. Fibre. 7 2016 1 8

49 Idota Y. Kogure Y. Kato T. Ogawa M. Kobayashi S. Kakinuma C. Yano K. Arakawa H. Miyajima C. Kasahara F. Cholesterol-lowering effect of calcium alginate in rats Biol. Pharm. Bull. 39 2016 62 67 26725428 10.1248/bpb.b15-00503

50 Freeman F.E. Kelly D.J. Tuning alginate bioink stiffness and composition for controlled growth factor delivery and to spatially direct MSC fate within bioprinted tissues Sci. Rep. 7 2017 17042 17053 29213126 10.1038/s41598-017-17286-1 PMC5719090

51 Tabriz A.G. Hermida M.A. Leslie N.R. Shu W. Three-dimensional bioprinting of complex cell laden alginate hydrogel structures Biofabrication 7 2015 045012-045022 10.1088/1758-5090/7/4/045012 26689257

52 Dalheim M. Vanacker J. Najmi M.A. Aachmann F.L. Strand B.L. Christensen B.E. Efficient functionalization of alginate biomaterials Biomaterials 80 2016 146 156 26708091 10.1016/j.biomaterials.2015.11.043

53 Zhu B. Ni F. Sun Y. Zhu X. Yin H. Yao Z. Du Y. Insight into carrageenases: major review of sources, category, property, purification method, structure, and applications Crit. Rev. Biotechnol. 38 2018 1261 1276 29764223 10.1080/07388551.2018.1472550

54 Sedayu B.B. Cran M.J. Bigger S.W. A review of property enhancement techniques for carrageenan-based films and coatings Carbohydr. Polym . 216 2019 287 302 31047069 10.1016/j.carbpol.2019.04.021

55 Khotimchenko M. Tiasto V. Kalitnik A. Begun M. Khotimchenko R. Leonteva E. Bryukhovetskiy I. Khotimchenko Y. Antitumor potential of carrageenans from marine red algae Carbohydr. Polym. 246 2020 116568 32747241 10.1016/j.carbpol.2020.116568

56 Cosenza V.A. Navarro D.A. Pujol C.A. Damonte E.B. Stortz C.A. Partial and total C-6 oxidation of gelling carrageenans. Modulation of the antiviral activity with the anionic character Carbohydr. Polym. 128 2015 199 206 26005156 10.1016/j.carbpol.2015.04.030

57 Dos Santos-Fidencio G.C. Gonçalves A.G. Noseda M.D. Duarte M.E.R. Ducatti D.R.B. Effects of carboxyl group on the anticoagulant activity of oxidized carrageenans Carbohydr. Polym. 214 2019 286 293 30925999 10.1016/j.carbpol.2019.03.057

58 Hauser C. Thielmann J. Muranyi P. Chapter 46 - organic acids: usage and potential in antimicrobial packaging Barros-Velázquez J. Antimicrobial Food Packaging 2016 Academic Press San Diego 563 580

59 Shankar S. Reddy J.P. Rhim J.W. Kim H.Y. Preparation, characterization, and antimicrobial activity of chitin nanofibrils reinforced carrageenan nanocomposite films Carbohydr. Polym. 117 2015 468 475 25498660 10.1016/j.carbpol.2014.10.010

60 David S. Shani Levi C. Fahoum L. Ungar Y. Meyron-Holtz E.G. Shpigelman A. Lesmes U. Revisiting the carrageenan controversy: do we really understand the digestive fate and safety of carrageenan in our foods? Food Funct. 9 2018 1344 1352 29469913 10.1039/c7fo01721a

61 Qin H.M. Gao D. Zhu M. Li C. Zhu Z. Wang H. Liu W. Tanokura M. Lu F. Biochemical characterization and structural analysis of ulvan lyase from marine alteromonas sp. Reveals the basis for its salt tolerance Int. J. Biol. Macromol. 147 2020 1309 1317 31751708 10.1016/j.ijbiomac.2019.10.095

62 Gao J. Du C. Chi Y. Zuo S. Ye H. Wang P. Cloning, expression, and characterization of a new PL25 family ulvan lyase from marine bacterium alteromonas sp. A321 Mar. Drugs 17 2019 568 578 10.3390/md17100568 PMC6836179 31597240

63 Li P. Wen S. Sun K. Zhao Y. Chen Y. Structure and bioactivity screening of a low molecular weight ulvan from the green alga ulothrix flacca Mar. Drugs 16 2018 281 293 10.3390/md16080281 PMC6117715 30111709

64 Berri M. Olivier M. Holbert S. Dupont J. Demais H. Le Goff M. Collen P.N. Ulvan from ulva armoricana (chlorophyta) activates the PI3K/Akt signalling pathway via TLR4 to induce intestinal cytokine production Algal Res. 28 2017 39 47

65 Berri M. Slugocki C. Olivier M. Helloin E. Jacques I. Salmon H. Demais H. Le Goff M. Collen P.N. Marine-sulfated polysaccharides extract of ulva armoricana green algae exhibits an antimicrobial activity and stimulates cytokine expression by intestinal epithelial cells J. Appl. Phycol. 28 2016 2999 3008

66 Chi Y. Zhang M. Wang X. Fu X. Guan H. Wang P. Ulvan lyase assisted structural characterization of ulvan from ulva pertusa and its antiviral activity against vesicular stomatitis virus Int. J. Biol. Macromol. 157 2020 75 82 32344076 10.1016/j.ijbiomac.2020.04.187

67 Tziveleka L.A. Ioannou E. Roussis V. Ulvan, a bioactive marine sulphated polysaccharide as a key constituent of hybrid biomaterials: a review Carbohydr. Polym. 218 2019 355 370 31221340 10.1016/j.carbpol.2019.04.074

68 Thanh T.T.T. T Quach T.M. Nguyen T.N. Vu Luong D. Bui M.L. Tran T.T. Van Structure and cytotoxic activity of ulvan extracted from green seaweed ulva lactuca Int. J. Biol. Macromol. 93 2016 695 702 27637450 10.1016/j.ijbiomac.2016.09.040

69 Li B. Xu H. Wang X. Wan Y. Jiang N. Qi H. Liu X. Antioxidant and antihyperlipidemic activities of high sulfate content purified polysaccharide from ulva pertusa Int. J. Biol. Macromol. 146 2020 756 762 31712152 10.1016/j.ijbiomac.2019.11.061

70 Wahlström N. Steinhagen S. Toth G. Pavia H. Edlund U. Ulvan dialdehyde-gelatin hydrogels for removal of heavy metals and methylene blue from aqueous solution Carbohydr. Polym. 249 2020 116841 116853 32933684 10.1016/j.carbpol.2020.116841

71 Wang Y. Xing M. Cao Q. Ji A. Liang H. Song S. Biological activities of fucoidan and the factors mediating its therapeutic effects: a review of recent studies Mar. Drugs 17 2019 183 200 10.3390/md17030183 PMC6471298 30897733

72 Lin Y. Qi X. Liu H. Xue K. Xu S. Tian Z. The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations Canc. Cell Int. 20 2020 154 167 10.1186/s12935-020-01233-8 PMC7206694 32410882

73 Zhang W. Oda T. Yu Q. Jin J.O. Fucoidan from Macrocystis pyrifera has powerful immune-modulatory effects compared to three other fucoidans Mar. Drugs 13 2015 1084 1104 25706632 10.3390/md13031084 PMC4377974

74 Tabarsa M. Dabaghian E.H. You S.G. Yelithao K. Cao R.A. Rezaei M. Alboofetileh M. Bita S. The activation of NF-ΚB and MAPKs signaling pathways of RAW264.7 murine macrophages and natural killer cells by fucoidan from Nizamuddinia zanardinii Int. J. Biol. Macromol. 148 2020 56 67 31953171 10.1016/j.ijbiomac.2020.01.125

75 Flórez-Fernández N. Torres M.D. González-Muñoz M.J. Domínguez H. Potential of intensification techniques for the extraction and depolymerization of fucoidan Algal Res. 30 2018 128 148

76 Jang J.Y. Moon S.Y. Joo H.G. Differential effects of fucoidans with low and high molecular weight on the viability and function of spleen cells Food Chem. Toxicol. 68 2014 234 238 24681238 10.1016/j.fct.2014.03.024

77 Atashrazm F. Lowenthal M.R. Woods G.M. Holloway A.F. Dickinson J.L. Fucoidan Cancer A multifunctional molecule with anti-tumor potential Mar. Drugs 13 2015 2327 2346 25874926 10.3390/md13042327 PMC4413214

78 Wang X. Yi K. Zhao Y. Fucoidan inhibits amyloid-β-induced toxicity in transgenic: Caenorhabditis elegans by reducing the accumulation of amyloid-β and decreasing the production of reactive oxygen species Food Funct. 9 2018 552 560 29260173 10.1039/c7fo00662d

79 Jin W. Ren L. Liu B. Zhang Q. Zhong W. Structural features of sulfated glucuronomannan oligosaccharides and their antioxidant activity Mar. Drugs 16 2018 291 302 10.3390/md16090291 PMC6165275 30134603

80 Cong Q. Chen H. Liao W. Xiao F. Wang P. Qin Y. Dong Q. Ding K. Structural characterization and effect on anti-angiogenic activity of a fucoidan from sargassum fusiforme Carbohydr. Polym. 136 2016 899 907 26572427 10.1016/j.carbpol.2015.09.087

81 Kim B.S. Park J.-Y. Kang H.-J. Kim H.-J. Lee J. Fucoidan/FGF-2 induces angiogenesis through JNK- and P38-mediated activation of AKT/MMP-2 signalling Biochem. Biophys. Res. Commun. 450 2014 1333 1338 25003321 10.1016/j.bbrc.2014.06.137

82 Goldberga I. Li R. Duer M.J. Collagen structure-function relationships from solid-state NMR spectroscopy Acc. Chem. Res. 51 2018 1621 1629 29931970 10.1021/acs.accounts.8b00092

83 Bazrafshan Z. Stylios G.K. International journal of biological macromolecules spinnability of collagen as a biomimetic material: a review Int. J. Biol. Macromol. 129 2019 693 705 30769042 10.1016/j.ijbiomac.2019.02.024

84 Holmes D.F. Lu Y. Starborg T. Kadler K.E. Chapter three - collagen fibril assembly and function Litscher E.S. Wassarman Extracellular Matrix and Egg Coats vol. 130 2018 Elsevier Inc. Amsterdam 107 142 10.1016/bs.ctdb.2018.02.004 29853175

85 Sorushanova A. Delgado L.M. Wu Z. Shologu N. Kshirsagar A. Raghunath R. Mullen A.M. Bayon Y. Pandit A. Raghunath M. The collagen suprafamily: from biosynthesis to advanced biomaterial development Adv. Mater. 31 2019 1801651 1801689 10.1002/adma.201801651 30126066

86 Gu L. Shan T. Ma Y. Tay F.R. Niu L. Novel biomedical applications of crosslinked collagen Trends Biotechnol. 37 2018 464 491 30447877 10.1016/j.tibtech.2018.10.007

87 Panwar P. Butler G.S. Jamroz A. Azizi P. Overall M. Br D. Aging-associated modifications of collagen affect its degradation by matrix metalloproteinases preety Matrix Biol. 65 2018 30 44 28634008 10.1016/j.matbio.2017.06.004

88 Squeglia F. Ruggiero A. Berisio R. Collagen degradation in tuberculosis pathogenesis: the biochemical consequences of hosting an undesired guest Biochem. J. 475 2018 3123 3140 30315001 10.1042/BCJ20180482

89 Subasinghe S.K. Ogbuehi K.C. Dias G.J. Current perspectives on corneal collagen crosslinking (CXL) Graefes Arch. Clin. Exp. Ophthalmol. 256 2018 1363 1384 29623463 10.1007/s00417-018-3966-0

90 Böhm S. Strauß C. Stoiber S. Kasper C. Charwat V. Impact of source and manufacturing of collagen matrices on fibroblast cell growth and platelet aggregation Materials (Basel) 10 2017 1086 1099 10.3390/ma10091086 PMC5615740 28914792

91 Salvatore L. Gallo N. Natali M.L. Campa L. Lunetti P. Madaghiele M. Blasi S.F. Corallo A. Capobianco L. Sannino A. Marine collagen and its derivatives: versatile and sustainable bio-resources for healthcare Mater. Sci. Eng. C 113 2020 110963 10.1016/j.msec.2020.110963 32487384

92 Pal G.K. Suresh P.V. Sustainable valorisation of seafood by-products: recovery of collagen and developmentof collagen-based novel functional food ingredients Innovat. Food Sci. Emerg. Technol. 37 2016 201 215

93 Zheng M.H. Hinterketiser K. Solomon K. Kunert V. Pavlos N.J. Xu J. Collagen-derived biomaterials in bone and cartilage repair Macromol. Symp. 253 2007 179 185

94 Swatschek D. Schatton W. Kellermann J. Müller W.E.G. Kreuter J. Marine sponge collagen: isolation, characterization and effects on the skin parameters surface-PH, moisture and sebum Eur. J. Pharm. Biopharm. 53 2002 107 113 11777758 10.1016/s0939-6411(01)00192-8

95 Barros A.A. Aroso I.M. Silva T.H. Mano J.F. Duarte A.R.C. Reis R.L. Water and carbon dioxide: green solvents for the extraction of collagen/gelatin from marine sponges Acs Sustain. Chem. Eng. 3 2015 254 260

96 Nagai N. Yunoki S. Suzuki T. Sakata M. Tajima K. Munekata M. Application of cross-linked salmon atelocollagen to the scaffold of human periodontal ligament cells J. Biosci. Bioeng. 97 2004 389 394 16233648 10.1016/S1389-1723(04)70224-8

97 Mahboob S. Isolation and characterization of collagen from fish waste material- skin, scales and fins of catla catla and cirrhinus mrigala J. Food Sci. Technol. 52 2015 4296 4305 26139894 10.1007/s13197-014-1520-6 PMC4486571

98 Zhang J. Sun Y. Zhao Y. Wei B. Xu C. He L. Oliveira C.L.P. Wang H. Centrifugation-induced fibrous orientation in fish-sourced collagen matrices Soft Matter 13 2017 9220 9228 29199311 10.1039/c7sm01871a

99 Heinemann B.S. Heinemann C. Ehrlich H. Meyer M. Baltzer H. Worch H. Hanke T. A novel biomimetic hybrid material made of silicified Collagen : perspectives for bone replacement Adv. Eng. Mater. 9 2007 1061 1068

100 Silva J.C. Barros A.A. Aroso I.M. Fassini D. Silva T.H. Reis R.L. Duarte A.R.C. Extraction of collagen/gelatin from the marine demosponge chondrosia reniformis (nardo, 1847) using water acidified with carbon dioxide – process optimization Ind. Eng. Chem. Res. 55 2016 6891 7060

101 Jafari H. Lista A. Siekapen M.M. Bohlouli P.G. Nie L. Alimoradi H. Shavandi A. Fish collagen: extraction, characterization, and applications for biomaterials engineering Polymers (Basel) 12 2020 2230 2266 10.3390/polym12102230 PMC7601392 32998331

102 Yang H. Wang H. Zhao Y. Zhang H. Effect of heat treatment on the enzymatic stability of grass carp skin collagen and its ability to form fibrils in vitro J. Sci. Food Agric. 95 2014 329 336 24798991 10.1002/jsfa.6724

103 Chen J. Gao K. Liu S. Wang S. Elango J. Bao B. Dong J. Liu N. Wu W. Fish collagen surgical compress repairing characteristics on wound healing process in vivo Mar. Drugs 17 2019 1 12 10.3390/md17010033 PMC6357035 30625985

104 Moreira-silva J. Diogo G.S. Marques A.L.P. Silva T.H. Reis R.L. Chapter 2-marine collagen isolation and processing envisaging biomedical applications Neves N.M. Reis R.L. Biomaterials from Nature for Advanced Devices and Therapies 2016 John Wiley & Sons, Inc. New Jersey 16 36

105 Ehrlich H. Heinemann S. Heinemann C. Simon P. V Bazhenov V. Shapkin N.P. Born R. Tabachnick K.R. Hanke T. Worch H. Nanostructural organization of naturally occurring composites—Part I: silica-collagen-based biocomposites J. Nanomater. 2008 2008 145 152

106 Heinemann S. Ehrlich H. Knieb C. Hanke T. Biomimetically inspired hybrid materials based on silicified collagen Int. J. Mater. Res. 98 2007 603 608

107 Ueberlein S. Machill S. Schupp P.J. Brunner E. Determination of the halogenated skeleton constituents of the marine demosponge Ianthella basta Mar. Drugs 15 2017 34 48 10.3390/md15020034 PMC5334614 28208597

108 Ehrlich H. Wysokowski M. Zółtowska-Aksamitowska S. Petrenko I. Jesionowski T. Collagens of poriferan origin Mar. Drugs 16 2018 1 21 10.3390/md16030079 PMC5867623 29510493

109 Khrunyk Y. Lach S. Petrenko I. Ehrlich H. Progress in modern marine biomaterials research Mar. Drugs 18 2020 1 46 10.3390/md18120589 PMC7760574 33255647

110 Jesionowski T. Norman M. Zółtowska-Aksamitowska S. Petrenko I. Joseph Y. Ehrlich H. Marine spongin: naturally prefabricated 3D scaffold-based biomaterial Mar. Drugs 16 2018 1 23 10.3390/md16030088 PMC5867632 29522478

111 Petrenko I. Summers A.P. Simon P. Żółtowska-Aksamitowska S. Motylenko M. Schimpf C. Rafaja D. Roth F. Kummer K. Brendler E. Extreme biomimetics: preservation of molecular detail in centimeter-scale samples of biological meshes laid down by sponges Sci. Adv. 5 2019 e2805 10.1126/sciadv.aax2805 PMC6777968 31620556

112 Tsurkan D. Wysokowski M. Petrenko I. Voronkina A. Khrunyk Y. Fursov A. Ehrlich H. Modern scaffolding strategies based on naturally pre-fabricated 3D biomaterials of poriferan origin Appl. Phys. A 126 2020 382-340

113 Morais Z. Raposo A. Gonçalves A. Healthy food innovation using natural resources, catostylus tagi jellyfish: sensory evaluation CEFood 2016-8th Central European Congress on Food 2016

114 Felician F.F. Yu R.-H. Li M.-Z. Li C.-J. Chen H.-Q. Jiang Y. Tang T. Qi W.-Y. Xu H.-M. The wound healing potential of collagen peptides derived from the jellyfish rhopilema esculentum Chin. J. Traumatol. 22 2019 12 20 30827814 10.1016/j.cjtee.2018.10.004 PMC6529365

115 Cheng X. Shao Z. Li C. Yu L. Raja M.A. Liu C. Isolation, characterization and evaluation of collagen from jellyfish rhopilema esculentum kishinouye for use in hemostatic applications PLoS One 12 2017 e0169731 10.1371/journal.pone.0169731 PMC5245839 28103327

116 Pustlauk W. Paul B. Brueggemeier S. Gelinsky M. Bernhardt A. Modulation of chondrogenic differentiation of human mesenchymal stem cells in jellyfish collagen scaffolds by cell density and culture medium J. Tissue Eng. Regen. Med. 11 2017 1710 1722 26178016 10.1002/term.2065

117 Paradiso F. Fitzgerald J. Yao S. Barry F. Taraballi F. Gonzalez D. Conlan R.S. Francis L. Marine collagen substrates for 2D and 3D ovarian cancer cell systems Front. Bioeng. Biotechnol. 7 2019 343 372 31921795 10.3389/fbioe.2019.00343 PMC6923181

118 Addad S. Exposito J.-Y. Faye C. Ricard-Blum S. Lethias C. Isolation, characterization and biological evaluation of jellyfish collagen for use in biomedical applications Mar. Drugs 9 2011 967 983 21747742 10.3390/md9060967 PMC3131555

119 Rastian Z. Pütz S. Wang Y. Kumar S. Fleissner F. Weidner T. Parekh S.H. Type I collagen from jellyfish catostylus mosaicus for biomaterial applications ACS Biomater. Eng. 4 2018 2115 2125 10.1021/acsbiomaterials.7b00979 33435035

120 Ferrario C. Rusconi F. Pulaj A. Macchi R. Landini P. Paroni M. Colombo G. Martinello T. Melotti L. Gomiero C. From food waste to innovative biomaterial: sea Urchin-derived collagen for applications in skin regenerative medicine Mar. Drugs 18 2020 414 431 10.3390/md18080414 PMC7460064 32781644

121 Goh K.L. Holmes D.F. Collagenous extracellular matrix biomaterials for tissue engineering: lessons from the common sea urchin tissue Int. J. Mol. Sci. 18 2017 901 948 10.3390/ijms18050901 PMC5454814 28441344

122 Dai M. Liu X. Wang N. Sun J. Squid type II collagen as a novel biomaterial: isolation, characterization, immunogenicity and relieving effect on degenerative osteoarthritis via inhibiting STAT1 signaling in pro-inflammatory macrophages Mater. Sci. Eng. C. Mater. Biol. Appl. 89 2018 283 294 29752100 10.1016/j.msec.2018.04.021

123 Delphi L. Sepehri H. Motevaseli E. Khorramizadeh M.R. Collagen extracted from Persian gulf squid exhibits anti-cytotoxic properties on apple pectic treated cells: assessment in an in vitro bioassay model, Iran J. Public Health 45 2016 1054 1063 PMC5139963 27928532

124 Blowes L.M. Egertová M. Liu Y. Davis G.R. Terrill N.J. Gupta H.S. Elphick M.R. Body wall structure in the starfish asterias rubens J. Anat. 231 2017 325 341 28714118 10.1111/joa.12646 PMC5554833

125 Tan Y. Chang S.K.C. Isolation and characterization of collagen extracted from channel catfish (Ictalurus punctatus) skin Food Chem. 242 2018 147 155 29037670 10.1016/j.foodchem.2017.09.013

126 Zhang Q. Wang Q. Lv S. Lu J. Jiang S. Regenstein J.M. Lin L. Comparison of collagen and gelatin extracted from the skins of nile Tilapia (Oreochromis niloticus) and channel catfish (Ictalurus punctatus) Food Bioence 13 2016 41 48

127 Hukmi N.M.M. Sarbon N.M. Isolation and characterization of acid soluble collagen (ASC) and pepsin soluble collagen (PSC) extracted from silver catfish (pangasius sp.) skin Int. Food Res. J. 25 2018 2601 2607

128 Pozzolini M. Millo E. Oliveri C. Mirata S. Salis A. Damonte G. Arkel M. Scarfì S. Elicited ROS scavenging activity, photoprotective, and wound-healing properties of collagen-derived peptides from the marine sponge chondrosia reniformis Mar. Drugs 16 2018 465 490 10.3390/md16120465 PMC6316299 30477144

129 Elango J. Lee J.W. Wang S. Henrotin Y. de Val J.E.M.S. Regenstein J.M. Lim S.Y. Bao B. Wu W. Evaluation of differentiated bone cells proliferation by blue shark skin collagen via biochemical for bone tissue engineering Mar. Drugs 16 2018 350 364 10.3390/md16100350 PMC6212988 30257422

130 Bu Y. Elango J. Zhang J. Bao B. Guo R. Palaniyandi K. Robinson J.S. Geevaretnam J. Regenstein J.M. Wu W. Immunological effects of collagen and collagen peptide from blue shark cartilage on 6T-CEM cells Process Biochem. 57 2017 219 227

131 Mei F. Liu J. Wu J. Duan Z. Chen M. Meng K. Chen S. Shen X. Xia G. Zhao M. Collagen peptides isolated from Salmo salar and Tilapia nilotica skin accelerate wound healing by altering cutaneous microbiome colonization via upregulated NOD2 and BD14 J. Agric. Food Chem. 68 2020 1621 1633 31967468 10.1021/acs.jafc.9b08002

132 Nurilmala M. Hizbullah H.H. Karnia E. Kusumaningtyas E. Ochiai Y. Characterization and antioxidant activity of collagen, gelatin, and the derived peptides from yellowfin tuna (Thunnus albacares) skin Mar. Drugs 18 2020 98 109 10.3390/md18020098 PMC7074124 32023998

133 Muthumari K. Anand M. Maruthupandy M. Collagen extract from marine finfish scales as a potential mosquito larvicide Protein J. 35 2016 391 400 27804059 10.1007/s10930-016-9685-7

134 Wu R. Wu C. Liu D. Yang X. Huang J. Zhang J. Liao B. He H. Antioxidant and anti-freezing peptides from salmon collagen hydrolysate prepared by bacterial extracellular protease Food Chem. 248 2018 346 352 29329864 10.1016/j.foodchem.2017.12.035

135 Bhuimbar M.V. Bhagwat P.K. Dandge P.B. Extraction and characterization of acid soluble collagen from fish waste: development of collagen-chitosan blend as food packaging film J. Environ. Chem. Eng. 7 2019 102983 102989

136 Kobayashi Y. Akiyama H. Huge J. Kubota H. Chikazawa S. Satoh T. Miyake T. Uhara H. Okuyama R. Nakagawara R. Fish collagen is an important panallergen in the Japanese population Allergy 71 2016 720 723 26785247 10.1111/all.12836

137 Barros A.A. Aroso I.M. Silva T.H. Mano J.F. Duarte A.R.C. Reis R.L. Water and carbon dioxide: green solvents for the extraction of collagen/gelatin from marine sponges ACS Sustain. Chem. Eng. 3 2014 254 260

138 Tziveleka L.-A. Ioannou E. Tsiourvas D. Berillis P. Foufa E. Roussis V. Collagen from the marine sponges axinella cannabina and Suberites carnosus: isolation and morphological, biochemical, and biophysical characterization Mar. Drugs 15 2017 152 168 10.3390/md15060152 PMC5484102 28555046

139 Chancharern P. Laohakunjit N. Kerdchoechuen O. Thumthanaruk B. Extraction of type A and type B gelatin from jellyfish (lobonema smithii) Food Res. Int. 23 2016 419 424

140 Abdelmalek B.E. Gómez-estaca J. Sila A. Martinez O. Gómez-guillén M.C. Chaabouni-ellouz S. Ayadi M.A. Characteristics and functional properties of gelatin extracted from squid (Loligo vulgaris) skin LWT - Food Sci. Technol. 65 2015 924 931

141 Enrique D. Angulo L. José P. International journal of biological macromolecules characterization of gelatin/chitosan scaffold blended with aloe vera and snail mucus for biomedical purpose Int. J. Biol. Macromol. 92 2016 645 653 27453523 10.1016/j.ijbiomac.2016.07.029

142 Mureithi A.W. Onyari J.M. Chisutia Wanyonyi W. Mulaa F.J. Amino acid composition of gelatin extracted from the scales of different marine fish species in Kenya Int. J. Sci. Res. Sci. Eng. Technol. 3 2017 558 563

143 Liu D. Nikoo M. Boran G. Zhou P. Regenstein J.M. Collagen and gelatin Annu. Rev. Food. Sci. Technol. 6 2015 527 557 25884286 10.1146/annurev-food-031414-111800

144 Gaspar-pintiliescu A. Stefan L.M. Anton E.D. Berger D. Matei C. Negreanu-pirjol T. Moldovan L. Physicochemical and biological properties of gelatin extracted from marine snail rapana venosa Mar. Drugs 17 2019 589 602 10.3390/md17100589 PMC6835507 31627413

145 Casanova F. Mohammadifar M.A. Jahromi M. Petersen H.O. Sloth J.J. Eybye K.L. Kobbelgaard S. Jakobsen G. Jessen F. Physico-chemical, structural and techno-functional properties of gelatin from saithe (pollachius virens) skin Int. J. Biol. Macromol. 156 2020 918 927 32283110 10.1016/j.ijbiomac.2020.04.047

146 Lopetuso L. Graziani C. Guarino A. Lamborghini A. Masi S. Stanghellini V. Gelatin tannate and tyndallized probiotics: a novel approach for treatment of diarrhea Eur. Rev. Med. Pharmacol. Sci. 21 2017 873 883 28272692

147 Madkhali O. Mekhail G. Wettig S.D. Modified gelatin nanoparticles for gene delivery Int. J. Pharm. 554 2019 224 234 30408531 10.1016/j.ijpharm.2018.11.001

148 Moeller C. Fleischmann C. Thomas-Rueddel D. Vlasakov V. Rochwerg B. Theurer P. Gattinoni L. Reinhart K. Hartog C.S. How safe is gelatin? A systematic review and meta-analysis of gelatin-containing plasma expanders vs crystalloids and albumin J. Crit. Care 35 2016 75 83 27481739 10.1016/j.jcrc.2016.04.011

149 Kang H.K. Lee H.H. Seo C.H. Park Y. Antimicrobial and immunomodulatory properties and applications of marine-derived proteins and peptides Mar. Drugs 17 2019 350 374 10.3390/md17060350 PMC6628016 31212723

150 Prihanto A.A. Wakayama M. Marine microorganism: an underexplored source of l-asparaginase Adv. Food Nutr. Res. 79 2016 1 25 27770857 10.1016/bs.afnr.2016.07.005

151 Long S. Zhang X. Rao Z. Chen K. Xu M. Yang T. Yang S. Amino acid residues adjacent to the catalytic cavity of tetramer L-asparaginase II contribute significantly to its catalytic efficiency and thermostability Enzym. Microb. Technol. 82 2016 15 22 10.1016/j.enzmictec.2015.08.009 26672444

152 Qeshmi F.I. Homaei A. Fernandes P. Javadpour S. Marine microbial L-asparaginase: biochemistry, molecular approaches and applications in tumor therapy and in food industry Microbiol. Res. 208 2018 99 112 29551216 10.1016/j.micres.2018.01.011

153 Batool T. Makky E.A. Jalal M. Yusoff M.M. A comprehensive review on L-asparaginase and its applications Appl. Biochem. Biotechnol. 178 2016 900 923 26547852 10.1007/s12010-015-1917-3

154 Solano F. Melanin and melanin-related polymers as materials with biomedical and biotechnological applications-cuttlefish ink and mussel foot proteins as inspired biomolecules Int. J. Mol. Sci. 18 2017 1561 1578 10.3390/ijms18071561 PMC5536049 28718807

155 Kim H.J. Yang B. Park T.Y. Lim S. Cha H.J. Complex coacervates based on recombinant mussel adhesive proteins: their characterization and applications Soft Matter 13 2017 7704 7716 29034934 10.1039/c7sm01735a

156 Park K.H. Seong K.Y. Yang S.Y. Seo S. Advances in medical adhesives inspired by aquatic organisms' adhesion Biomater. Res. 21 2017 16 25 29046821 10.1186/s40824-017-0101-y PMC5633886

157 Muneer F. Siddique M.H. Azeem F. Rasul I. Muzammil S. Zubair M. Afzal M. Nadeem H. Microbial L-asparaginase: purification, characterization and applications Arch. Microbiol. 202 2020 967 981 32052094 10.1007/s00203-020-01814-1

158 Lane T.W. Saito M.A. George G.N. Pickering I.J. Prince R.C. Morel F.M. Biochemistry: a cadmium enzyme from a marine diatom Nature 435 2005 42-42 10.1038/435042a 15875011

159 Alterio V. Langella E. De Simone G. Monti S.M. Cadmium-containing carbonic anhydrase CDCA1 in marine diatom Thalassiosira weissflogii Mar. Drugs 13 2015 1688 1697 25815892 10.3390/md13041688 PMC4413181

160 Barzkar N. Marine microbial alkaline protease: an efficient and essential tool for various industrial applications Int. J. Biol. Macromol. 161 2020 1216 1229 32534091 10.1016/j.ijbiomac.2020.06.072

161 Wu S. Liu G. Zhang D. Li C. Sun C. Purification and biochemical characterization of an alkaline protease from marine bacteria pseudoalteromonas sp. 129-1 J. Basic Microbiol. 55 2015 1427 1434 26213994 10.1002/jobm.201500327

162 Mo S. Kim J.H. Cho K.W. A novel extracellular phospholipase C purified from a marine bacterium, pseudoalteromonas sp. J937 Biotechnol. Lett. 31 2009 89 94 18784905 10.1007/s10529-008-9833-z

163 Mo S. Kim J.H. Cho K.W. Enzymatic properties of an extracellular phospholipase C purified from a marine streptomycete Biosci. Biotechnol. Biochem. 73 2009 2136 2137 19734650 10.1271/bbb.90323

164 Shehata A.N. Abd El Aty A.A. Darwish D.A. Abdel Wahab W.A. Mostafa F.A. Purification, physicochemical and thermodynamic studies of antifungal chitinase with production of bioactive chitosan-oligosaccharide from newly isolated Aspergillus griseoaurantiacus KX010988 Int. J. Biol. Macromol. 107 2018 990 999 28939517 10.1016/j.ijbiomac.2017.09.071

165 Itoh T. Kimoto H. Bacterial chitinase system as a model of chitin biodegradation Adv. Exp. Med. Biol. 1142 2019 131 151 31102245 10.1007/978-981-13-7318-3_7

166 Li Y. Lei X. Zhu H. Zhang H. Guan C. Chen Z. Zheng W. Fu L. Zheng T. Chitinase producing bacteria with direct algicidal activity on marine diatoms Sci. Rep. 6 2016 21984 21996 26902175 10.1038/srep21984 PMC4763246

167 Xu F. Wang P. Zhang Y.Z. Chen X.L. Diversity of three-dimensional structures and catalytic mechanisms of alginate lyases Appl. Environ. Microbiol. 84 2018 e02040 10.1128/AEM.02040-17 PMC5772247 29150496

168 Inoue A. Characterization of PL-7 family alginate lyases from marine organisms and their applications Methods Enzymol. 605 2018 499 524 29909836 10.1016/bs.mie.2018.01.030

169 Badur A.H. Jagtap S.S. Yalamanchili G. Lee J.K. Zhao H. Rao C.V. Alginate lyases from alginate-degrading Vibrio splendidus 12B01 are endolytic Appl. Environ. Microbiol. 81 2015 1865 1873 25556193 10.1128/AEM.03460-14 PMC4325137

170 Jahromi S.T. Barzkar N. Future direction in marine bacterial agarases for industrial applications Appl. Microbiol. Biotechnol. 102 2018 6847 6863 29909571 10.1007/s00253-018-9156-5

171 Fu W. Han B. Duan D. Liu W. Wang C. Purification and characterization of agarases from a marine bacterium Vibrio sp. F-6 J. Ind. Microbiol. Biotechnol. 35 2008 915 922 18478285 10.1007/s10295-008-0365-2

172 Matard-Mann M. Bernard T. Leroux C. Barbeyron T. Larocque R. Préchoux A. Jeudy A. Jam M. Nyvall Collén P. Michel G. Structural insights into marine carbohydrate degradation by family GH16 κ-carrageenases J. Biol. Chem. 922 2017 19919 19934 10.1074/jbc.M117.808279 PMC5712629 29030427

173 Chauhan P.S. Saxena A. Bacterial carrageenases: an overview of production and biotechnological applications 3 Biotech 6 2016 146 163 10.1007/s13205-016-0461-3 PMC4919138 28330218

174 Shen J. Chang Y. Chen F. Dong S. Expression and characterization of a κ-carrageenase from marine bacterium wenyingzhuangia aestuarii OF219: a biotechnological tool for the depolymerization of κ-carrageenan Int. J. Biol. Macromol. 112 2018 93 100 29355636 10.1016/j.ijbiomac.2018.01.075

175 Li S. Hao J. Sun M. Cloning and characterization of a new cold-adapted and thermo-tolerant ι-carrageenase from marine bacterium flavobacterium sp YS-80-122 Int. J. Biol. Macromol. 102 2017 1059 1065 28435055 10.1016/j.ijbiomac.2017.04.070

176 Trivedi N. Reddy C.R.K. Lali A.M. Chapter two - marine microbes as a potential source of cellulolytic enzymes Kim S.-K. Toldrá F. Marine Enzymes Biotechnology: Production and Industrial Applications, Part II - Marine Organisms Producing Enzymes vol. 79 2016 Academic Press. Amsterdam 27 41 10.1016/bs.afnr.2016.07.002 27770862

177 Klippel B. Lochner A. Bruce D.C. Davenport K.W. Detter C. Goodwin L.A. Han J. Han S. Land M.L. Mikhailova N. Complete genome sequence of the marine cellulose- and xylan-degrading bacterium glaciecolasp. strain 4H-3-7+YE-5 J. Bacteriol. 193 2011 4547 4548 21705587 10.1128/JB.05468-11 PMC3165521

178 Qeshmi F.I. Homaei A. Fernandes P. Hemmati R. Dijkstra B.W. Khajeh K. Xylanases from marine microorganisms: a brief overview on scope, sources, features and potential applications Biochim. Biophys. Acta Protein Proteonomics 1868 2020 140312 140325 10.1016/j.bbapap.2019.140312 31740412

179 Li W. Sunda W.G. Lin W. Hong H. Shi D. The effect of cell size on cellular Zn and Cd and Zn-Cd-CO2 colimitation of growth rate in marine diatoms Limnol. Oceanogr. 65 2020 2896 2911

180 Lane T.W. Saito M.A. George G.N. Pickering I.J. Prince R.C. Morel F.M. A cadmium enzyme from a marine diatom Nature 435 2005 42-42 10.1038/435042a 15875011

181 Park S.Y. Kim Y.S. Ahn C.B. Je J.Y. Partial purification and identification of three antioxidant peptides with hepatoprotective effects from blue mussel ( Mytilus edulis ) hydrolysate by peptic hydrolysis J. Funct. Foods 20 2016 88 95

182 Chi C.F. Hu F.Y. Wang B. Li T. Ding G.F. Antioxidant and anticancer peptides from the protein hydrolysate of blood clam (tegillarca granosa) muscle J. Funct. Foods 15 2015 301 313

183 Zhang Z. Zhou F. Liu X. Zhao M. Particulate nanocomposite from oyster (Crassostrea Rivularis) hydrolysates via zinc chelation improves zinc solubility and peptide activity Food Chem. 258 2018 269 277 29655733 10.1016/j.foodchem.2018.03.030

184 Vijaykrishnaraj M. Prabhasankar P. Marine protein hydrolysates: their present and future perspectives in food chemistry – a review RSC Adv. 5 2015 34864 34877

185 Miao J. Liao W. Kang M. Jia Y. Wang Q. Anti-fatigue and anti-oxidant activities of oyster (Ostrea rivularis) hydrolysate prepared by compound protease Food Funct. 9 2018 6577 6585 30488053 10.1039/c8fo01879k

186 Yuk H. Varela C.E. Nabzdyk C.S. Mao X. Padera R.F. Dry double-sided tape for adhesion of wet tissues and devices Nature 575 2019 169 174 31666696 10.1038/s41586-019-1710-5

187 Yang B. Jin S. Park Y. Jung Y.M. Cha H.J. Coacervation of interfacial adhesive proteins for initial mussel adhesion to a wet surface Small 14 2018 e1803377 10.1002/smll.201803377 30457699

188 Kaushik N.K. Kaushik N. Pardeshi S. Sharma J.G. Lee S.H. Choi E.H. Biomedical and clinical importance of mussel-inspired polymers and materials Mar. Drugs 13 2015 6792 6817 26569266 10.3390/md13116792 PMC4663554

189 Buffet J.P. Corre E. Duvernois-Berthet E. Fournier J. Lopez P.J. Adhesive gland transcriptomics uncovers a diversity of genes involved in glue formation in marine tube-building polychaetes Acta Biomater. 72 2018 316 328 29597026 10.1016/j.actbio.2018.03.037

190 Almeida M. Reis R.L. Silva T.H. Marine invertebrates are a source of bioadhesives with biomimetic interest Mater. Sci. Eng. C 108 2020 110467 110476 10.1016/j.msec.2019.110467 31924038

191 Jones J.P. Sima M. O'Hara R.G. Stewart R.J. Water-borne endovascular embolics inspired by the undersea adhesive of marine sandcastle worms Adv. Healthc. Mater. 5 2016 795 801 26806763 10.1002/adhm.201500825 PMC5703062

192 Mhlongo J.T. Brasil E. de la Torre B.G. Albericio F. Naturally occurring oxazole-containing peptides Mar. Drugs 18 2020 203 227 10.3390/md18040203 PMC7231064 32290087

193 Manfrin A. Borduas-Dedekind N. Lau K. McNeill K. Singlet oxygen photooxidation of peptidic oxazoles and thiazoles J. Org. Chem. 84 2019 2439 2447 30681338 10.1021/acs.joc.8b02684

194 Chen S. Ji X. Gao M. Dedkova L.M. Hecht S.M. In cellulo synthesis of proteins containing a fluorescent oxazole amino acid J. Am. Chem. Soc. 141 2019 5597 5601 30889951 10.1021/jacs.8b12767 PMC6733411

195 Joshi S. Bisht A.S. Juyal D. Systematic scientific study of 1 , 3-oxazole derivatives as a useful lead for Pharmaceuticals : a review Pharma Innov. 6 2017 109 117

196 Chiacchio M.A. Lanza G. Chiacchio U. Giofrè S.V. Romeo R. Iannazzo D. Legnani L. Oxazole-based compounds as anticancer agents Curr. Med. Chem. 26 2019 7337 7371 30501590 10.2174/0929867326666181203130402

197 Vishvakarma V.K. Shukla N. Reetu Kumari K. Patel R. Singh P. A model to study the inhibition of NsP2B-NsP3 protease of dengue virus with imidazole, oxazole, triazole thiadiazole, and thiazolidine based scaffolds Heliyon 5 2019 e02124 10.1016/j.heliyon.2019.e02124 PMC6684460 31406937

198 Yamamuro D. Uchida R. Ohtawa M. Arima S. Futamura Y. Katane M. Homma H. Nagamitsu T. Osada H. Tomoda H. Synthesis and biological activity of 5-(4-methoxyphenyl)-oxazole derivatives Bioorg. Med. Chem. Lett 25 2015 313 316 25488842 10.1016/j.bmcl.2014.11.042

199 Apostol T.V. Barbuceanu S.F. Socea L.I. Draghici C. Saramet G. Iscrulescu L. Olaru O.T. Synthesis, characterization and cytotoxicity evaluation of new heterocyclic compounds with oxazole ring containing 4- (phenylsulfonyl) phenyl moiety Rev. Chim. 70 2019 3793 3801

200 Imhoff J.F. Natural products from marine fungi — still an underrepresented resource Mar. Drugs 14 2016 19 37 26784209 10.3390/md14010019 PMC4728516

201 Khalifa S.A.M. Elias N. Farag M.A. Chen L. Saeed A. Hegazy M.F. Moustafa M.S. Abd El-Wahed A. Al-Mousawi S.M. Musharraf S.G. Marine natural products: a source of novel anticancer drugs Mar. Drugs 17 2019 491 521 10.3390/md17090491 PMC6780632 31443597

202 Naoki W. Sakamoto T. Matsugo S. Mycosporine-like amino acids and their derivatives as natural antioxidants Antioxidants (Basel) 4 2015 603 646 26783847 10.3390/antiox4030603 PMC4665425

203 Righi V. Parenti F. Schenetti L. Mucci A. Mycosporine-like amino acids and other phytochemicals directly detected by high-resolution NMR on Klamath (Aphanizomenon flos-aquae) blue-green algae J. Agric. Food Chem. 64 2016 6708 6715 27537083 10.1021/acs.jafc.6b02615

204 Gao X. Scytonemin plays a potential role in stabilizing the exopolysaccharidic matrix in terrestrial cyanobacteria Microb. Ecol. 73 2017 255 258 27623964 10.1007/s00248-016-0851-4

205 Colabella F. Moline M. Libkind D. UV sunscreens of microbial origin: mycosporines and mycosporine- like aminoacids Recent Pat. Biotechnol. 8 2014 179 193 25619303 10.2174/1872208309666150102104520

206 Chrapusta E. Kaminski A. Duchnik K. Bober B. Adamski M. Bialczyk J. Mycosporine-like amino acids: potential health and beauty ingredients Mar. Drugs 15 2017 326 354 10.3390/md15100326 PMC5666432 29065484

207 Öztaskın N. Taslimi P. Maraş A. Gülcin İ. Göksu S. Novel antioxidant bromophenols with acetylcholinesterase, butyrylcholinesterase and carbonic anhydrase inhibitory actions Bioorg. Chem. 74 2017 104 114 28772158 10.1016/j.bioorg.2017.07.010

208 Choi Y.K. Ye B.R. Kim E.A. Kim J. Kim M.S. Lee W.W. Ahn G.N. Kang N. Jung W.K. Heo S.J. Bis (3-bromo-4,5-dihydroxybenzyl) ether. A novel bromophenol from the marine red alga polysiphonia morrowii that suppresses LPS-induced inflammatory response by inhibiting ROS-mediated ERK signaling pathway in RAW 264.7 macrophages Biomed. Pharmacother. 103 2018 1170 1177 29864895 10.1016/j.biopha.2018.04.121

209 Amr A.E.E. El-Naggar M. Al-Omar M.A. Elsayed E.A. Abdalla M.M. In vitro and in vivo anti-breast cancer activities of some synthesized pyrazolinyl-estran-17-one candidates Molecules 23 2018 1572 1582 10.3390/molecules23071572 PMC6100451 29958453

210 Wang L.J. Guo C.L. Li X.Q. Wang S.Y. Jiang B. Zhao Y. Luo J. Xu K. Liu H. Guo S.J. Discovery of novel bromophenol hybrids as potential anticancer agents through the ros-mediated apoptotic pathway: design, synthesis and biological evaluation Mar. Drugs 15 2017 343 360 10.3390/md15110343 PMC5706033 29104274

211 Li X. Xu Q. Li C. Luo J. Li X. Wang L. Jiang B. Shi D. Toward a treatment of diabesity: in vitro and in vivo evaluation of uncharged bromophenol derivatives as a new series of PTP1B inhibitors Eur. J. Med. Chem. 166 2019 178 185 30711829 10.1016/j.ejmech.2019.01.057

212 Taslimi P. Aslan H.E. Demir Y. Oztaskin N. Maraş A. Gulçin İ. Beydemir S. Goksu S. Diarylmethanon, bromophenol and diarylmethane compounds: discovery of potent aldose reductase, α-amylase and α-glycosidase inhibitors as new therapeutic approach in diabetes and functional hyperglycemia Int. J. Biol. Macromol. 119 2018 857 863 30077669 10.1016/j.ijbiomac.2018.08.004

213 Demir Y. Taslimi P. Ozaslan M.S. Oztaskin N. Çetinkaya Y. Gulçin İ. Beydemir Ş. Goksu S. Antidiabetic potential: in vitro inhibition effects of bromophenol and diarylmethanones derivatives on metabolic enzymes Arch. Pharm. (Weinheim) 351 2018 e1800263 10.1002/ardp.201800263 30478943

214 Xu X. Yin L. Gao J. Gao L. Song F. Antifungal bromophenols from marine red alga Symphyocladia latiuscula Chem. Biodivers. 11 2014 807 811 24827691 10.1002/cbdv.201300239

215 Klinger C. ółtowska-Aksamitowska S. Wysokowski M. Tsurkan M.V. Galli R. Petrenko I. Machałowski T. Ereskovsky A. Martinović R. Muzychka L. Express method for isolation of ready-to-use 3D chitin scaffolds from aplysina archeri (aplysineidae: verongiida) demosponge Mar. Drugs 17 2019 131 155 10.3390/md17020131 PMC6409528 30813373

216 Muzychka L. Voronkina A. Kovalchuk V. Smolii O.B. Wysokowski M. Petrenko I. Youssef D.T.A. Ehrlich I. Ehrlich H. Marine biomimetics: bromotyrosines loaded chitinous skeleton as source of antibacterial agents Appl. Phys. Mater. Sci. Process 127 2021 15 25 10.1007/s00339-020-04167-0 PMC7776313 33424135

217 Niemann H. Marmann A. Lin W. Proksch P. Sponge derived bromotyrosines: structural diversity through natural combinatorial chemistry Nat. Prod. Commun. 10 2015 219 231 25920247

218 Wang Q. Tang X.L. Luo X.C. de Voog N.J. Li P.L. Li G.Q. Aplysinopsin-type and bromotyrosine-derived alkaloids from the south China sea sponge fascaplysinopsis reticulata Sci. Rep. 9 2019 2248 2257 30783134 10.1038/s41598-019-38696-3 PMC6381124

219 Binnewerg B. Schubert M. Voronkina A. Muzychka L. Wysokowski M. Petrenko I. Djurović M. Kovalchuk V. Tsurkan M. Martinovic R. Bechmann N. Fursov A. Ivanenko V.N. Tabachnick K.R. Smolii O.B. Joseph Y. Giovine M. Bornstein S.R. Stelling A.L. Tunger A. Schmitz M. Taniya O.S. Kovalev I.S. Zyryanov G.V. Guan K. Ehrlich H. Marine biomaterials: biomimetic and pharmacological potential of cultivated Aplysina aerophoba marine demosponge Mater. Sci. Eng. C. Mater. Biol. Appl. 109 2020 110566 110577 32228987 10.1016/j.msec.2019.110566

220 Moreels L. Bhat C. Voráčová M. Peigneur S. Goovaerts H. Mäki-Lohiluoma E. Zahed F. Pardo L.A. Yli-Kauhaluoma J. Kiuru P. Synthesis of novel purpurealidin analogs and evaluation of their effect on the cancer-relevant potassium channel KV10.1 PLoS One 12 2017 e0188811 10.1371/journal.pone.0188811 PMC5722316 29220359

221 Bhat C. Ilina P. Tilli I. Voráčová M. Bruun T. Barba V. Hribernik N. Lillsunde K.E. Mäki-Lohiluoma E. Rüffer T. Synthesis and antiproliferative activity of marine bromotyrosine purpurealidin I and its derivatives Mar. Drugs 16 2018 481 506 10.3390/md16120481 PMC6316490 30513862

222 Rosic N.N. Mycosporine-like amino acids: making the foundation for organic personalised sunscreens Mar. Drugs 17 2019 638 654 10.3390/md17110638 PMC6891770 31726795

223 Macha I.J. Ben-Nissan B. Marine skeletons: towards hard tissue repair and regeneration Mar. Drugs 16 2018 225 235 10.3390/md16070225 PMC6071272 30004435

224 Barros A.A. Aroso I.M. Silva T.H. Mano J.F. Duarte A.R.C. Reis R.L. Surface modification of silica-based marine sponge bioceramics induce hydroxyapatite formation Cryst. Growth Des. 14 2014 4545 4552

225 Granito R.N. Custódio M.R. Rennó A.C.M. Natural marine sponges for bone tissue engineering: the state of art and future perspectives J. Biomed. Mater. Res. B Appl. Biomater. 105 2017 1717 1727 27163295 10.1002/jbm.b.33706

226 Green D.W. Ben-Nissan B. Yoon K.S. Milthorpe B. Jung H.S. Natural and synthetic coral biomineralization for human bone revitalization Trends Biotechnol. 35 2017 43 54 27889241 10.1016/j.tibtech.2016.10.003

227 Falini G. Fermani S. Goffredo S. Coral biomineralization: a focus on intra-skeletal organic matrix and calcification Semin. Cell Dev. Biol. 46 2015 17 26 26344100 10.1016/j.semcdb.2015.09.005

228 Cao L. Li X. Zhou X. Li Y. Vecchio K.S. Yang L. Cui W. Yang R. Zhu Y. Guo Z. Zhang X. Lightweight open-cell scaffolds from sea urchin spines with superior material properties for bone defect repair ACS Appl. Mater. Interfaces 9 2017 9862 9870 28252933 10.1021/acsami.7b01645

229 Schoeppler V. Lemanis R. Reich E. Pusztai T. Gránásy L. Zlotnikov I. Crystal growth kinetics as an architectural constraint on the evolution of molluscan shells Proc. Natl. Acad. Sci. U. S. A 116 2019 20388 20397 31551265 10.1073/pnas.1907229116 PMC6789867

230 Ehrlich H. Martinović R. Joksimović D. Petrenko I. Schiaparelli S. Wysokowski M. Tsurkan D. Stelling A.L. Springer A. Gelinsky M. Joksimović A. Conchixes: organic scaffolds which resemble the size and shapes of mollusks shells, their isolation and potential multifunctional applications Appl. Phys. A 126 2020 562 574

231 Schröder H.C. Wang X. Tremel W. Ushijima H. Müller W.E. Biofabrication of biosilica-glass by living organisms Nat. Prod. Rep. 25 2008 455 474 18497895 10.1039/b612515h

232 Wysokowski M. Jesionowski T. Ehrlich H. Biosilica as a source for inspiration in biological materials science Am. Mineral. 103 2018 665 691

233 Sumper M. Brunner E. Learning from diatoms: nature's tools for the production of nanostructured silica Adv. Funct. Mater. 16 2006 17 26

234 Palaveniene A. Harkavenko V. Kharchenko V. Daugela P. Pranskunas M. Juodzbalys G. Babenko N. Liesiene J. Cuttlebone as a marine-derived material for preparing bone grafts Mar. Biotechnol. (NY) 20 2018 363 374 29616431 10.1007/s10126-018-9816-6

235 Ehrlich H. Elkin Y.N. Artyoukov A.A. Kozlovskaya E. Stonik V.A. Safronov P.P. Kurek D.V. Bazhenov V.V. Kummer K. Vyalykh D. Molodtsov S. Sivkov V. Born R. Ruhnow M. Meissner H. Richter G. Тhe spines of sand dollar Scaphechinus mirabilis (Agassiz 1863): analytical and structural study J. Adv. Microsc. Res. 5 2010 100 109

236 Li L. Kolle S. Weaver J.C. Ortiz C. Aizenberg J. Kolle M. A highly conspicuous mineralized composite photonic architecture in the translucent shell of the blue-rayed limpet Nat. Commun. 6 2015 6322 6332 25716102 10.1038/ncomms7322 PMC4351589

237 Aguirre L.E. Ouyang L. Elfwing A. Hedblom M. Wulff A. Inganäs O. Diatom frustules protect DNA from ultraviolet light Sci. Rep. 8 2018 5138 5143 29572445 10.1038/s41598-018-21810-2 PMC5865130

238 Ghoshal A. Eck E. Gordon M. Morse D.E. Wavelength-specific forward scattering of light by bragg-reflective iridocytes in giant clams J. R. Soc. Interface 13 2016 20160285 20160292 27383420 10.1098/rsif.2016.0285 PMC4971220

239 Lopez-Garcia M. Masters N. O'Brien H.E. Lennon J. Atkinson G. Cryan M.J. Oulton R. Whitney H.M. Light-induced dynamic structural color by intracellular 3D photonic crystals in Brown algae Sci. Adv. 4 2018 eaan8917 10.1126/sciadv.aan8917 PMC5895443 29651457

240 Iwasaka M. Mizukawa Y. Roberts N.W. Magnetic control of the light reflection anisotropy in a biogenic guanine microcrystal platelet Langmuir 32 2016 180 187 26652206 10.1021/acs.langmuir.5b03522

241 Pereira R.B. Evdokimov N.M. Lefranc F. Valentão P. Kornienko A. Pereira D.M. Andrade P.B. Gomes N.G.M. Marine-derived anticancer agents: clinical benefits, innovative mechanisms, and new targets Mar. Drugs 17 2019 329 349 10.3390/md17060329 PMC6627313 31159480

242 Burke P.J. Mitochondria, bioenergetics and apoptosis in cancer Trends Canc. 3 2017 857 870 10.1016/j.trecan.2017.10.006 PMC5957506 29198441

243 Jackson N.M. Ceresa B.P. EGFR-mediated apoptosis via STAT3 Exp. Cell Res. 356 2017 93 103 28433699 10.1016/j.yexcr.2017.04.016 PMC5514375

244 Kim H.J. Maiti P. Barrientos A. Mitochondrial ribosomes in cancer Semin. Canc. Biol. 47 2017 67 81 10.1016/j.semcancer.2017.04.004 PMC5662495 28445780

245 Zhang P. Zhang Y. Liu K. Liu B. Xu W. Gao J. Ding L. Tao L. Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway Cell Prolif 52 2019 e12543 30515909 10.1111/cpr.12543 PMC6496724

246 Yi F. Frazzette N. Cruz A.C. Klebanoff C.A. Siegel R.M. Beyond cell death: new functions for TNF family cytokines in autoimmunity and tumor immunotherapy Trends Mol. Med. 24 2018 642 653 29880309 10.1016/j.molmed.2018.05.004 PMC7466867

247 Gutiérrez-Rodríguez A.G. Juárez-Portilla C. Olivares-Bañuelos T. Zepeda R.C. Anticancer activity of seaweeds Drug Discov. Today 23 2018 434 447 29107095 10.1016/j.drudis.2017.10.019

248 Liu M. Liu Y. Cao M.J. Liu G.M. Chen Q. Sun L. Chen H. Antibacterial activity and mechanisms of depolymerized fucoidans isolated from Laminaria japonica Carbohydr. Polym. 172 2017 294 305 28606538 10.1016/j.carbpol.2017.05.060

249 Sanjeewa K.K.A. Lee J.S. Kim W.S. Jeon Y.J. The potential of Brown-algae polysaccharides for the development of anticancer agents: an update on anticancer effects reported for fucoidan and laminaran Carbohydr. Polym. 177 2017 451 459 28962791 10.1016/j.carbpol.2017.09.005

250 Choo G.S. Lee H.N. Shin S.A. Kim H.J. Jung J.Y. Anticancer effect of fucoidan on DU-145 prostate cancer cells through inhibition of PI3K/Akt and MAPK pathway expression Mar. Drugs 14 2016 126 137 10.3390/md14070126 PMC4962016 27399727

251 Jimenez P.C. Wilke D.V. Branco P.C. Bauermeister A. Rezende-Teixeira P. Gaudêncio S.P. Costa-Lotufo L.V. Enriching cancer pharmacology with drugs of marine origin Br. J. Pharmacol. 177 2020 3 27 31621891 10.1111/bph.14876 PMC6976878

252 Murphy T. Yee K.W.L. Cytarabine and daunorubicin for the treatment of acute myeloid leukemia Expet Opin. Pharmacother. 18 2017 1765 1780 10.1080/14656566.2017.1391216 29017371

253 Krauss A.C. Gao X. Li L. Manning M.L. Patel P. Fu W. Janoria K.G. Gieser G. Bateman D.A. Przepiorka D. FDA approval summary: (daunorubicin and cytarabine) liposome for injection for the treatment of adults with high-risk acute myeloid leukemia Clin. Canc. Res. 25 2019 2685 2690 10.1158/1078-0432.CCR-18-2990 30541745

254 Lancet J.E. Uy G.L. Cortes J.E. Newell L.F. Lin T.L. Ritchie E.K. Stuart R.K. Strickland S.A. Hogge D. Solomon S.R. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia J. Clin. Oncol. 36 2018 2684 2692 30024784 10.1200/JCO.2017.77.6112 PMC6127025

255 Ratan R. Patel S.R. Trabectedin and eribulin: where do they fit in the management of soft tissue sarcoma? Curr. Treat. Options Oncol. 18 2017 34 42 28534249 10.1007/s11864-017-0477-x

256 De Sanctis R. Marrari A. Santoro A. Trabectedin for the treatment of soft tissue sarcomas Expet Opin. Pharmacother. 17 2016 1569 1577 10.1080/14656566.2016.1204295 27328277

257 Assi T. Kattan J. El Rassy E. Honore C. Dumont S. Mir O. Le Cesne A. A comprehensive review of the current evidence for Trabectedin in advanced myxoid liposarcoma Canc. Treat Rev. 72 2019 37 44 10.1016/j.ctrv.2018.11.003 30468937

258 Demetri G.D. von Mehren M. Jones R.L. Hensley M.L. Schuetze S.M. Staddon A. Milhem M. Elias A. Ganjoo K. Tawbi H. Efficacy and safety of Trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial J. Clin. Oncol. 34 2016 786 793 26371143 10.1200/JCO.2015.62.4734 PMC5070559

259 Cortes J. Schöffski P. Littlefield B.A. Multiple modes of action of eribulin mesylate: emerging data and clinical implications Canc. Treat Rev. 70 2018 190 198 10.1016/j.ctrv.2018.08.008 30243063

260 Perez-Garcia J.M. Cortes J. The safety of eribulin for the treatment of metastatic breast cancer Expet Opin. Drug Saf. 18 2019 347 355 10.1080/14740338.2019.1608946 31107111

261 Aseyev O. Ribeiro J.M. Cardoso F. Review on the clinical use of eribulin mesylate for the treatment of breast cancer Expet Opin. Pharmacother. 17 2016 589 600 10.1517/14656566.2016.1146683 26809667

262 Tawbi H.A. Burgess M. Bolejack V. Van Tine B.A. Schuetze S.M. Hu J. D'Angelo S. Attia S. Riedel R.F. Priebat D.A. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial Lancet Oncol. 18 2017 1493 1501 28988646 10.1016/S1470-2045(17)30624-1 PMC7939029

263 Swami U. Shah U. Goel S. Eribulin in non-small cell lung cancer: challenges and potential strategies Expet Opin. Invest. Drugs 26 2017 495 508 10.1080/13543784.2017.1292250 28161993

264 Shah N. Mohammad A.S. Saralkar P. Sprowls S.A. Vickers S.D. John D. Tallman R.M. Lucke-Wold B.P. Jarrell K.E. Pinti M. Nolan R.L. Lockman P.R. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases Pharmacol. Res. 132 2018 47 68 29604436 10.1016/j.phrs.2018.03.021 PMC5997530

265 Kurata T. Fushida S. Kinoshita J. Oyama K. Yamaguchi T. Okazaki M. Miyashita T. Tajima H. Ninomiya I. Ohta T. Low-dose eribulin mesylate exerts antitumor effects in gastric cancer by inhibiting fibrosis via the suppression of epithelial-mesenchymal transition and acts synergistically with 5-fluorouracil Canc. Manag. Res. 10 2018 2729 2742 10.2147/CMAR.S167846 PMC6101023 30147370

266 Turner S.D. Inghirami G. Miranda R.N. Kadin M.E. Cell of origin and immunologic events in the pathogenesis of breast implant-associated anaplastic large-cell lymphoma Am. J. Pathol. 190 2020 2 10 31610171 10.1016/j.ajpath.2019.09.005 PMC7298558

267 Connors J.M. Jurczak W. Straus D.J. Ansell S.M. Kim W.S. Gallamini A. Younes A. Alekseev S. Illés Á. Picardi M. Lech-Maranda E. Oki Y. Feldman T. Smolewski P. Savage K.J. Bartlett N.L. Walewski J. Chen R. Ramchandren R. Zinzani P.L. Cunningham D. Rosta A. Josephson N.C. Song E. Sachs J. Liu R. Jolin H.A. Huebner D. ECHELON-1 study group, radford J brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma N. Engl. J. Med. 378 2018 331 344 29224502 10.1056/NEJMoa1708984 PMC5819601

268 Berger G.K. McBride A. Lawson S. Royball K. Yun S. Gee K. Bin Riaz I. Saleh A.A. Puvvada S. Anwer F. Brentuximab vedotin for treatment of non-hodgkin lymphomas: a systematic review Crit. Rev. Oncol. Hematol. 109 2017 42 50 28010897 10.1016/j.critrevonc.2016.11.009 PMC5218629

269 Moskowitz C.H. Walewski J. Nademanee A. Masszi T. Agura E. Holowiecki J. Abidi M.H. Chen A.I. Stiff P. Viviani S. Bachanova V. Sureda A. McClendon T. Lee C. Lisano J. Sweetenham J. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse Blood 132 2018 2639 2642 30266774 10.1182/blood-2018-07-861641

270 Delgado-Calle J. Kurihara N. Atkinson E.G. Nelson J. Miyagawa K. Galmarini C.M. Roodman G.D. Bellido T. Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts Oncotarget 10 2019 2709 2721 31105871 10.18632/oncotarget.26831 PMC6505631

271 Delgado-Calle J. Atkinson E.G. Nelson J. Kurihara N. Galmarini C. Roodman D.D. Bellido T. Aplidin (plitidepsin) regulates viability and function of myeloma cells and bone cells in combination with other anti-MM drugs Blood 130 Supplement 1 2017 3065-3065

272 Cimino P.J. Huang L. Du L. Wu Y. Bishop J. Dalsing-Hernandez J. Kotlarczyk K. Gonzales P. Carew J. Nawrocki S. Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling Biomed. Rep. 10 2019 218 224 30972217 10.3892/br.2019.1196 PMC6439430

273 Blayney D.W. Zhang Q. Feng J. Zhao Y. Bondarenko I. Vynnychenko I. Kovalenko N. Nair S. Ibrahim E. Udovista D.P. Efficacy of plinabulin vs pegfilgrastim for prevention of chemotherapy-induced neutropenia in adults with non–small cell lung cancer: a phase 2 randomized clinical trial JAMA Oncol. 6 2020 e204429 10.1001/jamaoncol.2020.4429 PMC7516815 32970104

274 Goss G.D. Vokes E.E. Gordon M.S. Gandhi L. Papadopoulos K.P. Rasco D.W. Fischer J.S. Chu K.L. Ames W.W. Mittapalli R.K. Lee H.J. Zeng J. Roberts-Rapp L.A. Loberg L.I. Ansell P.J. Reilly E.B. Ocampo C.J. Holen K.D. Tolcher A.W. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor Cancer 124 2018 2174 2183 29533458 10.1002/cncr.31304 PMC5969257

275 Lassman A.B. van den Bent M.J. Gan H.K. Reardon D.A. Kumthekar P. Butowski N. Lwin Z. Mikkelsen T. Nabors L.B. Papadopoulos K.P. Penas-Prado M. Simes J. Wheeler H. Walbert T. Scott A.M. Gomez E. Lee H.J. Roberts-Rapp L. Xiong H. Ansell P.J. Bain E. Holen K.D. Maag D. Merrell R. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial Neuro Oncol. 21 2019 106 114 29982805 10.1093/neuonc/noy091 PMC6303422

276 Farago A.F. Drapkin B.J. Lopez-Vilarino de Ramos J.A. Galmarini C.M. Núñez R. Kahatt C. Paz-Ares L. ATLANTIS: a phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line Future Oncol. 15 2019 231 239 30362375 10.2217/fon-2018-0597 PMC6331752

277 Morschhauser F. Flinn I.W. Advani R. Sehn L.H. Diefenbach C. Kolibaba K. Press O.W. Salles G. Tilly H. Chen A.I. Assouline S. Cheson B.D. Dreyling M. Hagenbeek A. Zinzani P.L. Jones S. Cheng J. Lu D. Penuel E. Hirata J. Wenger M. Chu Y.W. Sharman J. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS), lancet Haematol. 6 2019 e254 e265 10.1016/S2352-3026(19)30026-2 30935953

278 Kopp L.M. Malempati S. Krailo M. Gao Y. Buxton A. Weigel B.J. Hawthorne T. Crowley E. Moscow J.A. Reid J.M. Villalobos V. Randall R.L. Gorlick R. Janeway K.A. Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: a report from the children's oncology group Eur. J. Canc. 121 2019 177 183 10.1016/j.ejca.2019.08.015 PMC6952063 31586757

279 Ott P.A. Pavlick A.C. Johnson D.B. Hart L.L. Infante J.R. Luke J.J. Lutzky J. Rothschild N.E. Spitler L.E. Cowey C.L. Alizadeh A.R. Salama A.K. He Y. Hawthorne T.R. Bagley R.G. Zhang J. Turner C.D. Hamid O. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma Cancer 125 2019 1113 1123 30690710 10.1002/cncr.31892

280 Hasanov M. Rioth M.J. Kendra K. Hernandez-Aya L. Joseph R.W. Williamson S. Chandra S. Shirai K. Turner C.D. Lewis K. Crowley E. Moscow J. Carter B. Patel S. A phase II study of glembatumumab vedotin for metastatic uveal melanoma Cancers (Basel) 12 2020 2270 2281 10.3390/cancers12082270 PMC7465139 32823698

281 Hong D.S. Concin N. Vergote I. de Bono J.S. Slomovitz B.M. Drew Y. Arkenau H.T. Machiels J.P. Spicer J.F. Jones R. Forster M.D. Cornez N. Gennigens C. Johnson M.L. Thistlethwaite F.C. Rangwala R.A. Ghatta S. Windfeld K. Harris J.R. Lassen U.N. Coleman R.L. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer Clin. Canc. Res. 26 2020 1220 1228 10.1158/1078-0432.CCR-19-2962 31796521

282 Waqar S.N. Redman M.W. Arnold S.M. Hirsch F.R. Mack P.C. Schwartz L.H. Gandara D.R. Stinchcombe T.E. Leighl N.B. Ramalingam S.S. A phase II study of telisotuzumab vedotin in patients with c-MET-positive stage IV or recurrent squamous cell lung cancer (LUNG-MAP sub-study S1400K, NCT03574753 ) Clin. Lung Canc. 14 2020 S1525 S7304 10.1016/j.cllc.2020.09.013 PMC8044254 33221175

283 Trudel S. Lendvai N. Popat R. Voorhees P.M. Reeves B. Libby E.N. Richardson P.G. Anderson L.D.J. Sutherland H.J. Yong K. Hoos A. Gorczyca M.M. Lahiri S. He Z. Austin D.J. Opalinska J.B. Cohen A.D. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial Lancet Oncol. 19 2018 1641 1653 30442502 10.1016/S1470-2045(18)30576-X PMC6328058

284 Pereira F. Have marine natural product drug discovery efforts been productive and how can we improve their efficiency? Expet Opin. Drug Discov. 14 2019 717 722 10.1080/17460441.2019.1604675 30982363

285 Cortés J. Diab S. Basho R.K. Oliveira M. Pluard T. Alemany C. Brown-Glaberman U. Meisel J. Boni V. Sinha R. SGNLVA-002: single arm, open-label, phase ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer Ann. Oncol. 31 2020 S393-S393

286 Hoimes C.J. Petrylak D.P. Flaig T.W. Carret A.S. Melhem-Bertrandt A. Rosenberg J.E. EV-103 study: a phase 1b dose-escalation and dose-expansion study of enfortumab vedotin in combination with immune checkpoint inhibitor (CPI) therapy for treatment of patients with locally advanced or metastatic urothelial cancer Eur. Urol. Suppl. 2 2018 e1151

287 Balar A.V. Galsky M.D. Rosenberg J.E. Powles T. Petrylak D.P. Bellmunt J. Loriot Y. Necchi A. Hoffman-Censits J. Perez-Gracia J.L. Dawson N.A. van der Heijden M.S. Dreicer R. Srinivas S. Retz M.M. Joseph R.W. Drakaki A. Vaishampayan U.N. Sridhar S.S. Quinn D.I. Durán I. Shaffer D.R. Eigl B.J. Grivas P.D. Yu E.Y. Li S. Kadel E.E. 3rd Boyd Z. Bourgon R. Hegde P.S. Mariathasan S. Thåström A. Abidoye O.O. Fine G.D. Bajorin D.F. IMvigor210 Study Group Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Lancet (London, England) 389 2017 67 76 10.1016/S0140-6736(16)32455-2 PMC5568632 27939400

288 Purcell J.W. Tanlimco S.G. Hickson J. Fox M. Sho M. Durkin L. Uziel T. Powers R. Foster K. McGonigal T. LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates Canc. Res. 78 2018 4059 4072 10.1158/0008-5472.CAN-18-0327 29764866

289 Newman D.J. The “utility ” of highly toxic marine-sourced compounds Mar. Drugs 17 2019 324 342 10.3390/md17060324 PMC6627392 31159276

290 Damelin M. Bankovich A. Bernstein J. Lucas J. Chen L. Williams S. Park A. Aguilar J. Ernstoff E. Charati M. Dushin R. Aujay M. Lee C. Ramoth H. Milton M. Hampl J. Lazetic S. Pulito V. Rosfjord E. Sun Y. King L. Barletta F. Betts A. Guffroy M. Falahatpisheh H. O'Donnell C.J. Stull R. Pysz M. Escarpe P. Liu D. Foord O. Gerber H.P. Sapra P. Dylla S.J. A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions Sci. Transl. Med. 9 2017 2611 2621 10.1126/scitranslmed.aag2611 28077676

291 Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (review) Int. J. Oncol. 51 2017 1357 1369 29048660 10.3892/ijo.2017.4129 PMC5642388

292 Aravindan S. Somasundaram D.B. Somasundaram S.T. Natarajan M. Herman T.S. Aravindan N. Targeting acquired oncogenic burden in resilient pancreatic cancer: a novel benefit from marine polyphenols Mol. Cell. Biochem. 460 2019 175 193 31367889 10.1007/s11010-019-03579-8 PMC8895420

293 Morrison K. Challita-Eid P.M. Raitano A. An Z. Yang P. Abad J.D. Liu W. Lortie D.R. Snyder J.T. Capo L. Verlinsky A. Aviña H. Doñate F. Joseph I.B. Pereira D.S. Morrison K. Stover D.R. Development of ASG-15ME, a novel antibody-drug conjugate targeting SLITRK6, a new urothelial cancer biomarker Mol. Canc. Therapeut. 15 2016 1301 1310 10.1158/1535-7163.MCT-15-0570 26944921

294 Vlachostergios P.J. Jakubowski C.D. Niaz M.J. Lee A. Thomas C. Hackett A.L. Patel P. Rashid N. Tagawa S.T. Antibody-drug conjugates in bladder cancer Bladder Cancer 4 2018 247 259 30112436 10.3233/BLC-180169 PMC6087439

295 Newman D.J. Cragg G.M. Current status of marine-derived compounds as warheads in anti-tumor drug candidates Mar. Drugs 15 2017 99 117 10.3390/md15040099 PMC5408245 28353637

296 Pereira D.S. Guevara C.I. Jin L. Mbong N. Verlinsky A. Hsu S.J. Aviña H. Karki S. Abad J.D. Yang P. Moon S.J. Malik F. Choi M.Y. An Z. Morrison K. Challita-Eid P.M. Doñate F. Joseph I.B. Kipps T.J. Dick J.E. Stover D.R. AGS67E, an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B/T-Cell malignancies and AML: a new role for CD37 in AML Mol. Canc. Therapeut. 14 2015 1650 1660 10.1158/1535-7163.MCT-15-0067 PMC4557793 25934707

297 Cheung R.C.F. Ng T.B. Wong J.H. Marine peptides: bioactivities and applications Mar. Drugs 13 2015 4006 4043 26132844 10.3390/md13074006 PMC4515606

298 Falanga A. Lombardi L. Franci G. Vitiello M. Iovene M.R. Morelli G. Galdiero M. Galdiero S. Marine antimicrobial peptides: nature provides templates for the design of novel compounds against pathogenic bacteria Int. J. Mol. Sci. 17 2016 785 802 10.3390/ijms17050785 PMC4881601 27213366

299 Diogo G.S. Senra E.L. Pirraco R.P. Canadas R.F. Fernandes E.M. Serra J. Pérez-Martín R.I. Sotelo C.G. Marques A.P. González P. Moreira-Silva J. Silva T.H. Reis R.L. Marine collagen/apatite composite scaffolds envisaging hard tissue applications Mar. Drugs 16 2018 269 282 10.3390/md16080269 PMC6117652 30081528

300 Deepthi S. Venkatesan J. Kim S.K. Bumgardner J.D. Jayakumar R. An overview of chitin or chitosan/nano ceramic composite scaffolds for bone tissue engineering Int. J. Biol. Macromol. 93 2016 1338 1353 27012892 10.1016/j.ijbiomac.2016.03.041

301 Echave M.C. Sánchez P. Pedraz J.L. Orive G. Progress of gelatin-based 3D approaches for bone regeneration J. Drug Deliv. Sci. Technol. 42 2017 63 74

302 Narayana J.L. Huang H.N. Wu C.J. Chen J.Y. Efficacy of the antimicrobial peptide TP4 against Helicobacter pylori infection: In vitro membrane perturbation via micellization and in vivo suppression of host immune responses in a mouse model Oncotarget 6 2015 12936 12954 26002554 10.18632/oncotarget.4101 PMC4536990

303 Meng D.M. Lv Y.J. Zhao J.F. Liu Q.Y. Shi L.Y. Wang J.P. Yang Y.H. Fan Z.C. Efficient production of a recombinant venerupis philippinarum defensin (VpDef) in pichia pastoris and characterization of its antibacterial activity and stability Protein Expr. Purif. 147 2018 78 84 29524591 10.1016/j.pep.2018.03.001

304 Wei L. Gao J. Zhang S. Wu S. Xie Z. Ling G. Kuang Y.Q. Yang Y. Yu H. Wang Y. Identification and characterization of the first cathelicidin from sea snakes with potent antimicrobial and anti-inflammatory activity and special mechanism J. Biol. Chem. 290 2015 16633 16652 26013823 10.1074/jbc.M115.642645 PMC4505416

305 Chen C. Wang A. Zhang F. Zhang M. Yang H. Li J. Su P. Chen Y. Yu H. Wang Y. The protective effect of fish-derived cathelicidins on bacterial infections in zebrafish, Danio rerio Fish Shellfish Immunol. 92 2019 519 527 31202967 10.1016/j.fsi.2019.06.029

306 Kurata A. Yamaura Y. Tanaka T. Kato C. Nakasone K. Kishimoto N. Antifungal peptidic compound from the deep-sea bacterium Aneurinibacillus sp. YR247 World J. Microbiol. Biotechnol. 33 2017 73 80 28299556 10.1007/s11274-017-2239-0 PMC5352791

307 Espiritu R.A. Cornelio K. Kinoshita M. Matsumori N. Murata M. Nishimura S. Kakeya H. Yoshida M. Matsunaga S. Marine sponge cyclic peptide theonellamide A disrupts lipid bilayer integrity without forming distinct membrane pores Biochim. Biophys. Acta 1858 2016 1373 1379 27003125 10.1016/j.bbamem.2016.03.019

308 Binnewerg B. Schubert M. Voronkina A. Muzychka L. Wysokowski M. Petrenko I. Djurović M. Kovalchuk V. Tsurkan M. Martinovic R. Bechmann N. Fursov A. Ivanenko V.N. Tabachnik K.R. Smolii O.B. Joseph Y. Giovine M. Bornstein S.R. Stelling A.L. Tunger A. Schmitz M. Taniya O.S. Kovalev I.S. Zyryanov G.V. Guan K. Ehrlich H. Marine biomaterials: biomimetic and pharmacological potential of cultivated Aplysina aerophoba marine demosponge Mater. Sci. Eng. C Mater. Biol. Appl. 109 2020 110566 32228987 10.1016/j.msec.2019.110566

309 Machałowski T. Czajka M. Petrenko I. Meissner H. Schimpf C. Rafaja D. Ziętek J. Dzięgiel B. Adaszek Ł. Voronkina A. Kovalchuk V. Jaroszewicz J. Fursov A. Rahimi-Nasrabadi M. Stawski D. Bechmann N. Jesionowski T. Ehrlich H. Functionalization of 3D chitinous skeletal scaffolds of sponge origin using silver nanoparticles and their antibacterial properties Mar. Drugs 18 2020 304 319 10.3390/md18060304 PMC7345230 32531909

310 Gui L. Zhang P. Zhang Q. Zhang J. Two hepcidins from spotted scat (Scatophagus argus) possess antibacterial and antiviral functions in vitro Fish Shellfish Immunol. 50 2016 191 199 26845697 10.1016/j.fsi.2016.01.038

311 Wysokowski M. Machalowski T. Petrenko I. Schimpf C. Rafaja D. Galli R. Zietek J. Pantović S. Voronkina A. Kovalchuk V. Ivanenko V.N. Hoeksema B.W. Diaz C. Khrunyk Y. Stelling A.L. Giovine M. Jesionowski T. Ehrlich H. 3D chitin scaffolds of marine demosponge origin for biomimetic mollusk hemolymph-associated biomineralization ex-vivo Mar. Drugs 18 2020 574 590 10.3390/md18020123 PMC7074400 32092907

312 Jing Q. Hu X. Ma Y. Mu J. Liu W. Xu F. Li Z. Bai J. Hua H. Li D. Marine-derived natural lead compound disulfide-linked dimer psammaplin A: biological activity and structural modification Mar. Drugs 17 2019 384 406 10.3390/md17070384 PMC6669562 31252563

313 Kovalchuk V. Voronkina A. Binnewerg B. Schubert M. Muzychka L. Wysokowski M. Tsurkan M.V. Bechmann N. Petrenko I. Fursov A. Martinovic R. Ivanenko V.N. Fromont J. Smolii O.B. Joseph Y. Giovine M. Erpenbeck D. Gelinsky M. Springer A. Guan K. Bornstein S.R. Ehrlich H. Naturally drug-loaded chitin: isolation and applications Mar. Drugs 17 2019 1 17 10.3390/md17100574 PMC6835269 31658704

314 Tabudravu J.N. Eijsink V.G.H. Gooday G.W. Jaspars M. Komander D. Legg M. Synstad B. van Aalten D.M.F. Psammaplin A. A chitinase inhibitor isolated from the Fijian marine sponge Aplysinella rhax Bioorg. Med. Chem. 10 2002 1123 1128 11836123 10.1016/s0968-0896(01)00372-8

315 Roseti L. Parisi V. Petretta M. Cavallo C. Desando G. Bartolotti I. Grigolo B. Scaffolds for bone tissue engineering: state of the art and new perspectives Mater. Sci. Eng. C 78 2017 1246 1262 10.1016/j.msec.2017.05.017 28575964

316 Neto A.S. Ferreira J.M.F. Synthetic and marine-derived porous scaffolds for bone tissue engineering Materials (Basel) 11 2018 1702 1741 10.3390/ma11091702 PMC6165145 30216991

317 Kuttappan S. Mathew D. Nair M.B. Biomimetic composite scaffolds containing bioceramics and collagen/gelatin for bone tissue engineering - a mini review Int. J. Biol. Macromol. 93 2016 1390 1401 27316767 10.1016/j.ijbiomac.2016.06.043

318 Georgopoulou A. Kaliva M. Vamvakaki M. Chatzinikolaidou M. Osteogenic potential of pre-osteoblastic cells on a chitosan-graft-polycaprolactone copolymer Materials (Basel) 11 2018 490 505 10.3390/ma11040490 PMC5951336 29587410

319 Aguilar A. Zein N. Harmouch E. Hafdi B. Bornert F. Offner D. Clauss F. Fioretti F. Huck O. Benkirane-Jessel N. Hua G. Application of chitosan in bone and dental engineering Molecules 24 2019 3009 3025 10.3390/molecules24163009 PMC6720623 31431001

320 Mohammadi R. Amini K. Guided bone regeneration of mandibles using chitosan scaffold seeded with characterized uncultured omental adipose-derived stromal vascular fraction: an animal study Int. J. Oral Maxillofac. Implants 30 2015 216 222 25615927 10.11607/jomi.3542

321 Ehrlich H. Steck E. Ilan M. Maldonado M. Muricy G. Bavestrello G. Kljajic Z. Carballo J.L. Shiaparelli S. Ereskovsky A.V. Schupp P. Born R. Worch H. Bazhenov V.V. Kurek D. Varlamow V. Vyalikh D. Kummer K. Sivkov V.V. Molodtsov S.L. Meissner H. Richter G. Hunoldt S. Kammer M. Paasch S. Krasokhin V. Patzke G. Brunner E. Richter W. Three dimensional chitin-based scaffolds from Verongida sponges (Demospongiae: Porifera). Part II. Biomimetic potential and applications Int. J. Biol. Macromol. 47 2010 141 145 20478334 10.1016/j.ijbiomac.2010.05.009

322 Zhou D. Qi C. Chen Y.X. Zhu Y.J. Sun T.W. Chen F. Zhang C.Q. Comparative study of porous hydroxyapatite/chitosan and whitlockite/chitosan scaffolds for bone regeneration in calvarial defects Int. J. Nanomed. 12 2017 2673 2687 10.2147/IJN.S131251 PMC5388207 28435251

323 Bordini E.A.F. Cassiano F.B. Silva I.S.P. Usberti F.R. Anovazzi G. Pacheco L.E. Pansani T.N. Leite M.L. Hebling J. de Souza Costa C.A. Soares D.G. Synergistic potential of 1α,25-dihydroxyvitamin D3 and calcium–aluminate–chitosan scaffolds with dental pulp cells, Clin. Oral Invest. 24 2020 663 674 10.1007/s00784-019-02906-z 31119382

324 Zhu N. Chatzistavrou X. Ge L. Qin M. Papagerakis P. Wang Y. Biological properties of modified bioactive glass on dental pulp cells J. Dent. 83 2019 18 26 30776406 10.1016/j.jdent.2019.01.017

325 Klinger C. Żółtowska-Aksamitowska S. Wysokowski M. Tsurkan M.V. Galli R. Petrenko P. Machałowski T. Ereskovsky A. Martinović R. Muzychka L. Smolii R.B. Bechmann N. Ivanenko V. Schupp P.J. Jesionowski T. Giovine M. Joseph Y. Bornstein S.R. Voronkina A. Ehrlich H. Express Method for isolation of ready-to-use 3d chitin scaffolds from Aplysinaarcheri (Aplysineidae: verongiida) demosponge Mar. Drugs 17 2019 131 154 10.3390/md17020131 PMC6409528 30813373

326 Gopinathan J. Noh I. Recent trends in bioinks for 3D printing Biomater. Res. 22 2018 11 25 29636985 10.1186/s40824-018-0122-1 PMC5889544

327 Sakamoto A. Saotome M. Iguchi K. Maekawa Y. Marine-derived omega-3 polyunsaturated fatty acids and heart failure: current understanding for basic to clinical relevance Int. J. Mol. Sci. 20 2019 4025 4043 10.3390/ijms20164025 PMC6719114 31426560

328 Cardoso M.J. Costa R.R. Mano J.F. Marine origin polysaccharides in drug delivery systems Mar. Drugs 14 2016 34 60 10.3390/md14020034 PMC4771987 26861358

329 Popov A.A. Sergeeva N.S. Britaev T.A. Komlev V.S. Sviridova I.K. Kirsanova V.A. Akhmedova S.A. Dgebuadze P.Y. Teterina A.Y. Kuvshinova E.A. Schanskii Y.D. Some physical, chemical, and biological parameters of samples of scleractinium coral aquaculture skeleton used for reconstruction/engineering of the bone tissue Bull. Exp. Biol. Med. 159 2015 494 497 26388568 10.1007/s10517-015-3001-y

330 Lordan R. Redfern S. Tsoupras A. Zabetakis I. Inflammation and cardiovascular disease: are marine phospholipids the answer? Food Funct. 11 2020 2861 2885 32270798 10.1039/c9fo01742a

331 Chaugule S.R. Indap M.M. Chiplunkar S.V. Marine natural products: new avenue in treatment of osteoporosis Front. Mar. Sci. 4 2017 384 398

332 Zhang J. Wehrle E. Vetsch J.R. Paul G.R. Rubert M. Müller R. Alginate dependent changes of physical properties in 3D bioprinted cell-laden porous scaffolds affect cell viability and cell morphology Biomed. Mater. 14 2019 65009 65042 10.1088/1748-605X/ab3c74 31426033

333 Raftery R.M. Woods B. Marques A.L.P. Moreira-Silva J. Silva T.H. Cryan S.A. Reis R.L. O'Brien F.J. Multifunctional biomaterials from the sea: assessing the effects of chitosan incorporation into collagen scaffolds on mechanical and biological functionality Acta Biomater. 43 2016 160 169 27402181 10.1016/j.actbio.2016.07.009

334 Elango J. Zhang J. Bao B. Palaniyandi K. Wang S. Wenhui W. Robinson J.S. Rheological, biocompatibility and osteogenesis assessment of fish collagen scaffold for bone tissue engineering Int. J. Biol. Macromol. 91 2016 51 59 27211297 10.1016/j.ijbiomac.2016.05.067

335 Luo Y. Lode A. Wu C. Chang J. Gelinsky M. Alginate/nanohydroxyapatite scaffolds with designed core/shell structures fabricated by 3D plotting and in situ mineralization for bone tissue engineering ACS Appl. Mater. Interfaces 7 2015 6541 6549 25761464 10.1021/am508469h

336 Yan J. Miao Y. Tan H. Zhou T. Ling Z. Chen Y. Xing X. Hu X. Injectable Alginate/hydroxyapatite gel scaffold combined with gelatin microspheres for drug delivery and bone tissue engineering Mater. Sci. Eng. C 63 2016 274 284 10.1016/j.msec.2016.02.071 27040220

337 Mutsenko V.V. Gryshkov O. Lauterboeck L. Rogulska O. Tarusin D.N. Bazhenov V.V. Schütz K. Brüggemeier S. Gossla E. Akkineni A.R. Meißner H. Lode A. Meschke S. Fromont J. Stelling A.L. Tabachnik K.R. Gelinsky M. Nikulin S. Rodin S. Tonevitsky A.G. Petrenko A.Y. Glasmacher B. Schupp P.J. Ehrlich H. Novel chitin scaffolds derived from marine sponge Ianthella basta for tissue engineering approaches based on human mesenchymal stromal cells: biocompatibility and cryopreservation Int. J. Biol. Macromol. 104 2017 1955 1965 28365291 10.1016/j.ijbiomac.2017.03.161

338 Mutsenko V.V. Bazhenov V.V. Rogulska O. Tarusin D.N. Schütz K. Brüggemeier S. Gossla E. Akkineni A.R. Meißner H. Lode A. Meschke S. Ehrlich A. Petović S. Martinović R. Djurović M. Stelling A.L. Nikulin S. Rodin S. Tonevitsky A. Gelinsky M. Petrenko A.Y. Glasmacher B. Ehrlich H. 3D chitinous scaffolds derived from cultivated marine demosponge aplysina aerophoba for tissue engineering approaches based on human mesenchymal stromal cells Int. J. Biol. Macromol. 104 2017 1966 1974 28347785 10.1016/j.ijbiomac.2017.03.116

339 Carvalho D.N. López-Cebral R. Sousa R.O. Alves A.L. Reys L.L. Silva S.S. Oliveira J.M. Reis R.L. Silva T.H. Marine collagen-chitosan-fucoidan cryogels as cell-laden biocomposites envisaging tissue engineering Biomed. Mater. 15 2020 55030 55351 10.1088/1748-605X/ab9f04 32570224

340 Freeman F.E. Kelly D.J. Tuning alginate bioink stiffness and composition for controlled growth factor delivery and to spatially direct MSC fate within bioprinted tissues Sci. Rep. 7 2017 17042 17053 29213126 10.1038/s41598-017-17286-1 PMC5719090

341 Park T.Y. Yang Y.J. Ha D.H. Cho D.W. Cha H.J. Marine-derived natural polymer-based bioprinting ink for biocompatible, durable, and controllable 3D constructs Biofabrication 11 2019 35001 35034 10.1088/1758-5090/ab0c6f 30831562

342 Liu J. Tagami T. Ozeki T. Fabrication of 3D-printed fish-gelatin-based polymer hydrogel patches for local delivery of PEGylated liposomal doxorubicin Mar. Drugs 18 2020 325 335 10.3390/md18060325 PMC7344981 32575787

343 Kang M.G. Lee M.Y. Cha J.M. Lee J.K. Lee S.C. Kim J. Hwang Y.S. Bae H. Nanogels derived from fish gelatin: application to drug delivery system Mar. Drugs 17 2019 246 256 10.3390/md17040246 PMC6521307 31027308

344 Li H. Tan Y.J. Li L. A strategy for strong interface bonding by 3D bioprinting of oppositely charged κ-carrageenan and gelatin hydrogels Carbohydr. Polym. 198 2018 261 269 30092999 10.1016/j.carbpol.2018.06.081

345 Demirtaş T.T. Irmak G. Gümüşderelioğlu M. A bioprintable form of chitosan hydrogel for bone tissue engineering Biofabrication 9 2017 35003 35033 10.1088/1758-5090/aa7b1d 28639943

346 Kim M.H. Lee Y.W. Jung W.K. Oh J. Nam S.Y. Enhanced rheological behaviors of alginate hydrogels with carrageenan for extrusion-based bioprinting J. Mech. Behav. Biomed. Mater. 98 2019 187 194 31252328 10.1016/j.jmbbm.2019.06.014

347 Köpf M. Campos D.F.D. Blaeser A. Sen K.S. Fischer H. A tailored three-dimensionally printable Agarose–collagen blend allows encapsulation, spreading, and attachment of human umbilical artery smooth muscle cells Biofabrication 8 2016 25011 25025 10.1088/1758-5090/8/2/025011 27205890

348 Kreimendahl F. Köpf M. Thiebes A.L. Duarte Campos D.F. Blaeser A. Schmitz-Rode T. Apel C. Jockenhoevel S. Fischer H. Three-dimensional printing and angiogenesis: tailored agarose-type I collagen blends comprise three-dimensional printability and angiogenesis potential for tissue-engineered substitutes, tissue eng. Part C Methods 23 2017 604 615 10.1089/ten.TEC.2017.0234 28826357

349 Yoon H.J. Shin S.R. Cha J.M. Lee S.H. Kim J.H. Do J.T. Song H. Bae H. Cold water fish gelatin methacryloyl hydrogel for tissue engineering application PLoS One 11 2016 e0163902 2016 10.1371/journal.pone.0163902 PMC5056724 27723807

350 Zhang X. Kim G.J. Kang M.G. Lee J.K. Seo J.W. Do J.T. Hong K. Cha J.M. Shin S.R. Bae H. Marine biomaterial-based bioinks for generating 3D printed tissue constructs Mar. Drugs 16 2018 484 496 10.3390/md16120484 PMC6315353 30518062

351 Diaz-Rodriguez P. López-Álvarez M. Serra J. González P. Landín M. Current stage of marine ceramic grafts for 3D bone tissue regeneration Mar. Drugs 17 2019 1 16 10.3390/md17080471 PMC6723791 31443166

352 López-Álvarez M. Pérez-Davila S. Rodríguez-Valencia C. González P. Serra J. The improved biological response of shark tooth bioapatites in a comparative in vitro study with synthetic and bovine bone grafts Biomed. Mater. 11 2016 35011 35023 10.1088/1748-6041/11/3/035011 27271863

353 Diaz-Rodriguez P. Garcia-Triñanes P. Echezarreta López M.M. Santoveña A. Landin M. Mineralized alginate hydrogels using marine carbonates for bone tissue engineering applications Carbohydr. Polym. 195 2018 235 242 29804973 10.1016/j.carbpol.2018.04.101

354 Nandi S.K. Kundu B. Mukherjee J. Mahato A. Datta S. Balla V.K. Converted marine coral hydroxyapatite implants with growth factors: in vivo bone regeneration Mater. Sci. Eng. C 49 2015 816 823 10.1016/j.msec.2015.01.078 25687013

355 Decambron A. Fournet A. Bensidhoum M. Manassero M. Sailhan F. Petite H. Logeart-Avramoglou D. Viateau V. Low-dose BMP-2 and MSC dual delivery onto coral scaffold for critical-size bone defect regeneration in sheep J. Orthop. Res. 35 2017 2637 2645 28401593 10.1002/jor.23577

356 Hongmin L. Wei Z. Xingrong Y. Jing W. Wenxin G. Jihong C. Xin X. Fulin C. Osteoinductive nanohydroxyapatite bone substitute prepared via in situ hydrothermal transformation of cuttlefish bone J. Biomed. Mater. Res. B Appl. Biomater. 103 2015 816 824 25115654 10.1002/jbm.b.33261

357 Neto A.S. Brazete D. Ferreira J.M.F. Cuttlefish bone-derived biphasic calcium phosphate scaffolds coated with sol-gel derived bioactive glass Mater (Basel) 12 2019 2711 2721 10.3390/ma12172711 PMC6747785 31450554

358 Wysokowski M. Machalowski T. Petrenko I. Schimpf C. Rafaja D. Galli R. Zietek J. Pantovic S. Voronkina A. Kovalchuk V. 3D chitin scaffolds of marine demosponge origin for biomimetic mollusk hemolymph-associated biomineralization ex-vivo Mar. Drugs 18 2020 123 148 10.3390/md18020123 PMC7074400 32092907

359 Sheehy E.J. Lemoine M. Clarke D. Gonzalez Vazquez A. O'Brien F.J. The incorporation of marine coral microparticles into collagen-based scaffolds promotes osteogenesis of human mesenchymal stromal cells via calcium ion signalling Mar. Drugs 18 2020 74 93 10.3390/md18020074 PMC7073845 31979233

360 Ehrlich H. Etnoyer P. Litvinov S. Olennikova M. Domaschke H. Hanke T. Born R. Worch H. Biomaterial structure in deep-sea bamboo coral (Anthozoa: gorgonacea: Isididae): perspectives for the development of bone implants and templates for tissue engineering Mater. Werkst. 37 2006 552 557

361 Du B. Gao Y. Deng Y. Zhao Y. Lai C. Guo Z. Rong M. Zhou L. Local delivery of RhVEGF165 through biocoated NHA/coral block grafts in critical-sized dog mandible defects: a histological study at the early stages of bone healing Int. J. Clin. Exp. Med. 8 2015 4940 4953 26131067 PMC4483881

362 Schubert M. Binnewerg B. Voronkina A. Muzychka L. Wysokowski M. Petrenko I. Kovalchuk V. Tsurkan M. Martinovic R. Bechmann N. Ivanenko V.N. Fursov A. Smolii O.B. Fromont J. Joseph Y. Bornstein S.R. Giovine M. Erpenbeck D. Guan K. Ehrlich H. Naturally prefabricated marine biomaterials: isolation and applications of flat chitinous 3D scaffolds from Ianthella labyrinthus (Demospongiae: verongiida) Int. J. Mol. Sci. 20 2019 5105 10.3390/ijms20205105 PMC6829448 31618840

363 Nandi S.K. Kundu B. Mahato A. Thakur N.L. Joardar S.N. Mandal B.B. In vitro and in vivo evaluation of the marine sponge skeleton as a bone mimicking biomaterial Integr. Biol. (Camb). 7 2015 250 262 25578396 10.1039/c4ib00289j

364 Carpena N.T. Min Y.K. Lee B.T. Improved in vitro biocompatibility of surface-modified hydroxyapatite sponge scaffold with gelatin and BMP-2 in comparison against a commercial bone allograft ASAIO J. 61 2015 78 86 25248041 10.1097/MAT.0000000000000155

365 Wysokowski M. Machalowski T. Petrenko I. Schimpf C. Rafaja D. Galli R. Ziętek J. Pantović S. Voronkina A. Kovalchuk V. Ivanenko V.N. Hoeksma B.W. Diaz C. Khrunyk Y. Stelling A.L. Giovine M. Jesionowski T. Ehrlich H. 3D chitin scaffolds of marine demosponge origin for biomimetic mollusk hemolymph-associated biomineralization ex-vivo Mar. Drugs 18 2020 123 149 10.3390/md18020123 PMC7074400 32092907

366 Cozza N. Monte F. Bonani W. Aswath P. Motta A. Migliaresi C. Bioactivity and mineralization of natural hydroxyapatite from cuttlefish bone and Bioglass(®) Co-sintered bioceramics J. Tissue Eng. Regen. Med. 12 2018 e1131 e1142 28500666 10.1002/term.2448

367 Kim B.S. Yang S.S. Yoon J.H. Lee J. Enhanced bone regeneration by silicon-substituted hydroxyapatite derived from cuttlefish bone Clin. Oral Implants Res. 28 2017 49 56 26073102 10.1111/clr.12613

368 López-Álvarez M. Vigo E. Rodríguez-Valencia C. Outeiriño-Iglesias V. González P. Serra J. In vivo evaluation of shark teeth-derived bioapatites Clin. Oral Implants Res. 28 2017 e91 e100 27492736 10.1111/clr.12934

369 Higa K. Kitamura N. Kurokawa T. Goto K. Wada S. Nonoyama T. Kanaya F. Sugahara K. Gong J.P. Yasuda K. Fundamental biomaterial properties of tough glycosaminoglycan-containing double network hydrogels newly developed using the molecular stent method Acta Biomater. 43 2016 38 49 27427226 10.1016/j.actbio.2016.07.023

370 Kuo C.Y. Chen C.H. Hsiao C.Y. Chen J.P. Incorporation of chitosan in biomimetic gelatin/chondroitin-6-sulfate/hyaluronan cryogel for cartilage tissue engineering, carbohydr Polym 117 2015 722 730 10.1016/j.carbpol.2014.10.056 25498693

371 Luo Z. Sun W. Fang J. Lee K. Li S. Gu Z. Dokmeci M.R. Khademhosseini A. Biodegradable gelatin methacryloyl microneedles for transdermal drug delivery Adv. Healthc. Mater. 8 2019 e1801054 10.1002/adhm.201801054 PMC6588190 30565887

372 Tihan G.T. Rău I. Zgârian R.G. Ungureanu C. Barbaresso R.C. Kaya M.G.A. Dinu-Pîrvu C. Ghica M.V. Oxytetracycline versus doxycycline collagen sponges designed as potential carrier supports in biomedical applications Pharmaceutics 11 2019 363 383 10.3390/pharmaceutics11080363 PMC6722625 31344927

373 Biasin V. Wygrecka M. Marsh L.M. Becker-Pauly C. Brcic L. Ghanim B. Klepetko W. Olschewski A. Kwapiszewska G. Meprin β contributes to collagen deposition in lung fibrosis Sci. Rep. 7 2017 39969 28059112 10.1038/srep39969 PMC5216360

374 An B. Lin Y.S. Brodsky B. Collagen interactions: drug design and delivery Adv. Drug Deliv. Rev. 97 2016 69 84 26631222 10.1016/j.addr.2015.11.013

375 Morath I. Hartmann T.N. Orian-Rousseau V. CD44: more than a mere stem cell marker Int. J. Biochem. Cell Biol. 81 2016 166 173 27640754 10.1016/j.biocel.2016.09.009

376 Ndinguri M.W. Zheleznyak A. Lauer J.L. Anderson C.J. Fields G.B. Application of collagen-model triple-helical peptide-amphiphiles for CD44-targeted drug delivery systems J. Drug Deliv. 2012 2012 592602 23213537 10.1155/2012/592602 PMC3505660

377 Severino P. da Silva C.F. Andrade L.N. de Lima Oliveira D. Campos J. Souto E.B. Alginate nanoparticles for drug delivery and targeting Curr. Pharmaceut. Des. 25 2019 1312 1334 10.2174/1381612825666190425163424 31465282

378 Flórez-Fernández N. Domínguez H. Torres M.D. A green approach for alginate extraction from sargassum muticum Brown seaweed using ultrasound-assisted technique Int. J. Biol. Macromol. 124 2019 451 459 30496857 10.1016/j.ijbiomac.2018.11.232

379 Agüero L. Zaldivar-Silva D. Peña L. Dias M.L. Alginate microparticles as oral colon drug delivery device: a review Carbohydr. Polym. 168 2017 32 43 28457455 10.1016/j.carbpol.2017.03.033

380 Prasad K. Kaneko Y. Kadokawa J. Novel gelling systems of kappa-, iota- and lambda-carrageenans and their composite gels with cellulose using ionic liquid Macromol. Biosci. 9 2009 376 382 19003847 10.1002/mabi.200800179

381 Posocco B. Dreussi E. De Santa J. Toffoli G. Abrami M. Musiani F. Grassi M. Farra R. Tonon F. Grassi G. Polysaccharides for the delivery of antitumor drugs Materials (Basel) 8 2015 2569 2615

382 Obaidat R.M. Alnaief M. Mashaqbeh H. Investigation of carrageenan aerogel microparticles as a potential drug carrier AAPS PharmSciTech 19 2018 2226 2236 29736886 10.1208/s12249-018-1021-4

383 Kalsoom Khan A. Saba A.U. Nawazish S. Akhtar F. Rashid R. Mir S. Nasir B. Iqbal F. Afzal S. Pervaiz F. Murtaza G. Carrageenan based bionanocomposites as drug delivery tool with special emphasis on the influence of ferromagnetic nanoparticles Oxid. Med. Cell. Longev. 2017 2017 8158315 28303171 10.1155/2017/8158315 PMC5337884

384 Yegappan R. Selvaprithiviraj V. Amirthalingam S. Jayakumar R. Carrageenan based hydrogels for drug delivery, tissue engineering and wound healing Carbohydr. Polym. 198 2018 385 400 30093014 10.1016/j.carbpol.2018.06.086

385 S. Toumi, M.M. Yahoum, S. Lefnaoui, A. Hadjsadok, Synthesis, characterization and potential application of hydrophobically modified carrageenan derivatives as pharmaceutical excipients, Carbohydr. Polym. 251 (2021), 116997. 10.1016/j.carbpol.2020.116997 33142566

386 Thakur A. Jaiswal M.K. Peak C.W. Carrow J.K. Gentry J. Dolatshahi-Pirouz A. Gaharwar A.K. Injectable shear-thinning nanoengineered hydrogels for stem cell delivery Nanoscale 8 2016 12362 12372 27270567 10.1039/c6nr02299e

387 Huang Y.C. Li R.Y. Chen J.Y. Chen J.K. Biphasic release of gentamicin from chitosan/fucoidan nanoparticles for pulmonary delivery Carbohydr. Polym. 138 2016 114 122 26794744 10.1016/j.carbpol.2015.11.072

388 Yu S.H. Wu S.J. Wu J.Y. Wen D.Y. Mi F.L. Preparation of fucoidan-shelled and genipin-crosslinked chitosan beads for antibacterial application Carbohydr. Polym. 126 2015 97 107 25933528 10.1016/j.carbpol.2015.02.068

389 Ustyuzhanina N.E. Bilan M.I. Gerbst A.G. Ushakova N.A. Tsvetkova E.A. Dmitrenok A.S. Usov A.I. Nifantiev N.E. Anticoagulant and antithrombotic activities of modified xylofucan sulfate from the Brown alga punctaria plantaginea Carbohydr. Polym. 136 2016 826 833 26572418 10.1016/j.carbpol.2015.09.102

390 Kim J.M. Bae I. Lim K.S. Park J. Park D.S. Lee S. Jang E. Ji M.S. Sim D.S. Hong Y.J. Ahn Y. Park J.C. Cho J.G. Kang J.C. Kim I.S. Jeong M.H. A method for coating fucoidan onto bare metal stent and in vivo evaluation Prog. Org. Coating 78 2014 348 356

391 Ozaltin K. Lehocky M. Humpolicek P. Pelkova J. Di Martino A. Karakurt I. Saha P. Anticoagulant polyethylene terephthalate surface by plasma-mediated fucoidan immobilization Polymers (Basel) 11 2019 750 761 10.3390/polym11050750 PMC6572684 31035326

392 da Silva L.C.R.P. Todaro V. do Carmo F.A. Frattani F.S. de Sousa V.P. Rodrigues C.R. Sathler P.C. Cabral L.M. A promising oral fucoidan-based antithrombotic nanosystem: development, activity and safety Nanotechnology 29 2018 165102 10.1088/1361-6528/aaae5b 29424698

393 Zhao X. Guo F. Hu J. Zhang L. Xue C. Zhang Z. Li B. Antithrombotic activity of oral administered low molecular weight fucoidan from Laminaria japonica Thromb. Res. 144 2016 46 52 27289072 10.1016/j.thromres.2016.03.008

394 Yang Z.H. Emma-Okon B. Remaley A.T. Dietary marine-derived long-chain monounsaturated fatty acids and cardiovascular disease risk: a mini review Lipids Health Dis. 15 2016 201 209 27876051 10.1186/s12944-016-0366-5 PMC5120510

395 Endo J. Arita M. Cardioprotective mechanism of omega-3 polyunsaturated fatty acids J. Cardiol. 67 2016 22 27 26359712 10.1016/j.jjcc.2015.08.002

396 Calder P.C. Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance Biochim. Biophys. Acta 1851 2015 469 484 25149823 10.1016/j.bbalip.2014.08.010

397 Yang Z.H. Bando M. Sakurai T. Chen Y. Emma-Okon B. Wilhite B. Fukuda D. Vaisman B. Pryor M. Wakabayashi Y. Sampson M. Yu Z.X. Sakurai A. Zarzour A. Miyahara H. Takeo J. Sakaue H. Sata M. Remaley A.T. Long-chain monounsaturated fatty acid-rich fish oil attenuates the development of atherosclerosis in mouse models Mol. Nutr. Food Res. 60 2016 2208 2218 27273599 10.1002/mnfr.201600142 PMC5056854

398 Heydari B. Abdullah S. Pottala J.V. Shah R. Abbasi S. Mandry D. Francis S.A. Lumish H. Ghoshhajra B.B. Hoffmann U. Appelbaum E. Feng J.H. Blankstein R. Steigner M. McConnell J.P. Harris W. Antman E.M. Jerosch-Herold M. Kwong R.Y. Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the OMEGA-REMODEL randomized clinical trial Circulation 134 2016 378 391 27482002 10.1161/CIRCULATIONAHA.115.019949 PMC4973577

399 Oh G.W. Nguyen V.T. Heo S.Y. Ko S.C. Kim C.S. Park W.S. Choi I.W. Jung W.K. 3D PCL/fish collagen composite scaffolds incorporating osteogenic abalone protein hydrolysates for bone regeneration application: in vitro and in vivo studies J. Biomater. Sci. Polym. Ed. 22 2020 1 17 10.1080/09205063.2020.1834908 33063639

400 Brion A. Zhang G. Dossot M. Moby V. Dumas D. Hupont S. Piet M.H. Bianchi A. Mainard D. Galois L. Gillet P P. Nacre extract restores the mineralization capacity of subchondral osteoarthritis osteoblasts J. Struct. Biol. 192 2015 500 509 26496825 10.1016/j.jsb.2015.10.012

401 Morita M. Ogawa H. Ohno O. Yamori T. Suenaga K. Toyoshima C. Biselyngbyasides, cytotoxic marine macrolides, are novel and potent inhibitors of the Ca 2+ pumps with a unique mode of binding FEBS Lett. 589 2015 1406 1411 25957767 10.1016/j.febslet.2015.04.056

402 Sato E. Sato M. Tanabe Y. Nakajima N. Ohkubo A. Suenaga K. Total synthesis of biselyngbyaside J. Org. Chem. 82 2017 6770 6777 28589717 10.1021/acs.joc.7b00905

403 Decroos C. Clausen D.J. Haines B.E. Wiest O. Williams R.M. Christianson D.W. Variable active site loop conformations accommodate the binding of macrocyclic largazole analogues to HDAC8 Biochemistry 54 2015 2126 2135 25793284 10.1021/acs.biochem.5b00010 PMC4382410

404 Cantley M.D. Zannettino A.C.W. Bartold P.M. Fairlie D.P. Haynes D.R. Histone deacetylases (HDAC) in physiological and pathological bone remodelling Bone 95 2017 162 174 27913271 10.1016/j.bone.2016.11.028

405 Thao N.P. Luyen B.T.T. Lee S.H. Jang H.D. Kiem P.V. Minh C.V. Kim Y.H. Antiosteoporotic and antioxidant activities of diterpenoids from the Vietnamese soft corals Sinularia maxima and Lobophytum crassum Med. Chem. Res. 24 2015 3551 3560

406 Yuan Y. Zheng Y. Zhou J. Geng Y. Zou P. Li Y. Zhang C. Polyphenol-rich extracts from Brown macroalgae Lessonia trabeculate attenuate hyperglycemia and modulate gut microbiota in high-fat diet and streptozotocin-induced diabetic rats J. Agric. Food Chem. 67 2019 12472 12480 31642672 10.1021/acs.jafc.9b05118

407 Lee S.H. Jeon Y.J. Efficacy and safety of a dieckol-rich extract (AG-Dieckol) of Brown algae, Ecklonia cava, in pre-diabetic individuals: a double-blind, randomized, placebo-controlled clinical trial Food Funct. 6 2015 853 858 25608849 10.1039/c4fo00940a

408 Xia E.Q. Zhu S.S. He M.J. Luo F. Fu C.Z. Zou T.B. Marine peptides as potential agents for the management of type 2 diabetes mellitus-A prospect Mar. Drugs 15 2017 88 103 10.3390/md15040088 PMC5408234 28333091

409 Venkatesan J. Anil S. Kim S.K. Shim M.S. Marine fish proteins and peptides for cosmeceuticals: a review Mar. Drugs 15 2017 143 160 10.3390/md15050143 PMC5450549 28524092

410 Mitura S. Sionkowska A. Jaiswal A. Biopolymers for hydrogels in cosmetics: review J. Mater. Sci. Mater. Med. 31 2020 50 63 32451785 10.1007/s10856-020-06390-w PMC7248025

411 Avila Rodríguez M.I. Rodríguez Barroso L.G. Sánchez M.L. Collagen: a review on its sources and potential cosmetic applications J. Cosmet. Dermatol. 17 2018 20 26 29144022 10.1111/jocd.12450

412 Sionkowska A. Skrzyński S. Śmiechowski K. Kołodziejczak A. The review of versatile application of collagen Polym. Adv. Technol. 28 2017 4 9

413 Sionkowska A. Kaczmarek B. Michalska M. Lewandowska K. Grabska S. Preparation and characterization of collagen/chitosan/hyaluronic acid thin films for application in hair care cosmetics Pure Appl. Chem. 89 2017 1829 1839

414 Kong S.Z. Li D.D. Luo H. Li W.J. Huang Y.M. Li J.C. Hu Z. Huang N. Guo M.H. Chen Y. Li S.D. Anti-photoaging effects of chitosan oligosaccharide in ultraviolet-irradiated hairless mouse skin Exp. Gerontol. 103 2018 27 34 29275159 10.1016/j.exger.2017.12.018

415 Aranaz I. Acosta N. Civera C. Elorza B. Mingo J. Castro C. Gandía M.L.L. Heras Caballero A. Cosmetics and cosmeceutical applications of chitin, chitosan and their derivatives Polymers (Basel) 10 2018 213 237 10.3390/polym10020213 PMC6414895 30966249

416 Stepniak I. Galinski M. Nowacki K. Wysokowski M. Jakubowska P. Bazhenov V.V. Leisegang T. Ehrlich H. Jesionowski T. A novel chitosan/sponge chitin origin material as a membrane for supercapacitors - preparation and characterization RSC Adv. 6 2016 4007 4013

417 Ruocco N. Costantini S. Guariniello S. Costantini M. Polysaccharides from the marine environment with pharmacological, cosmeceutical and nutraceutical potential Molecules 21 2016 551 566 10.3390/molecules21050551 PMC6273702 27128892

418 Ahn J.H. Kim D.W. Park C.W. Kim B. Sim H. Kim H.S. Lee T.K. Lee J.C. Yang G.E. Her Y. Park J.H. Sim T.H. Lee H.S. Won M.H. Laminarin attenuates ultraviolet-induced skin damage by reducing superoxide anion levels and increasing endogenous antioxidants in the dorsal skin of mice Mar. Drugs 18 2020 345 358 10.3390/md18070345 PMC7401269 32629814

419 Al-Sibani M. Al-Harrasi A. Neubert R.H.H. Effect of hyaluronic acid initial concentration on cross-linking efficiency of hyaluronic acid - based hydrogels used in biomedical and cosmetic applications Pharmazie 72 2017 81 86 29441857 10.1691/ph.2017.6133

420 Bukhari S.N.A. Roswandi N.L. Waqas M. Habib H. Hussain F. Khan S. Sohail M. Ramli N.A. Thu H.E. Hussain Z. Hyaluronic acid, a promising skin rejuvenating biomedicine: a review of recent updates and pre-clinical and clinical investigations on cosmetic and nutricosmetic effects Int. J. Biol. Macromol. 120 2018 1682 1695 30287361 10.1016/j.ijbiomac.2018.09.188

421 Hu Z. Gänzle M.G. Challenges and opportunities related to the use of chitosan as a food preservative J. Appl. Microbiol. 126 2019 1318 1331 30325559 10.1111/jam.14131

422 Brasselet C. Pierre G. Dubessay P. Dols-Lafargue M. Coulon J. Maupeu J. Vallet-Courbin A. de Baynast H. Doco T. Michaud P. Delattre C. Modification of chitosan for the generation of functional derivatives Appl. Sci. 9 2019 1321 1353

423 Nešić A. Cabrera-Barjas G. Dimitrijević-Branković S. Davidović S. Radovanović N. Delattre C. Prospect of polysaccharide-based materials as advanced food packaging Molecules 25 2020 135 169 10.3390/molecules25010135 PMC6983128 31905753

424 Gheorghita R.P. Lobiuc A. Dimian M. Covasa M. Alginate: from food industry to biomedical applications and management of metabolic disorders Polymers (Basel) 12 2020 2417 2444 10.3390/polym12102417 PMC7589871 33092194

425 Singh S. Gaikwad K.K. Lee Y.S. Antimicrobial and antioxidant properties of polyvinyl alcohol bio composite films containing seaweed extracted cellulose nano-crystal and basil leaves extract Int. J. Biol. Macromol. 107 2018 1879 1887 29032083 10.1016/j.ijbiomac.2017.10.057

426 Gao H. Duan B. Lu A. Deng H. Du Y. Shi X. Zhang L. Fabrication of cellulose nanofibers from waste Brown algae and their potential application as milk thickeners Food Hydrocolloids 79 2018 473 481

Acknowledgements

This work was supported by the 10.13039/501100001809 National Natural Science Foundation of China (81722015 and 81870805), the Shaanxi Key Scientific and Technological Innovation Team (2020TD-033), the Innovative research team of high-level local universities in Shanghai and the Oral and maxillofacial regeneration and functional restoration.

Peer review under responsibility of KeAi Communications Co., Ltd.